Page last updated: 2024-12-05

dronabinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dronabinol is a synthetic cannabinoid, chemically identical to tetrahydrocannabinol (THC), the psychoactive compound in cannabis. It is prescribed for treating nausea and vomiting caused by chemotherapy and for stimulating appetite in HIV/AIDS patients. Dronabinol is synthesized through a multi-step process involving the manipulation of various organic compounds to create the desired molecular structure. The effects of dronabinol mirror those of THC, including psychoactive effects, relaxation, altered perception, and appetite stimulation. It is studied to further understand its therapeutic potential in treating conditions like chronic pain, anxiety, and multiple sclerosis. Its research significance stems from its potential as a therapeutic agent in various conditions, particularly those where conventional medications fall short.'

Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CannabisgenusThe plant genus in the Cannabaceae plant family, Urticales order, Hamamelidae subclass. The flowering tops are called many slang terms including pot, marijuana, hashish, bhang, and ganja. The stem is an important source of hemp fiber.[MeSH]CannabaceaeA plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]
Cannabis sativaspecies[no description available]CannabaceaeA plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. It is most notable for the members, Cannabis and Hops.[MeSH]

Cross-References

ID SourceID
PubMed CID16078
CHEMBL ID465
CHEBI ID66964
SCHEMBL ID4609
MeSH IDM0021229

Synonyms (182)

Synonym
TCI ,
BIDD:GT0427
gtpl2424
6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-
.delta.9-thc
abbott 40566
sp 104
nsc134454
l-.delta.1-tetrahydrocannabinol
14c-.delta.1-tetrahydrocannabinol
.delta.9-tetrahydrocannabinol
.delta.1-thc
nsc-134454
trans-.delta.9-tetrahydrocannabinol
(-)-.delta.(sup9)-trans-tetrahydrocannabinol
.delta.-9-thc
qcd 84924
6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-
6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-
cannabinol, 1-trans-.delta.(sup9)-tetrahydro-
1-trans-.delta.(sup9)-tetrahydrocannabinol
6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyran-1-ol
.delta.(sup9)-thc
relivar
compassia
cat-310
int-0010/06
qcd-84924
int-0010
namisol
(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
1-trans-delta-9-tetrahydrocannabinol
delta-9-tetrahydrocannabinol
PDSP2_000714
(-)-delta9-trans-tetrahydrocannabinol
(6ar-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol
delta(sup 1)-tetrahydrocannabinol
drg-0138
delta(sup 9)-tetrahydrocannabinol
6h-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar,10ar)-
(-)-3,4-trans-delta1-tetrahydrocannabinol
cannabinol, 1-trans-delta(sup 9)-tetrahydro-
delta(sup 1)-thc
(-)-delta9-tetrahydrocannabinol
(-)-trans-delta9-tetrahydrocannabinol
delta(sup 9)-thc
tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol
6,6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-6h-dibenzo(b,d)pyran-1-ol
delta9-trans-tetrahydrocannabinol
(-)-trans-delta1-tetrahydrocannabinol
6h-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-
delta1-tetrahydrocannabinol
marinol
l-delta1-trans-tetrahydrocannabinol
cannabinol, delta1-tetrahydro- (7ci)
(-)-delta1-tetrahydrocannabinol
delta1-thc
trans-delta9-tetrahydrocannabinol
cannabinol, delta1-tetrahydro-
deltanyne
l-trans-delta9-tetrahydrocannabinol
(-)-trans-delta9-thc
ccris 4726
(-)-delta(sup 1)-3,4-trans-tetrahydrocannabinol(l)-delta(sup 1)-tetrahydrocannabinol
1-trans-delta(sup9)-tetrahydrocannabinol
cannabinol, tetrahydro- (6ci)
(l)-delta1-tetrahydrocannabinol
3-pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6h-dibenzo(b,d)pyran-1-ol
delta9-thc
tetrahydrocannabinols (-)-delta1-3,4-trans-form
(-)-(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
9-ene-tetrahydrocannabinol
delta9-tetrahydrocannabinol (van)
(6ar,10ar)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol
dronabinolum [latin]
delta1-tetrahydrocannabinol (van)
1-trans-delta(sup 9)-tetrahydrocannabinol
dea no. 7369
(l)-delta(sup 1)-tetrahydrocannabinol
(-)-delta(sup 1)-3,4-trans-tetrahydrocannabinol
nsc 134454
delta(1)-thc
6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar,10ar)-
hsdb 6471
delta(9)-tetrahydrocannibinol
1-trans-delta9-tetrahydrocannabinol
6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-
delta(9)-tetrahydrocannabinol
THC ,
tetrahydrocannabinol
dronabinol
delta9-tetrahydrocannabinol
C06972
1972-08-3
tetrahydrocannabinol delta9
6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
delta(1)-tetrahydrocannabinol
DB00470
delta(9)-thc
delta-9-thc
marinol (tn)
D00306
dronabinol (usp/inn)
9 ene tetrahydrocannabinol
9-tetrahydrocannabinol
trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol
.delta.-9-tetrahydrocannabinol
j882f ,
chebi:66964 ,
CHEMBL465 ,
abbott-40566
sp-104
tetrahydrocannabinols (-)-trans-.delta.9-form
(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
bdbm50007391
(s)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
8,8-dimethyl-11-methylene-5-pentyl-3,4,8a,9,10,11,12,12a-octahydro-2h,8h-1,7-dioxa-benzo[c]phenanthrene
(10r,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol
6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol(delta9-thc(delta9-tetrahydrocannabinol))
6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol(deltae-9-thc)
unii-7j8897w37s
delta 9-tetrahydrocannabinol
dronabinol [usan:usp:inn]
7j8897w37s ,
dronabinolum
syndros
delta-9 tetrahydrocannabinol
dtxsid6021327 ,
cas-1972-08-3
tox21_112616
dtxcid101327
6465-30-1
6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, trans-
dronabinol [vandf]
tetrahydrocannabinols (-)-trans-.delta.9-form [mi]
dronabinol [hsdb]
(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-dibenzo(b,d)pyran-1-ol
dronabinol [usp monograph]
sci-110 component dronabinol
dronabinol [mart.]
(-)-.delta.1-3,4-trans-tetrahydrocannabinol
dronabinol [usan]
dronabinol [inn]
tetrahydrocannabinol, delta-9 trans
dronabinol [orange book]
dronabinol [who-dd]
(6ar,10ar)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo[b,d]pyran-1-ol
EPITOPE ID:224552
SCHEMBL4609
3LS4
(6ar-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo[b,d]pyran-1-ol
(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6h,6ah,7h,8h,10ah-benzo[c]isochromen-1-ol
delta-9-tetrahydrocannabinol, united states pharmacopeia (usp) reference standard
(-)-delta9-thc (dronabinol) 1.0 mg/ml in methanol
(-)-delta9-thc (dronabinol) 0.1 mg/ml in methanol
(-)-delta-9-thc (dronabinol) 5.0 mg/ml in methanol
bdbm60994
us9416103, delta9-thc
delta-tetrahydrocannabinol (thc)
Q190067
(-)-delta9-tetrahydrocannabinol (delta9-thc) 100 microg/ml in methanol
(-)-delta 9-tetrahydrocannabinol (delta9-thc) 1000 microg/ml in methanol
delta9-tetrahydrocannabinol 250 microg/ml in acetonitrile
dronabinol (synthetic)
(+/-)-delta9-tetrahydrocannabinol
DTXSID001038830
dronabinolum (latin)
(6ar,10ar)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo
dronabinol (mart.)
(6ar-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo
tetrahydrocannabinols (-)-trans-delta9-form
dronabinol (usp monograph)
(-)-delta1-3,4-trans-tetrahydrocannabinol
delta 1-tetrahydrocannabinol
dronabinol (usan:usp:inn)
(-)-delta 9-trans-tetrahydrocannabinol
(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo(c)chromen-1-ol
a04ad10
(-)-trans-delta-9-thc (dronabinol), 100mg/ml in ethanol
(-)-trans-delta-9-thc (dronabinol), 1mg/ml in ethanol
(-)-trans-delta-9-thc (dronabinol), 10mg/ml in ethanol
(-)-trans-delta-9-thc (dronabinol), 50mg/ml in ethanol

Research Excerpts

Overview

Dronabinol is a drug composed of synthetic delta-9-tetrahydrocannabinol. It is indicated for treatment of anorexia associated with weight loss in individuals with AIDS and nausea and vomiting associated with cancer chemotherapy.

ExcerptReferenceRelevance
"Dronabinol is a drug composed of synthetic delta-9-tetrahydrocannabinol. "( [Use of dronabinol in the treatment of resistant neuropathic pain: Feedback from patients followed in a multidisciplinary pain center].
Boursier, A; Charpentier, P; Dujardin, L; Ferret, L; Fulcrand, J; Gaboriau, L; Richet, E, 2023
)
2.79
"Dronabinol is an effective adjunct to antiemetic regimens during cancer treatment in several populations of patients with cancer. "( Dronabinol Therapy: Central Nervous System Adverse Events in Adults With Primary Brain Tumors.
Allen, D, 2019
)
3.4
"Dronabinol is a synthetic Delta-tetrahydrocannabinol."( [Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases].
Emmert, S; Hänssle, H; Kretschmer, L; Neumann, C; Zutt, M, 2006
)
1.97
"Dronabinol is an oral form of delta-9-tetrahydrocannabinol indicated for treatment of anorexia associated with weight loss in individuals with AIDS, and nausea and vomiting associated with cancer chemotherapy. "( Abuse potential of dronabinol (Marinol).
Calhoun, SR; Galloway, GP; Smith, DE,
)
1.9

Effects

Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study. The drug has a modest but clinically relevant analgesic effect on central pain in patients with multiple sclerosis.

ExcerptReferenceRelevance
"Dronabinol has a modest but clinically relevant analgesic effect on central pain in patients with multiple sclerosis. "( Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Bach, FW; Jensen, TS; Svendsen, KB, 2004
)
2.09
"Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study."( Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.
Abbott, SM; Attarian, H; Carley, DW; Malkani, R; Prasad, B; Reid, KJ; Vern, B; Xie, H; Yuan, C; Zee, PC, 2018
)
1.42
"Dronabinol has poor bioavailability, which may contribute to its poor efficacy."( Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Vosburg, SK, 2013
)
1.11
"Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse."( Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Bedi, G; Cooper, ZD; Haney, M, 2013
)
1.34
"Dronabinol has a modest but clinically relevant analgesic effect on central pain in patients with multiple sclerosis. "( Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Bach, FW; Jensen, TS; Svendsen, KB, 2004
)
2.09
"Dronabinol has been studied in a double-blind appetite stimulation study run in 18 centers."( AIDS-associated anorexia.
Beal, J; Flynn, N, 1995
)
1.01

Treatment

Both dronabinol and placebo treatment were associated with significant reductions in BFRB symptoms. DronabinOL treatment decreased severity of disturbed behavior and this effect persisted during the placebo period in patients who received dron Cabinol first.

ExcerptReferenceRelevance
"Both dronabinol and placebo treatment were associated with significant reductions in BFRB symptoms."( Tetrahydrocannabinol fails to reduce hair pulling or skin picking: results of a double-blind, placebo-controlled study of dronabinol.
Chesivoir, E; Ehsan, D; Grant, JE; Valle, S, 2022
)
1.38
"Dronabinol treatment decreased severity of disturbed behavior and this effect persisted during the placebo period in patients who received dronabinol first."( Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease.
McLaughlin, J; Morris, J; Stelly, M; Volicer, BJ; Volicer, L, 1997
)
1.41
"Treatment with dronabinol at a dose of 10 mg twice a day, then reduced to 5 mg twice a day, relieved all of her symptoms."( Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: a case report.
Modica, PA; Murtaugh, K; Raby, WN; Wolintz, RJ, 2006
)
2.12

Toxicity

ExcerptReferenceRelevance
" The oral LD50 in mice and rats for nabilone formulated as a polyvinylpyrrolidone (PVP) codispersion was in excess of 1000 mg/kg."( A species comparison of the toxicity of nabilone, a new synthetic cannabinoid.
Emmerson, JL; Gries, CL; Hanasono, GK; Jordan, WH; Sullivan, HR, 1987
)
0.27
" Except for a transient decrease in dam respiration rates, other gross toxic signs were absent."( Marihuana-induced embryotoxicity in the rabbit.
Baker, JR; Fleischman, RW; Grant, RJ; Rosenkrantz, H, 1986
)
0.27
" Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%)."( Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
Ahmedzai, S; Calder, IT; Carlyle, DL; Moran, F, 1983
)
0.27
" Occurrence of adverse events, drug discontinuation, new AIDS-defining conditions, or CD4+ T lymphocyte changes were not statistically significantly different among arms."( The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.
Egorin, MJ; Enama, ME; Galetto, G; Li, N; Mayers, J; Timpone, JG; Wright, DJ, 1997
)
0.51
" Adverse events were primarily related to known central nervous system effects of dronabinol."( Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.
Beal, JE; Bellman, P; Laubenstein, L; Lefkowitz, L; Morales, JO; Mosdell, KW; Murphy, R; Olson, R; Plasse, TF; Powderly, W; Shepard, KV; Yangco, B, 1997
)
0.8
" Here we report that Delta9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is toxic for hippocampal neurons."( Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol.
Chan, GC; Hinds, TR; Impey, S; Storm, DR, 1998
)
0.3
" Both drugs were safe, but adverse events were more common with plant-extract treatment."( Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Gorter, RW; Hoogervorst, EL; Kalkers, NF; Killestein, J; Polman, CH; Reif, M; Staats, PG; Uitdehaag, BM; Van Loenen, AC, 2002
)
0.31
" Measurements of cellular ATP revealed that both THC and BHA reduced ATP levels in A549 cells, consistent with toxic effects on mitochondrial electron transport."( Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole.
Kouyoumjian, S; Roth, MD; Sarafian, TA; Tashkin, D, 2002
)
0.31
" 2 Delta(9)-and Delta(8)-tetrahydrocannabinol (THC) were toxic when added directly to SH-SY5Y neuroblastoma cells."( Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Bissonnette, CJ; Klegeris, A; McGeer, PL, 2003
)
0.32
" Minor adverse events were slightly more frequent and severe during active treatment, and toxicity symptoms, which were generally mild, were more pronounced in the active phase."( Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Gattlen, B; Hagen, U; Heinzel-Gutenbrunner, M; Jobin, P; Reif, M; Schnelle, M; Tschopp, F; Vaney, C, 2004
)
0.32
"Recent research has clarified a number of important questions concerning adverse effects of cannabis on health."( Adverse effects of cannabis on health: an update of the literature since 1996.
Kalant, H, 2004
)
0.32
" A recently published randomized double-blind crossover clinical trial described the pain-reducing effects and side effect profile of AJA on 21 patients with chronic neuropathic pain."( Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.
Burstein, S; Hoy, L; Karst, M; Salim, K; Schneider, U, 2005
)
0.33
" Studies to date indicate a unique mechanism of action for AJA that may explain its lack of adverse side effects."( Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.
Burstein, S, 2005
)
0.33
" The large majority of adverse effects were mild or moderate, and there were no adverse effect-related withdrawals or serious adverse effects in the active treatment group."( Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.
Blake, DR; Ho, M; Jubb, RW; McCabe, CS; Robson, P, 2006
)
0.33
" Dexanabinol was not associated with hepatic, renal, or cardiac toxic effects."( Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial.
Henney, H; Kassem, N; Knoller, N; Legrand, V; Maas, AI; Mangelus, M; Muizelaar, JP; Murray, G; Stocchetti, N, 2006
)
0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" However, the well-publicized adverse reports about these medications in acquired immunodeficiency syndrome (AIDS) and in the cancer population has led to some concern and much subsequent discussion over the safety of these medications being used in geriatric population."( Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.
Lovitt, S; Schuster, MW; Yeh, SS, 2007
)
0.34
" These results suggest that the adverse effects of THC were related either to THC accumulation or to cannabinoid receptor activation and associated with IL-6 upregulation."( Delta-9-tetrahydrocannabinol accumulation, metabolism and cell-type-specific adverse effects in aggregating brain cell cultures.
Giroud, C; Hazekamp, A; Honegger, P; Mangin, P; Monnet-Tschudi, F; Perret, N; Zurich, MG, 2008
)
0.35
" Most drug-related adverse events were mild/moderate in severity."( Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Burnell-Nugent, M; Fallon, MT; Ganae-Motan, ED; Johnson, JR; Lossignol, D; Potts, R, 2010
)
0.36
" High numbers of subjects experienced at least one adverse event, but most were mild to moderate in severity and all drug-related serious adverse events resolved."( Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
Collin, C; Duncombe, P; Stott, C; Wade, DT, 2010
)
0.36
" Tolerability was measured as the number of withdrawals from the study during the titration period because of adverse events (AEs)."( Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
Abanades, S; Arriola, E; Capellà, D; Duran, M; Farré, M; Laporte, JR; Majem, M; Pastor, A; Pérez, E; Rabanal, M; Rams, N; Saura, C; Vidal, X, 2010
)
0.36
"Marijuana (cannabis) is the most widely used illicit substance globally, and cannabis use is associated with a range of adverse consequences."( The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.
Poling, J; Sofuoglu, M; Sugarman, DE, 2011
)
0.37
" What are the adverse effects of cannabis on health? During consumption? And in the long term? Does cannabis predispose users to the development of psychotic disorders? To answer these questions, we reviewed the available evidence using the standard Prescrire methodology."( Adverse effects of cannabis.
, 2011
)
0.37
" Subjects were monitored for subjective and physical adverse events and followed up to 12 months beyond study participation."( The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.
Bhakta, S; Braley, G; Carbuto, M; D'Souza, DC; Elander, J; Forselius-Bielen, K; Perry, E; Pittman, B; Ranganathan, M; Schnakenberg, A; Sewell, RA; Williams, A, 2012
)
0.38
" Safeguards are generally sufficient and effective, reducing both the duration and severity of adverse events."( The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.
Bhakta, S; Braley, G; Carbuto, M; D'Souza, DC; Elander, J; Forselius-Bielen, K; Perry, E; Pittman, B; Ranganathan, M; Schnakenberg, A; Sewell, RA; Williams, A, 2012
)
0.38
" Furthermore, following withdrawal of Sativex, symptoms often return, but, beyond this, sudden cessation is generally safe with no evidence of physiological or psychological dependence."( Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
Wade, D, 2012
)
0.38
" Collectively, evidence reported in this mini-review suggests that K2 products are neither safe nor legal alternatives to marijuana."( Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?
Fantegrossi, WE; Moran, JH; Prather, PL; Radominska-Pandya, A, 2014
)
0.4
" The majority of patients (84%) did not report adverse events."( Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker, P; Henze, T; Zettl, UK, 2014
)
0.4
" THC was safe and well tolerated."( Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial.
Ahmed, AI; Burger, DM; Colbers, A; Feuth, TB; Kramers, C; Rikkert, MG; van den Elsen, GA; van der Marck, MA, 2014
)
0.4
" Pain intensity (0-10 VAS), adverse events, and satisfaction score were monitored following the inhalation."( The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study.
Almog, S; Eisenberg, E; Ogintz, M, 2014
)
0.4
"Only 6 of the 98 reported adverse events were related to THC."( Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.
Ahmed, AI; Burger, DM; Colbers, A; Kramers, C; Olde Rikkert, MG; van den Elsen, GA; van der Marck, MA, 2015
)
0.42
" Pharmacodynamic effects, including adverse events, were minor."( Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.
Ahmed, AI; Burger, DM; Colbers, A; Kramers, C; Olde Rikkert, MG; van den Elsen, GA; van der Marck, MA, 2015
)
0.42
" The primary outcome consisted of serious adverse events and non-serious adverse events."( Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
Collet, JP; Shapiro, S; Wang, T; Ware, MA, 2015
)
0.42
"The purpose of this report is to present a review of the medical uses, efficacy, and adverse effects of the three approved cannabis-based medications and ingested marijuana."( Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs.
Forrest, BD; Freeman, RA; Parmar, JR,
)
0.13
" Confusion/ideomotor slowing, fatigue and dizziness were the most frequent side effects; no major adverse events were reported."( Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Colombo, B; Comi, G; Esposito, F; Ferrè, L; Keller Sarmiento, IJ; Leocani, L; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Nuara, A; Pavan, G; Radaelli, M; Rodegher, M, 2016
)
0.43
" The incidence of adverse events (AEs) was 40."( Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
D'Onghia, M; Di Lecce, V; Direnzo, V; Iaffaldano, A; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S, 2016
)
0.43
" This review aims to discuss metabolomics of Δ(9)-THC, namely by presenting all known metabolites of Δ(9)-THC described both in vitro and in vivo, and their roles in the Δ(9)-THC-mediated toxic effects."( Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity.
Dinis-Oliveira, RJ, 2016
)
0.43
" The aim of our study was to describe Sativex effectiveness and adverse events profile in a large population of Italian patients with MS in the daily practice setting."( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016
)
0.43
"2%) and/or adverse events (n=268, 18."( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016
)
0.43
"Sativex can be a useful and safe option for patients with MS with moderate to severe spasticity resistant to common antispastic drugs."( Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M, 2016
)
0.43
" Safety was assessed on the basis of adverse reactions (ARs), signs of dependency and abuse."( Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients.
Abramov-Sommariva, D; Kugler, EM; Marziniak, M; Neubauer, C; Schimrigk, S; Werner, G, 2017
)
1.9
" Adverse effects associated with nabilone use were noted."( Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review.
Dupuis, LL; Jupp, J; Khanna, M; MacDonald, T; Ning, W; Patel, P; Polito, S; Romanick, M; Sung, L; Vennettilli, A; Wiernikowski, J, 2018
)
0.48
" Adverse effects associated with nabilone were experienced by 34% (37/110) of children."( Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review.
Dupuis, LL; Jupp, J; Khanna, M; MacDonald, T; Ning, W; Patel, P; Polito, S; Romanick, M; Sung, L; Vennettilli, A; Wiernikowski, J, 2018
)
0.48
" Secondary outcomes included documented improvement in appetite, change in weight and various laboratory parameters, and incidence of adverse effects."( Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.
Gaviola, ML; Hossaini, R; Howard, ML; Tolar, C, 2019
)
0.51
" No serious adverse effects were observed."( Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.
Gaviola, ML; Hossaini, R; Howard, ML; Tolar, C, 2019
)
0.51
" No serious adverse effects occurred."( Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Comi, G; Comola, M; Falzone, Y; Fazio, R; Ferraro, OE; Leocani, L; Lunetta, C; Mora, G; Riva, N; Sorarù, G, 2019
)
0.51
" Before planning large interventional studies, it is important to ensure that cannabis taken orally is safe and well tolerated in people living with HIV."( Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.
Brouillette, MJ; Chomont, N; Costiniuk, CT; Cox, J; Jenabian, MA; Klein, MB; Lebouché, B; Mandarino, E; Margolese, S; Routy, JP; Saneei, Z; Singer, J; Szabo, J, 2019
)
0.51
" However, it has been used little in central nervous system (CNS) cancers because of concerns regarding potential CNS adverse events."( Dronabinol Therapy: Central Nervous System Adverse Events in Adults With Primary Brain Tumors.
Allen, D, 2019
)
1.96
" These products contain extremely high concentrations of cannabinoids, and lead to sedation, respiratory depression, and other adverse effects."( Cannabinoid toxicity in pediatrics.
Blohm, E; Neavyn, M; Sell, P, 2019
)
0.51
" Side effects occurred, but severe adverse effects were mentioned in single cases only."( How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Friemel, CM; Hasan, A; Hoch, E; Niemann, D; Pogarell, O; Preuss, UW; Schneider, M; von Keller, R, 2019
)
0.51
" Disease characteristics, psychological parameters, demographics, comorbidities, lifestyle factors, blood samples and serious adverse events are collected at baseline, after 12 and 24 weeks of treatment, and at a follow-up visit at 36 weeks."( Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study
Andersen, TE; Bachmann, AG; Bojesen, AB; Christiansen, AA; Ellingsen, T; Hauge, EM; Hendricks, O; Horsted, TI; Krogh, NS; Loft, AG; Lund Hetland, M; Petersen, KH; Primdahl, J; Roessler, KK; Østergaard, M, 2019
)
0.51
" In 29% of patients treatment was terminated due to either a lack of efficacy or adverse events."( [Cannabis-based medicines for chronic pain: indications, selection of drugs, effectiveness and safety : Experiences of pain physicians in Saarland].
Bialas, P; Drescher, B; Gottschling, S; Häuser, W; Juckenhöfel, S; Konietzke, D; Kühne-Adler, I; Kuntz, W; Merl-Ripplinger, H; Preisegger, D; Schneider, K; Strauß, M; Welsch, P, 2019
)
0.51
" Adverse events were predominantly mild or moderate in severity; however, three cases of hallucinations were reported."( Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
Checketts, D; Fairhurst, C; Kumar, R; Tayo, B; Turner, S, 2020
)
0.56
"Nabiximols was generally well tolerated; however, neuropsychiatric adverse events were observed."( Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
Checketts, D; Fairhurst, C; Kumar, R; Tayo, B; Turner, S, 2020
)
0.56
" The primary objective is to assess the effect of escalating doses of a 1:1 THC/CBD cannabinoid preparation against placebo on change in total symptom score, with secondary objectives including establishing a patient-determined effective dose, the change in total physical and emotional sores, global impression of change, anxiety and depression, opioid use, quality of life and adverse effects."( Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (
Gogna, G; Good, P; Greer, R; Hardy, J; Haywood, A; Martin, J; Yates, P, 2020
)
0.56
" No deaths or serious or severe adverse events (AE) were considered related to lenabasum."( Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
Chmiel, JF; Colombo, C; Conley, B; Constantine, S; Dgetluck, N; Dinh, Q; Downey, DG; Dozor, AJ; Elborn, JS; Flume, P; Mazurek, H; Rachel, M; Sapiejka, E; White, B, 2021
)
0.62
" Three serious adverse events (SAE) were reported but were not associated with the treatment."( Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G, 2021
)
0.62
"Treatment with medical cannabis oils was safe and well tolerated, and resulted in a reduction in pain intensity, spasticity and sleep disturbances in MS patients."( Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G, 2021
)
0.62
" Treatment-emergent adverse events (TEAEs); plasma and urine concentrations of THC, CBD and metabolites; and self-reported subjective effects were collected."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
" Aligning with the known safety profile of nabiximols as demonstrated in randomized controlled trials, common adverse events reported consistently across studies conducted under clinical practice conditions were dizziness, fatigue and somnolence."( Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González, JM; Vila Silván, C, 2021
)
0.62
" All observed adverse events (AEs) were mild, transient and resolved without medical intervention."( Safety and tolerability of escalating cannabinoid doses in healthy cats.
Eglit, GM; Kulpa, JE; Paulionis, LJ; Vaughn, DM, 2021
)
0.62
" All treatment-emergent adverse events (TEAEs) (65/65) were of mild-to-moderate severity; none was serious."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
" Altogether, the results of the current study showed that THC is not directly toxic in isolated cardiac mitochondria, and even may be helpful in reducing mitochondrial toxicity."( Analysis of toxicity effects of delta-9-tetrahydrocannabinol on isolated rat heart mitochondria.
Minouei, M; Mojarad Aylar, E; Niknejad, M; Salimi, A, 2022
)
0.72
" Fewer patients treated with NBX than LAO experienced treatment-related adverse events (25."( Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
Essner, U; Mueller-Schwefe, GHH; Ueberall, MA; Vila Silván, C, 2022
)
0.72
" One mortality was reported during the study, a high dose female, and test substance-related adverse clinical signs were reported in the high dose group."( Toxicological safety of VOHO Hemp Oil; a supercritical fluid extract from the aerial parts of hemp.
Dolan, L; Dziwenka, M; Mitchell, J, 2021
)
0.62
"This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use."( Cannabinoid-Related Acute Pancreatitis: An Update from International Literature and Individual Case Safety Reports.
Azam, C; Buscail, L; Culetto, A; Lapeyre-Mestre, M, 2022
)
0.72
"Cannabinoid-based products submitted by consumers experiencing adverse effects were analyzed to identify and quantitate ingredients."( Cannabinoid-based vaping products and supplement formulations reported by consumers to precipitate adverse effects.
Butler, SN; Ferreira, AR; Holt, AK; Karin, KN; Krotulski, AJ; Peace, MR; Poklis, JL, 2023
)
0.91
" No serious or severe adverse events were related to lenabasum, and no participants discontinued the study."( Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M, 2022
)
0.72
" Isolated cannabinoids illustrated different toxic effects on the viability of cells derived from colorectal polyps."( The Cytotoxic Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue.
Ben-Ami Shor, D; Gluck, N; Hochman, I; Scapa, E; Shibolet, O, 2022
)
0.72
"This study aimed to explore the incidence of adverse events (AEs) reported by patients when initiating medicinal cannabis treatment for chronic pain, and the association of cannabis constituents, dose and concomitant medicines with AE incidence."( Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications.
Alffenaar, JC; Barlow, JW; Johnstone, MT; Schubert, EA; Wheate, NJ, 2023
)
0.91
" THC use appears to be associated with a higher proportion of serious adverse effects, including neuropsychological and cardiovascular effects."( Place of therapeutic cannabis in France and safety data: A literature review.
Bacle, A; Corso, B; Demay, E; Gicquel, T; Le Daré, B; Mercerolle, M; Pelletier, R, 2023
)
0.91
"The literature reports several frequent but rarely serious adverse effects of CBD during chronic use as well as a significant risk of drug interactions."( Place of therapeutic cannabis in France and safety data: A literature review.
Bacle, A; Corso, B; Demay, E; Gicquel, T; Le Daré, B; Mercerolle, M; Pelletier, R, 2023
)
0.91
" Thus, the exact same dose and preparation of cannabis may be beneficial for some but toxic to others."( An Individuality of Response to Cannabinoids: Challenges in Safety and Efficacy of Cannabis Products.
Kitdumrongthum, S; Trachootham, D, 2023
)
0.91
" No deaths or excess in serious or severe adverse events related to lenabasum were observed."( Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B, 2023
)
0.91
" Cognitive adverse events were collected."( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023
)
0.91
" Adverse cognitive events were reported at least twice as often by the CBD/THC than the placebo group."( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023
)
0.91
" Cannabis was considered safe in older adults by 81."( Dispensary Staff Perceptions About the Benefits, Risks, and Safety of Cannabis for Medical Purposes.
Althouse, AD; Arnsten, JH; Bulls, HW; Feldman, R; Kansagara, D; Liebschutz, JM; Merlin, JS; Morasco, BJ; Nugent, SM; Orris, SR; Rohac, R; Slawek, DE; Starrels, JL, 2023
)
0.91
"The potentially adverse effects of cannabis (marijuana), a common leisure compound, on male reproductive performance are a reason for concern."( In vitro evaluation of cell viability and expression profile of growth factors in mouse Sertoli cells exposed to Delta-9-tetrahydrocannabinol: a mechanistic insight into the cannabinoid-induced testicular toxicity.
Abdollahzade Fard, A; Golchin, A; Mohammadpour-Asl, S; Roshan-Milani, S, 2023
)
0.91
" The outcomes of the studies included the efficacy of medical cannabinoids administered for spasticity, motor components, pain control, sleep difficulties, adverse effects, and seizure control."( Efficacy and safety of medical cannabinoids in children with cerebral palsy: a systematic review.
Hasugian, AR; Idaiani, S; Jonlean, R; Kusuma, KS; Murni, W; Oktarina, C; Purwoko, RY; Putra, A; Simatupang, A; Stevanny, B; Sugiyono, SP; Tandarto, K; Tango, T; Umar, TP, 2023
)
0.91

Pharmacokinetics

We present pharmacokinetic data from a randomized placebo-controlled study. The study was designed to evaluate the metabolic effects of smoked marijuana and dronabinol in HIV-infected patients receiving indinavir or nelfinavir.

ExcerptReferenceRelevance
" CTX half-life was not significantly changed with use of THC (7."( Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin.
Aisner, J; Bachur, NR; Colvin, OM; Duffey, P; Egorin, MJ; Fuks, JZ; Riggs, CE; Schnaper, N; Wiernik, PH,
)
0.13
"This study explored the relationships in man between various pharmacological effect of delta 9-tetrahydrocannabinol (THC), plasma THC concentration, and pharmacokinetic parameters of THC."( Relationships between several pharmacokinetic parameters and psychometric indices of subjective effects of delta 9-tetrahydrocannabinol in man.
Cocchetto, DM; Miller, LL; Perez-Reyes, M, 1983
)
0.27
" The purpose of this work was to link an indoor air quality model (IAQ) with a pharmacokinetic (PK) model to predict a passive marijuana smoker's resultant concentration of the major urinary metabolite THCA."( An indoor air quality-pharmacokinetic simulation of passive inhalation of marijuana smoke and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in urine.
Giardino, NJ, 1997
)
0.3
" The elimination of dexanabinol was best fitted to a 3-compartment model with a rapid distribution half-life (< 5 min), an intermediate phase half-life of approximately 90 min, and a slow terminal elimination half-life (approximately 9 h)."( Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers.
Amselem, S; Biegon, A; Brewster, ME; Foltz, RL; Griffith, W; Pop, E; Reuschel, S, 1997
)
0.3
" We present pharmacokinetic data from a randomized placebo-controlled study designed to evaluate the metabolic effects of smoked marijuana and dronabinol in HIV-infected patients receiving indinavir (IDV) or nelfinavir (NFV)."( The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB, 2002
)
0.52
"Despite a statistically significant decrease in C(max) of IDV in the marijuana arm, the magnitude of changes in IDV and NFV pharmacokinetic parameters in the marijuana arm are likely to have no short-term clinical consequence."( The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.
Abrams, DI; Aweeka, FT; Benowitz, NL; Hilton, JF; Kosel, BW; Lizak, PS; Shade, SB, 2002
)
0.31
" During chronic exposure to THC the pharmacokinetic molecular mechanisms which limit the storage of THC in the brain and testis are not sufficient to prevent a persistent deregulation of membrane signalling and the induction of functional and morphological changes which reflect a premature apoptosis of spermatogenic cells."( Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa.
Frick, HC; Harvey, D; Latour, C; Lattimer, JK; Nahas, GG, 2002
)
0.31
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" This assay method utilizes the increased sensitivity and selectivity of mass spectrometric (MS) detection and a simple extraction step for the determination of Delta(9)-tetrahydrocannabinol and its metabolites in plasma, and thus yields a more efficient pharmacokinetic analysis method than has previously been described."( Liquid chromatographic-mass spectrometric quantitation of Delta9-tetrahydrocannabinol and two metabolites in pharmacokinetic study plasma samples.
Stinchcomb, AL; Valiveti, S, 2004
)
0.32
"The aim of the present study was to develop a physiologically compatible inhalation solution of delta-9-tetrahydrocannabinol (THC), and to compare the pharmacokinetic and analgesic properties of pulmonal THC versus pulmonal placebo and intravenous (iv) THC, respectively."( Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans.
Brenneisen, R; Naef, M; Petersen-Felix, S; Russmann, S, 2004
)
0.32
"05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67."( Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
George, MP; Gustafson, RA; Huestis, MA; Kim, I; Klette, KL; Levine, B; Moolchan, ET; Stout, PR, 2004
)
0.32
" As a reason, pharmacodynamic as well as pharmacokinetic mechanisms were suggested."( Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Fronk, EM; Nadulski, T; Pragst, F; Roser, P; Schnelle, M; Stadelmann, AM; Weinberg, G, 2005
)
0.33
" A drug's pharmacokinetics determines the onset, magnitude, and duration of its pharmacodynamic effects."( Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol.
Huestis, MA, 2005
)
0.33
"After cannabis consumption there is only limited knowledge about the pharmacokinetic (PK) and metabolic properties of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC), which is formed by oxidative breakdown from Delta(9)-tetrahydrocannabinol (THC)."( Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects.
Aderjan, R; Dietz, L; Glaz-Sandberg, A; Mikus, G; Nguyen, H; Oberwittler, H, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" In the present study, blood pharmacokinetic properties were investigated in occasional and heavy users in cannabis and placebo conditions."( Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint.
Kauert, GF; Moeller, MR; Ramaekers, JG; Theunissen, EL; Toennes, SW, 2008
)
0.35
" The current within-subject, randomized, double-blind, placebo-controlled study sought to directly compare the subjective, physiological, and pharmacokinetic effects of marijuana smoked by these two methods."( Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.
Cooper, ZD; Haney, M, 2009
)
0.35
" No plasma pharmacokinetic data after repeated oral THC administration are available."( Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
Darwin, WD; Goodwin, RS; Gorelick, DA; Huestis, MA; Karschner, EL; Kelly, DL; Lowe, RH; Schwilke, EW; Schwope, DM, 2009
)
0.35
" The pharmacokinetic parameters (Cmax and AUC0-inf) of the main metabolite Org 26761 were proportional to dose."( Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.
Cohen, AF; de Kam, ML; Kleijn, HJ; Passier, PC; van Gerven, JM; Zuurman, L, 2010
)
0.36
" Beside pharmacokinetic differences, these data therefore denote distinct pharmacodynamic profiles for HU 210 and CP 55,940."( Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists.
Bosier, B; Hermans, E; Lambert, DM; Michotte, Y; Sarre, S; Smolders, I, 2010
)
0.36
" There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
"These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
" Pharmacokinetic parameters and their between animal variability were obtained using standard non-compartmental analysis as well as a compartmental analysis using nonlinear mixed effects modeling."( Pharmacokinetics of a combination of Δ9-tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock.
Mehrotra, N; Meibohm, B; Moore, BM; Vaddady, PK; Yates, CR; Zhang, X, 2011
)
0.37
"We here determined pharmacokinetic profiles of the above phytocannabinoids after acute single-dose intraperitoneal and oral administration in mice and rats."( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi
Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012
)
0.38
" CBD inhibited obsessive-compulsive behaviour in a time-dependent manner matching its pharmacokinetic profile."( Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behavi
Amada, N; Arthur, M; Close, S; Deiana, S; Dorward, P; Fleming, S; Pigliacampo, B; Platt, B; Riedel, G; Watanabe, A; Woodcock, H; Yamasaki, Y, 2012
)
0.38
"• Namisol is a new tablet containing pure THC (>98%) that has a beneficial pharmacokinetic profile after oral administration."( Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Beumer, TL; de Kam, ML; Freijer, JI; Karger, LB; Kleinloog, HD; Klumpers, LE; Lipplaa, A; van Gerven, JM; van Hasselt, JG, 2012
)
0.38
"Among the main disadvantages of currently available Δ(9) -tetrahydrocannabinol (THC) formulations are dosing difficulties due to poor pharmacokinetic characteristics."( Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Beumer, TL; de Kam, ML; Freijer, JI; Karger, LB; Kleinloog, HD; Klumpers, LE; Lipplaa, A; van Gerven, JM; van Hasselt, JG, 2012
)
0.38
"The mean Cmax values (<12 ng/mL) recorded in this study were well below those reported in patients who smoked/inhaled cannabis, which is reassuring since elevated Cmax values are linked to significant psychoactivity."( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013
)
0.39
"This review examines the characteristics of nabiximols, its pharmacokinetic properties and data on efficacy and tolerability in MS-related neuropathic pain."( Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
Constantinescu, CS; Tanasescu, R, 2013
)
0.39
" The pharmacokinetic and pharmacodynamic profile of oral Δ(9) -THC, administered in ascending order in 15 mg increments across separate sessions, up to a maximum of 90 mg, was determined in seven cannabis users."( Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users.
Charnigo, RJ; Hays, LR; Kelly, TH; Lile, JA; Stinchcomb, AL, 2013
)
0.39
"To establish a fast sensitive, reproducible LC-MS/MS method to study pharmacokinetic properties of THC, and compare relative bioavailability of THC and its solid dispersion in mice."( [Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose].
Hua, H; Liao, L; Luo, H; Yang, AD; Zhao, JN, 2014
)
0.4
" A uniform pharmacokinetic profile was exhibited across all participants (Δ(9)-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC₀→infinity ± SD was 607 ± 200 ng·min/mL)."( The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study.
Almog, S; Eisenberg, E; Ogintz, M, 2014
)
0.4
" However, this characteristic is often ignored in pharmacokinetic (PK) studies of THC, which may affect the accuracy of predictions in different pharmacologic areas."( Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.
Beumer, TL; Cohen, AF; Freijer, J; Guan, Z; Heuberger, JA; Klumpers, L; Morrison, PD; Oyetayo, OO; van Gerven, JM, 2015
)
0.42
" Pharmacodynamic effects, including adverse events, were minor."( Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.
Ahmed, AI; Burger, DM; Colbers, A; Kramers, C; Olde Rikkert, MG; van den Elsen, GA; van der Marck, MA, 2015
)
0.42
" This particular pharmacokinetic behavior explains the lack of correlation between the THC blood level and clinical effects, contrary to ethanol."( [Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis].
Goullé, JP; Guerbet, M, 2014
)
0.4
" Δ9-THC was well absorbed with a mean tmax of 123 min."( Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
de Vries, M; Van Goor, H; Van Rijckevorsel, DC; Vissers, KC; Wilder-Smith, OH, 2016
)
0.43
"The pharmacokinetic models of THC and four CB1 antagonists were built separately."( Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
Guan, Z; Heuberger, J; Klumpers, LE; Oyetayo, OO; Stevens, J; van Gerven, JM, 2016
)
0.43
" Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population."( Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.
Martin, JH; Reuter, SE, 2016
)
0.43
" Thus, controlled human pharmacokinetic (PK) studies are not allowed, although being relevant for interpretation of analytical results in cases of misuse or poisoning."( Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology.
Ewald, AH; Kettner, M; Laschke, MW; Lehr, T; Maurer, HH; Menger, MD; Schaefer, N; Schlote, J; Schmidt, PH; Wojtyniak, JG, 2016
)
0.43
" Study objectives were to evaluate the safety and tolerability of PTL101 containing 10 and 100 mg CBD, following single administrations to healthy volunteers and to compare the pharmacokinetic profiles and relative bioavailability of CBD with Sativex oromucosal spray (the reference product) in a randomized, crossover study design."( Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Atsmon, J; Deutsch, F; Deutsch, L; Heffetz, D; Sacks, H, 2018
)
0.48
" The pharmacokinetic properties of cannabis administered by traditional routes has been described but to date, there is no literature on the pharmacokinetic properties of an intraperitoneal cannabinoid emulsion."( Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.
Galettis, P; Lucas, CJ; Martin, JH; Reuter, SE; Schneider, J; Solowij, N; Song, S, 2018
)
0.48
"THC concentrations were consistent with the clinical state but not with the known pharmacokinetic properties of cannabis nor of intraperitoneal absorption."( Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.
Galettis, P; Lucas, CJ; Martin, JH; Reuter, SE; Schneider, J; Solowij, N; Song, S, 2018
)
0.48
"The unusual pharmacokinetic properties of the case suggest that there is a large amount unknown about cannabis pharmacokinetic properties."( Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.
Galettis, P; Lucas, CJ; Martin, JH; Reuter, SE; Schneider, J; Solowij, N; Song, S, 2018
)
0.48
"Model-based prediction on clinical doses for cannabinoids therapy is beneficial in the clinical setting, especially for seriously ill patients with both altered pharmacokinetics and pharmacodynamic responses."( Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.
Liu, Z; Martin, JH, 2018
)
0.48
" As both THC and CBD are hepatically metabolized, the potential exists for pharmacokinetic drug interactions via inhibition or induction of enzymes or transporters."( The pharmacokinetics and the pharmacodynamics of cannabinoids.
Galettis, P; Lucas, CJ; Schneider, J, 2018
)
0.48
" Blood and/or oral fluid cannabinoid concentrations were weakly to moderately correlated with pharmacodynamic outcomes."( Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
Bigelow, GE; Cone, EJ; Flegel, R; Hayes, E; Mitchell, JM; Schlienz, NJ; Spindle, TR; Vandrey, R, 2019
)
0.51
" A pharmacokinetic study was conducted with 12 blood samplings over a 24-h period before and after controlled random inhalation of placebo or 10 mg or 30 mg of THC."( Effect of Smoked Cannabis on Vigilance and Accident Risk Using Simulated Driving in Occasional and Chronic Users and the Pharmacokinetic-Pharmacodynamic Relationship.
Alvarez, JC; Barbot, F; Hartley, S; Larabi, A; Quera-Salva, MA; Simon, N; Vaugier, I, 2019
)
0.51
" We therefore sought to characterize the pharmacokinetics of THC and its major metabolites 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in healthy volunteers with known CYP2C9 status by non-compartmental analysis (NCA), compartmental modeling (CM) and minimal physiologically based pharmacokinetic (mPBPK) modeling."( Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Bernhard, W; Greif, R; Kleine-Brueggeney, M; Theiler, L; Wolowich, WR, 2019
)
0.51
" The pharmacodynamic model relates neuroadaptive changes in the brain to a blunted response to cannabis."( Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance.
Mason, NL; Ramaekers, JG; Theunissen, EL, 2020
)
0.56
" However, few controlled clinical laboratory studies have evaluated the pharmacodynamic effects of oral or vaporized CBD or CBD-dominant cannabis."( Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Mitchell, JM; Spindle, TR; Vandrey, R; Weerts, EM; Winecker, RE, 2020
)
0.56
" THC pharmacokinetics are important for designing optimal dosing regimens, and physiologically-based pharmacokinetic (PBPK) models are used to predict a compound's actions in target organs."( Development of a Physiologically-Based Pharmacokinetic Model of Δ
Kaewworasut, P; Lohitnavy, M; Methaneethorn, J; Naosang, K; Poomsaidorn, C, 2020
)
0.56
" Most prior controlled pharmacokinetic evaluations of cannabis have focused on smoked cannabis and included males who were frequent cannabis users."( Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.
Bigelow, GE; Cone, EJ; Flegel, R; Herrmann, ES; LoDico, C; Mitchell, JM; Spindle, TR; Vandrey, R, 2020
)
0.56
" Importantly, pharmacokinetic interactions of alcohol and THC were observed during pregnancy."( Combined vapor exposure to THC and alcohol in pregnant rats: Maternal outcomes and pharmacokinetic effects.
Breit, KR; Lei, A; Rodriguez, CG; Thomas, JD,
)
0.13
"To develop a population pharmacokinetic (PP) model of delta-9-tetrahydrocannabinol (THC) and its metabolites in blood and to determine the relationship between blood THC pharmacokinetics and results of on-site oral fluid (OF) testing in chronic (CC) and occasional (OC) cannabis users."( Population pharmacokinetic model of blood THC and its metabolites in chronic and occasional cannabis users and relationship with on-site oral fluid testing.
Alvarez, JC; Derridj-Ait-Younes, N; Etting, I; Hartley, S; Larabi, IA; Ribot, M; Simon, N; Verstuyft, C, 2021
)
0.62
" The plasma half-life of THC is 1 to 3 days in occasional users and 5 to 13 days in chronic users."( Mechanisms of Action and Pharmacokinetics of Cannabis.
Chayasirisobhon, S, 2020
)
0.56
" Population pharmacokinetic modeling of plasma THC and metabolite concentrations by incorporating self-reported and weighed products as covariates could improve estimates of THC exposure in regular cannabis users."( Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado.
Bidwell, LC; Christians, U; Henthorn, TK; Huestis, MA; Hutchison, K; Klawitter, J; Sempio, C, 2021
)
0.62
"Inclusion of self-reported questionnaire data of THC consumption improved pharmacokinetic model-derived estimates based on measured THC and metabolite concentrations."( Using Population Pharmacokinetic Modeling to Estimate Exposure to Δ9-Tetrahydrocannabinol in an Observational Study of Cannabis Smokers in Colorado.
Bidwell, LC; Christians, U; Henthorn, TK; Huestis, MA; Hutchison, K; Klawitter, J; Sempio, C, 2021
)
0.62
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, decision-making surrounding appropriate dosing of cannabis used for medical purposes is limited."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
" The computational results demonstrated that multiple parameters had noticeable influences on THC particle deposition and vapor absorption in the upper airways, as well as the resultant pharmacokinetic behaviors."( Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study.
Arden, NS; Feng, Y; Taylor, C; Tian, G; Zhao, J, 2021
)
0.62
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, informed physician and patient decision-making surrounding appropriate dosing of cannabis for medical purposes is limited."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
"3 h, n = 18), and oral dose formulation significantly impacted mean Cmax (Epidiolex = 1,274 ng/mL, capsule = 776 ng/mL, syrup = 151 ng/mL, n = 6/group) with little difference in Tmax."( Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Kuntz, D; Mitchell, JM; Sholler, DJ; Spindle, TR; Vandrey, R; Winecker, RE, 2022
)
0.72
" Our results provide evidence of different pharmacokinetic profiles following inhalation versus injection."( Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats.
Aukema, RJ; Baglot, SL; Borgland, SL; Brechenmacher, L; Grace, LM; Hill, MN; Hume, C; Lightfoot, SHM; McLaughlin, RJ; Parker, L; Petrie, GN; Rho, JM; Zhou, R, 2021
)
0.62
" Although high serum concentrations of M7 (and other active metabolites) have been suggested to contribute to 5F-MDMB-PINACA toxicity, the affinity of M7 for CB1 receptors is unknown and more complete pharmacodynamic characterization of 5F-MDMB-PINACA and its active metabolites is needed."( Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.
Cabanlong, CV; Fantegrossi, WE; Prather, PL; Russell, LN, 2022
)
0.72
" This within-subject, double-blind, double-dummy, placebo-controlled laboratory study analyzed the pharmacokinetic profile of CBD, ∆9-tetrahydrocannabinol (∆9-THC) and related metabolites in blood and oral fluid (OF) after participants (n = 18) administered 100 mg of CBD in each of the following formulations: (1) oral CBD, (2) vaporized CBD and (3) vaporized CBD-dominant cannabis containing 10."( Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria, CL; Bigelow, GE; Cone, EJ; Flegel, R; Goffi, E; Mitchell, JM; Sholler, D; Spindle, TR; Vandrey, R; Winecker, RE, 2022
)
0.72
" Dependent measures included pharmacokinetic assessment of THC and cocaine and their respective metabolites, in addition to subjective and cardiovascular effects."( Smoked cannabis reduces peak cocaine plasma levels and subjective effects in a controlled drug administration study of polysubstance use in men.
Bedi, G; Cooper, ZD; Foltin, RW; Haney, M; Manubay, J; Murray, CH, 2023
)
0.91
" Relative to CYP cocktail + Δ9-THC, CYP cocktail + Δ9-THC + CBD produced a higher Cmax and area under the plasma concentration vs time curve for Δ9-THC, 11-OH-Δ9-THC, and Δ9-THC-COOH."( Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Bansal, S; Paine, MF; Spindle, TR; Surujunarain, R; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA, 2023
)
0.91
" Cannabidiol, Δ9-tetrahydrocannabinol, cannabinol, cannabichromene, cannabigerol, cannabidiolic acid, cannabigerolic acid, Δ9-tetrahydrocannabinolic acid, and 5 specific metabolites were measured by liquid chromatography-tandem/mass-spectrometry, and pharmacokinetic parameters were calculated."( Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile.
Beaufrère, H; Gomez, B; Guzman, DS; Knych, H; Lyubimov, A; Sosa-Higareda, M; Zakharov, A, 2023
)
0.91
" For the multiple-dose study, cannabidiol/cannabidiolic acid mean Cmax was 337."( Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile.
Beaufrère, H; Gomez, B; Guzman, DS; Knych, H; Lyubimov, A; Sosa-Higareda, M; Zakharov, A, 2023
)
0.91
"The goal of pharmacokinetic (PK) studies is to provide a basis for appropriate dosing regimens with novel therapeutic agents."( A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals.
Schwark, WS; Wakshlag, JJ, 2023
)
0.91
"We sought to characterize the pharmacokinetic and phenotypic profile of acutely inhaled THC in female rats, compared to intraperitoneal injection, to identify any differences in exposure of THC between routes of administration."( Vaporized Delta-9-tetrahydrocannabinol Inhalation in Female Sprague Dawley Rats: A Pharmacokinetic and Behavioral Assessment.
Berthold, EC; Blum, K; Eiden, RD; Hammond, N; McCurdy, CR; Mihalkovic, A; Penman, SL; Sharma, A; Thanos, PK, 2023
)
0.91
" A systematic pharmacokinetic study was performed to determine whether there are differences in the pharmacokinetic parameters and systemic exposure of CBD after oral dosing as an isolate, broad-spectrum, or full-spectrum product."( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thus, THC in combination with other drugs seems to be a much more frequent reason for impairment than THC alone among Norwegian drugged drivers."( Impairment in drivers due to cannabis in combination with other drugs.
Gjerde, H; Kinn, G,
)
0.13
" The effects of cocaine alone and in combination with d-amphetamine, caffeine, morphine or delta-9-tetrahydrocannabinol were determined in five male white Carneaux pigeons responding under a multiple fixed-ratio 30, fixed-interval 600 schedule (mult FR FI)."( The effects of cocaine in combination with other drugs of abuse on schedule-controlled behavior in the pigeon.
Evans, EB; Wenger, GR, 1990
)
0.28
"32-10 mg/kg) was administered with scopolamine (0."( Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys.
Moerschbaecher, JM; Nakamura-Palacios, EM; Winsauer, PJ, 2000
)
0.31
"A headspace solid-phase microextraction combined with GC-MS method was developed for the extraction and analysis of cannabinoids from Cannabis samples."( Extraction and analysis of different Cannabis samples by headspace solid-phase microextraction combined with gas chromatography-mass spectrometry.
Christen, P; Ilias, Y; Mathieu, P; Rudaz, S; Veuthey, JL, 2005
)
0.33
" alone and in combination with at least one dose of rimonabant."( Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon, LR, 2009
)
0.35
" tropisetron) combined with dexamethasone are effective for the acute phase of cisplatin (CIS)-induced emesis."( The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.
Darmani, NA; McClanahan, BA; Ray, AP; Wang, Y, 2009
)
0.35
"A method was developed for the determination of Delta(9)-Tetrahydrocannabinol (THC) in saliva by polymer monolith microextraction (PMME) combined with gas chromatography-mass spectrometry."( Rapid determination of Delta9-Tetrahydrocannabinol in saliva by polymer monolith microextraction combined with gas chromatography-mass spectrometry.
Chen, F; Feng, YQ; Luo, D; Xiao, K, 2009
)
0.35
"A simple, rapid and highly sensitive method for the analysis of THC-COOH in urine, using automated on-line solid-phase extraction (SPE) combined with liquid chromatography (LC)-mass spectrometry (MS/MS), is developed and fully validated according to international guidelines."( On-line solid-phase extraction combined with liquid chromatography-tandem mass spectrometry for high throughput analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in urine.
De Boeck, G; Fernández, Mdel M; López-Rivadulla, M; Samyn, N; Wille, SM; Wood, M, 2009
)
0.35
"5 h); (3) MDMA in combination with alcohol or THC; and (4) placebo."( Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol).
Buitelaar, JK; Dumont, GJ; Lansbergen, MM; van Gerven, JM; Verkes, RJ, 2011
)
0.37
" The goals of this study were to examine the safety and efficacy of a potential treatment medication, modafinil, in combination with oral ∆9-tetrahydrocannabinol (THC)."( The safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans.
Poling, J; Sofuoglu, M; Sugarman, DE, 2011
)
0.37
"This placebo-controlled study examined the effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory measure of relapse."( Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Ramesh, D; Reed, SC, 2016
)
0.43
"Both medication conditions decreased withdrawal-related disruptions in sleep, but only zolpidem in combination with nabilone decreased withdrawal-related disruptions in mood and food intake relative to placebo."( Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Ramesh, D; Reed, SC, 2016
)
0.43
"Clinical testing of nabilone, either alone, or in combination with zolpidem is warranted."( Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Herrmann, ES; Ramesh, D; Reed, SC, 2016
)
0.43
"To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways would be predicted to result in clinically significant drug-drug interactions (DDIs) with commonly prescribed psychotropic agents."( Drug-drug interactions as a result of co-administering Δ
Alageel, A; Almatham, F; Carmona, NE; Ho, RC; Lee, YL; Mansur, R; McIntyre, RS; Pan, Z; Ragguett, RM; Rong, C; Rosenblat, JD; Shekotikhina, M; Subramaniapillai, M, 2018
)
0.48
"Nabiximols in combination with MET/CBT was well tolerated and allowed for reduction of cannabis use."( Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
Barnes, AJ; Fischer, B; George, TP; Huestis, MA; Le Foll, B; Quilty, LC; Rehm, J; Selby, P; Soliman, A; Staios, G; Streiner, DL; Trigo, JM, 2018
)
0.48
"Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale."( Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
Kawohl, W; Pichler, EM; Roser, P; Seifritz, E, 2019
)
0.51
"We have reported a case of a drug-drug interaction (DDI) involving warfarin and Δ-9-tetrahydrocannabinol (THC) that resulted in a supratherapeutic international normalized ratio (INR) level."( Δ-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR.
Bellnier, TJ; Brown, GW; Janda, M; Miskowitz, K,
)
0.13
"Our model is a useful tool for predicting the pharmacokinetics of lenabasum and adjustments to its dosing in possible drug-drug interaction scenarios."( A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum.
Atamas, SP; Fu, Q; Jones, HM; Sun, G, 2021
)
0.62
"The legalization of cannabis in many parts of the United States and other countries has led to a need for a more comprehensive understanding of cannabis constituents and their potential for drug-drug interactions."( Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Lazarus, P; Nasrin, S; Perez-Paramo, YX; Watson, CJW, 2021
)
0.62

Bioavailability

The FDA-approved synthetic analog of THC, nabilone, has higher bioavailability and clearer dose-linearity than dronabinol.

ExcerptReferenceRelevance
"Oral administration of delta-9-tetrahydrocannabinal (delta 9-THC) was shown to result in low and erratic bioavailability, while the drug showed no bioavailability from various suppository formulations."( Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys.
ElSohly, MA; Harland, EC; Hikal, AH; Jones, AB; Little, TL; Rider, JN; Stanford, DF; Walker, LA, 1991
)
0.28
"The bioavailability of delta-9-tetrahydrocannabinol (delta 9-THC) from suppository formulations containing several polar esters was studied."( Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters.
Elsohly, MA; Harland, E; Hikal, A; Little, TL; Stanford, DF; Walker, L, 1991
)
0.28
" The THC plasma concentrations, ratings of "high" and heart rate effects produced by the combined drug administration were measured, and absolute bioavailability of smoked THC was calculated on Days 1 and 22."( The pharmacologic effects of daily marijuana smoking in humans.
Cook, CE; Hicks, RE; Jeffcoat, AR; McDonald, SA; Perez-Reyes, M; White, WR, 1991
)
0.28
"Oral delta 9-tetrahydrocannabinol (THC) in gelatin capsules is under evaluation as an antiemetic agent in cancer patients, but knowledge concerning its bioavailability is incomplete and, furthermore, alternative routes of administration may be desirable."( Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.
Almirez, R; Cradock, JC; Flora, KP; Nichols, AI; Peck, CC; Perlin, E; Smith, CG, 1985
)
0.27
" A comparison of the results for AUC/dose (delta 9-THC) after oral dosing with comparable data from intravenous administration indicated bioavailability of the order of 10% to 20% for both sexes."( Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
Brine, D; Perez-Reyes, M; Sadler, BM; Taylor, H; Wall, ME, 1983
)
0.27
"2 ng/ml) and the apparent bioavailability as determined by area under the curve (AUC) analysis."( Marihuana smoking increases plasma cocaine levels and subjective reports of euphoria in male volunteers.
Fukuzako, H; Kouri, E; Lukas, SE; Mendelson, JH; Sholar, M, 1994
)
0.29
" The bioavailability resulting from the oral formulation was 45-53% relative to the rectal route of administration, due to a lower absorption and higher first-pass metabolism."( The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.
Brenneisen, R; Egli, A; Elsohly, MA; Henn, V; Spiess, Y, 1996
)
0.29
" Research studies with experienced heroin and cocaine users indicated that an intranasally administered drug generally provided lower blood concentrations of drug and a slower onset of action compared to the intravenous route; however, intranasal doses are easily manipulated by the user and adequate bioavailability and desired drug effects can be achieved."( Recent discoveries in pharmacokinetics of drugs of abuse.
Cone, EJ, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The aim of this study was to develop a dry powder formulation that stabilises the chemically labile lipophilic Delta(9)-tetrahydrocannabinol (THC), that rapidly dissolves in water in order to increase the bioavailability and that opens new routes of administration."( Solid dispersions based on inulin for the stabilisation and formulation of delta 9-tetrahydrocannabinol.
Eissens, AC; Frijlink, HW; Hinrichs, WL; van Drooge, DJ; Visser, MR; Wegman, KA, 2004
)
0.32
" The bioavailability of the pulmonal THC was 28."( Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans.
Brenneisen, R; Naef, M; Petersen-Felix, S; Russmann, S, 2004
)
0.32
" The absolute bioavailability (F) of THC decreased in the following order: sublingual THC/RM-beta-CD solution (F = 12."( Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.
Jarho, P; Järvinen, K; Järvinen, T; Mannila, J; Tarvainen, M, 2005
)
0.33
" Whether the increase in THC levels causes increased health risks for users can only be concluded when more data are available on adjusted patterns of use, abuse liability, bioavailability and levels of THC in the brain."( Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops.
Goldschmidt, HM; Hoek, J; Niesink, RJ; Pijlman, FT; Rigter, SM, 2005
)
0.33
"The bioavailability of Delta(9)-tetrahydrocannabinol (THC) was determined after its sublingual administration as solid THC/beta-cyclodextrin (THC/beta-CD) complex, and was compared to oral administration of ethanolic THC, in rabbits."( Sublingual administration of Delta9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits.
Jarho, P; Järvinen, K; Järvinen, T; Mannila, J; Tervonen, J, 2006
)
0.33
" Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6."( Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats.
Agu, RU; Earles, DC; Hammell, DC; Paudel, KS; Stinchcomb, AL; Valiveti, S; Wermeling, DP, 2007
)
0.34
"The aim of this article was to investigate the role of intestinal lymphatic transport in the oral bioavailability of two structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220."( Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220.
Amselem, S; Gershkovich, P; Hoffman, A; Qadri, B; Yacovan, A, 2007
)
0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" As a consequence, the oral bioavailability of THC and digoxin was higher in naturally P-gp-deficient mice."( Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Abbara, C; Benyamina, A; Bonhomme-Faivre, L; Farinotti, R; Reynaud, M, 2008
)
0.35
" After smoking THC bioavailability averages 30%."( [Delta-9-tetrahydrocannabinol pharmacokinetics].
Goullé, JP; Lacroix, C; Saussereau, E, 2008
)
0.35
" Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
" A further aim was to investigate the effect of nasally administered chitosan-based nasal bioadhesive gel on THC bioavailability as a formulation strategy to decrease normal mucociliary drug clearance."( Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits.
Al-Ghananeem, AM; Crooks, PA; Malkawi, AH, 2011
)
0.37
" The absolute bioavailability of THC after nasal delivery was studied to compare plasma THC concentrations after nasal administration with those after intravenous injection."( Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits.
Al-Ghananeem, AM; Crooks, PA; Malkawi, AH, 2011
)
0.37
" The synthetic THC analogue, nabilone, has better bioavailability than dronabinol."( Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Bedi, G; Cooper, ZD; Haney, M, 2013
)
0.85
" The intravenous route has the most reliable pharmacokinetics, reducing inter-individual variation in bioavailability and is well suited for the delivery of synthetic compounds containing a sole pharmacological moiety."( Cannabis in the arm: what can we learn from intravenous cannabinoid studies?
Englund, A; Morrison, PD; Stone, JM, 2012
)
0.38
"To assess the effect of food on the single-dose bioavailability of delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) spray, an endocannabinoid system modulator, when administered to healthy male subjects."( A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013
)
0.39
" The bioavailability of THC was greater than CBD at single and multiple doses, and there was no evidence of accumulation for any analyte with multiple dosing."( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013
)
0.39
" The FDA-approved synthetic analog of THC, nabilone, has higher bioavailability and clearer dose-linearity than dronabinol."( Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Bedi, G; Comer, SD; Cooper, ZD; Foltin, RW; Haney, M; Vosburg, SK, 2013
)
0.6
"To establish a fast sensitive, reproducible LC-MS/MS method to study pharmacokinetic properties of THC, and compare relative bioavailability of THC and its solid dispersion in mice."( [Pharmacokinetics and relative bioavailability of THC and THC-solid dispersion orally to mice at single dose].
Hua, H; Liao, L; Luo, H; Yang, AD; Zhao, JN, 2014
)
0.4
" This increase has important implications not only for the pharmacokinetics but also for the pharmacology of THC The mean bioavailability of THC in smoked cannabis is about 25%."( [Tetrahydrocannabinol pharmacokinetics; new synthetic cannabinoids; road safety and cannabis].
Goullé, JP; Guerbet, M, 2014
)
0.4
" Δ9-THC was well absorbed with a mean tmax of 123 min."( Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
de Vries, M; Van Goor, H; Van Rijckevorsel, DC; Vissers, KC; Wilder-Smith, OH, 2016
)
0.43
" A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose-concentration and concentration-response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population."( Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome.
Martin, JH; Reuter, SE, 2016
)
0.43
"" Lack of standardization, bioavailability issues, and ultimately prohibition were all factors in cannabis-based medicines failing to maintain mainstream usage in seizure treatment, but investigation was resumed in the 1970s with interesting signals noted in both laboratory and clinical settings."( Cannabis and epilepsy: An ancient treatment returns to the fore.
Russo, EB, 2017
)
0.46
" Study objectives were to evaluate the safety and tolerability of PTL101 containing 10 and 100 mg CBD, following single administrations to healthy volunteers and to compare the pharmacokinetic profiles and relative bioavailability of CBD with Sativex oromucosal spray (the reference product) in a randomized, crossover study design."( Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Atsmon, J; Deutsch, F; Deutsch, L; Heffetz, D; Sacks, H, 2018
)
0.48
" The oral bioavailability of THC and CBD is very low due to extensive "first-pass" metabolism."( PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Atsmon, J; Cherniakov, I; Deutsch, F; Deutsch, L; Domb, AJ; Heffetz, D; Hoffman, A; Izgelov, D; Sacks, H, 2018
)
0.48
" A larger AUC was found in the fasted group; the relative oral bioavailability in fed animals was 48."( Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study.
Chericoni, S; Giorgi, M; Lisowski, A; Owen, H; Poapolathep, A; Stefanelli, F; Łebkowska-Wieruszewska, B, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when the medication is co-administered with a high-fat meal."( Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.
Bialer, M; Perucca, E, 2020
)
0.56
" The bioavailability of inhaled THC is 10% to 35%."( Mechanisms of Action and Pharmacokinetics of Cannabis.
Chayasirisobhon, S, 2020
)
0.56
" These include low oral bioavailability due to hepatic degradation, gastric instability, poor water solubility, and the side effects experienced upon the use of high doses of psychotropic cannabinoids associated with heightened plasma concentrations of the drug."( Delivering therapeutic cannabinoids via skin: Current state and future perspectives.
Chukwunyere, UI; Frempong, D; Mishra, D; Puri, A; Thakur, D; Tijani, AO, 2021
)
0.62
" However, the potential therapeutic use of cannabis and cannabinoids for the treatment of respiratory diseases has not been widely investigated, in part because of local irritation of airways by needing to smoke the cannabis, poor bioavailability when administered orally due to the lipophilic nature of cannabinoids, and the psychoactive effects of Δ9-Tetrahydrocannabinol (Δ9-THC) found in cannabis."( The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Clarkson, N; Horniman, N; Keir-Rudman, S; Page, C; Robaina Cabrera, CL, 2021
)
0.62
" The water-soluble cannabis-based medicine provided acceptable bioavailability for Δ9-THC/CBD, appeared safe and tolerable in advanced incurable cancers with uncontrolled pain with preliminary evidence of analgesic efficacy."( Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain.
Butcher, BE; Clarke, S; Hall, S; Henson, JD; McLachlan, AJ; Rutolo, D; Vitetta, L, 2022
)
0.72
"There was an increase in the oral bioavailability of CBD (12% and 21% in male and female rats, respectively) when administered as a full-spectrum product compared with the isolate and broad-spectrum products."( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023
)
0.91
"2% THC increased the oral bioavailability of CBD in male and female rats, indicating that full-spectrum products may produce increased effectiveness of CBD due to a greater exposure available systemically."( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023
)
0.91

Dosage Studied

Dronabinol has psychoactive effects in a dose-response relationship, whose peak effects are comparable with smoking marijuana. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinols abstinence. These results have important implications for future dosing strategies.

ExcerptRelevanceReference
"In the course of examining the complete dose-response relationship for the behavioral effects of LSD in the cat, we discovered that, in addition to large increases in investigatory and hallucinatory-like responses, two behaviors, not previously reported, are emitted with a high probability under LSD."( Behavioral effects of LSD in the cat: proposal of an animal behavior model for studying the actions of hallucinogenic drugs.
Jacobs, BL; Stern, WC; Trulson, ME, 1977
)
0.26
" In the second series of experiments the dose-response curve of morphine for the motor activity has been found to shift to the left by the pretreatment of mice with 10 mg/kg of THC."( Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice.
Ayhan, IH; Kaymakçalan, S; Tulunay, FC, 1979
)
0.26
" Four subjects were studied for 3 baseline nights, 3 nights under initial dosage of 70 mg/day, the last 3 nights of a 2-wk period of 210 mg/day, and the first 3 nights of withdrawal."( Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man.
Cavness, C; Feinberg, I; Jones, R; March, J; Walker, JM, 1975
)
0.25
"The present study examines the dose-response pattern of delta 9-tetrahydrocannabinol self-injection in naive rats at 80% reduced body weight and 100% body weight, both conditions with a fixed-time 1 min (FT-1) food delivery schedule."( Self-administration of delta 9-tetrahydrocannabinol by rats.
Singer, G; Takahashi, RN, 1979
)
0.26
" Neither multiple preimmunization dosings nor a single postimmunization dosing was effective."( Alterations in murine delayed type hypersensitivity responses by delta-8-THC and cannabinol.
Heppner, GH; Levy, JA,
)
0.13
" Ratings of potency and changes in pulse rate were highly correlated, but this relationship did not hold within a given dosage group as determined by partial correlations."( Marijuana: dose-response effects on pulse rate, subjective estimates of potency, pleasantness, and recognition memory.
Brightwell, D; Cornett, T; Drew, W; McFarland, D; Miller, L; Wikler, A, 1977
)
0.26
"Recent advances in development of immunoassay methods for marijuana constituents in body fluids provide a rapid means of detection for forensic purposes and a useful research tool for accurate quantitation of dose-response relation."( Cannabis, 1977.
, 1978
)
0.26
" We report now the dose-response relationship of precoital single doses of delta9-THC on luteinizing hormone (LH) release and ovulation in the rabbit."( Precoital single doses of delta9-tetrahydrocannabinol block ovulation in the rabbit.
Asch, RH; Fernandez, EO; Pauerstein, CJ; Smith, CG, 1979
)
0.26
" Both of two dosage levels of THC, similar to an amount ingested by a human from a single cigarette, significantly elevated the absolute visual threshold of all animals."( Delta 9-tetrahydrocannabinol: elevation of absolute visual thresholds of rabbits.
Dwyer, WO; Rose, SE; Yehle, AL, 1979
)
0.26
" With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo."( Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Creagan, ET; Frytak, S; Moertel, CG; O'Connell, MJ; O'Fallon, JR; Rubin, J; Schutt, AJ; Schwartau, NW, 1979
)
0.26
" A dose-response effect was apparent."( Nabilone: a potent antiemetic cannabinol with minimal euphoria.
Dean, J; Dorr, R; Herman, TS; Jones, SE; Leigh, S; Moon, TE; Salmon, SE, 1977
)
0.26
" Tolerance to the antiepileptic effects of THC developed very rapidly when the drugs were give repeatedly, and there was evidence that the repeated administration of a high dosage of delta9-THC resulted in a state of acute physical dependence."( Antiepileptic and prophylactic effects of tetrahydrocannabinols in amygdaloid kindled rats.
Corcoran, ME; McCaughran, JA; Wada, JA, 1978
)
0.26
" Total daily drug intake was related to the unit dose delivered per injection in that a higher drug dosage led to more drug intake."( Intravenous self-administration of drugs in rats.
de Wied, D; Slangen, JL; van Ree, JM, 1978
)
0.26
" 3 Clomipramine modified these responses of delta9-THC in that the dose-response curves appeared to be shifted to the right."( Antagonism of the effects on thermoregulation of delta9-tetrahydrocannabinol by clomipramine in the rat.
Fennessy, MR; Taylor, DA, 1978
)
0.26
" Intrusion errors increased following intoxication but this effect was not systematically related to dosage of delta9-THC."( Marijuana: dose effects on pulse rate, subjective estimates of intoxication, free recall and recognition memory.
Cornett, TL; Miller, LL, 1978
)
0.26
" Maximal effective dosage of THC was 15 mg/kg with higer dosages of 30 and 60 mg/kg producing a decrease from maximum in locomotor activity."( Stimulant actions of delta9-tetrahydrocannabinol in mice.
Brown, DJ; Evans, MA; Forney, RB; Harbison, RD, 1976
)
0.26
" When animals were dosed on consecutive days with delta9-tetrahydrocannabinol and killed on the third day, thymidine-3H incorporation was increased while delta8-tetrahydrocannabinol retained its inhibitory activity under the same conditions."( Effects of cannabinoids on L1210 murine leukemia. 1. Inhibition of DNA synthesis.
Friedman, MA; Tucker, AN, 1977
)
0.26
" Food and water consumption were dramatically reduced by each test drug at feeding periods immediately following and in some instances up to 4 days after dosing in all 3 groups."( Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats.
Knobloch, LC; Sofia, RD, 1976
)
0.26
" Delta-THC in a dosage of 1 mg/kg had no effect on avoidance learning."( The effect of delta 9-tetrahydrocannabinol and LSD on the acquisition of an active avoidance response in the rat.
Heer-Carcano, L; Martin, A; Waser, PG, 1976
)
0.26
" Significant differential dosage differences were obtained in terms of disruption of cognitive processes, and emotional tone."( The effects of marijauna on verbalization and thought processes.
Clark, C; Crockett, D; Klonoff, H, 1976
)
0.26
" Six rabbits bearing chronically implanted cortical and hippocampal electrodes were dosed intravenously with delta6-THC (2."( EEG spectral analysis for the evaluation of the central effects of delta6-tetrahydrocannabinol in rabbits.
Loizzo, A; Longo, VG; Willinsky, MD, 1975
)
0.25
" The dosing schedules for SKF-525A and phenobarbital were sufficient to alter hexobarbital sleeping time significantly, but they did not affect the normal VI 60 sec performance."( Tolerance development to the effect of delta9-tetrahydrocannabinol on conditioned behavior: role of treatment interval and influence of microsomal metabolism.
Borgen, LA; Davis, WM, 1975
)
0.25
" Marihuana produced significant dose-response effects of impaired performance in all test scores."( Dose effects of smoked marihuana on human cognitive and motor functions.
Alpert, M; Borg, J; Gershon, S, 1975
)
0.25
" When mice were dosed and tested at 24 hrs intervals it was apparent that tolerance was complete to its hypothermic and locomotor depressant effects after the first doses and to depression of intestinal motility after the fourth dose."( Tolerance to the effect of delta9-tetrahydrocannabinol in mice on intestinal motility, temperature and locomotor activity.
Anderson, PF; Chesher, GB; Jackson, DM; Malor, R, 1975
)
0.25
" Comparison of the dose-response data indicated that some other constituents of cannabis may reduce the Flight reaction from delta-9-tetrahydrocannabinol although not interfering with Immobility."( Effects of delta-9-tetrahydrocannabinol on social behaviour in the laboratory mouse and rat.
Cutler, MG; Mackintosh, JH, 1975
)
0.25
" No teratogenic effects were visible with the dosage schedules used."( Effects of delta9-tetrahydrocannabinol and ethanol on body weight protein and nucleic acid synthesis in chick embryos.
Jakubović, A; McGeer, PL, 1976
)
0.26
" Dosing (30 mg/kg intragastrically) continued once daily, 3 hr before testing, for 1 to 6 weeks."( Chronic delta-9-tetrahydrocannabinol. Transient and lasting effects on avoidance behavior.
Manning, RJ, 1976
)
0.26
"The purpose of this study was to determine marijuana dose-effects on subjective and performance measures over a wider dosage range than previously reported using technology which allowed for specification of both the volume and delta 9-tetrahydrocannabinol (THC) content of smoke delivered, and to relate these effects to plasma THC levels."( Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs.
Azorlosa, JL; Heishman, SJ; Mahaffey, JM; Stitzer, ML, 1992
)
0.28
" Methodologic weaknesses of opiate animal models, especially with respect of appropriate dosing schedules, have hampered meaningful extrapolation of these studies to human risk assessment."( Animal models of opiate, cocaine, and cannabis use.
Dow-Edwards, D; Hutchings, DE, 1991
)
0.28
"The acute dose-response effects of delta-9-tetrahydrocannabinol (THC), cannabinol (CBN) and cannabidiol (CBD) on gonadotropin and testosterone (T) secretion and on hypothalamic norepinephrine (NE) metabolism were tested in adult male rats."( Effects of psychoactive and nonpsychoactive cannabinoids on the hypothalamic-pituitary axis of the adult male rat.
Bartke, A; Murphy, LL; Smith, MS; Steger, RW, 1990
)
0.28
" Drug interactions were studied by redetermining the cocaine dose-response curve in the presence of various fixed doses of the other drugs."( The effects of cocaine in combination with other drugs of abuse on schedule-controlled behavior in the pigeon.
Evans, EB; Wenger, GR, 1990
)
0.28
"A dose-response study of the effect of orally administered delta 9-tetrahydrocannabinol (THC) on human mood and skills performance was conducted."( The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study.
Bird, KD; Chesher, GB; Jackson, DM; Perrignon, A; Starmer, GA, 1990
)
0.28
" Proper dosage and route of administration are additional important factors with such treatment."( Emergency treatments for police dogs used for illicit drug detection.
Beasley, VR; Dumonceaux, GA, 1990
)
0.28
" In the dosage of THC used no altered consciousness occurred."( Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.
Dittrich, A; Henn, V; Hofmann, A; Maurer, M, 1990
)
0.28
"Delta-9-tetrahydrocannabinol (THC) was administered by gastric intubation to pregnant rats to study the effects of dose-level and dosing regimen on plasma concentration in dams and fetuses."( Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats.
Fico, T; Gamagaris, Z; Hutchings, DE; Martin, BR; Miller, N, 1989
)
0.28
" Dose-response curves comparing TDx and EMIT gave paralell results, with comparable cross-reactivity for the major metabolite, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (delta-9-THC-COOH)."( Comparison of fluorescence polarization immunoassay, enzyme immunoassay, and thin-layer chromatography for urine cannabinoid screening. Effects of analyte adsorption and vigorous mixing of specimen on detectability.
Audette, L; Camara, P; Dextraze, P; Griffiths, WC; Rosner, M,
)
0.13
" In this experiment, we dosed the animals by gavage with 0, 5, 10 or 20 mg THC/kg daily, 5 days/week or with 20 mg THC/kg Monday through Thursday and 60 mg/kg on Friday for 90 days."( Effects of chronic delta-9-tetrahydrocannabinol (THC) administration on neurotransmitter concentrations and receptor binding in the rat brain.
Ali, SF; Brown, RM; Gee, KW; Newport, GD; Paule, MG; Scallet, AC; Slikker, W, 1989
)
0.28
" Simultaneous blood samples were obtained from a maternal uterine vein and an intraplacental artery at 0, 3, 15, 30, 45, 60, 90, 120, and 180 min after dosing using an intraplacental cannulation technique."( Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey.
Bailey, JR; Cunny, HC; Paule, MG; Slikker, W, 1987
)
0.27
" Rats dosed orally for 90 days with 10 to 60 mg/kg THC or vehicle were evaluated by light and electron microscopy up to 7 months after their last dose of drug."( Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC).
Ali, SF; Andrews, A; Brown, RM; McMillan, DE; Paule, MG; Scallet, AC; Slikker, W; Uemura, E, 1987
)
0.27
" This age-related difference was seen in the dose-response studies as well as in the studies with varying cell numbers in culture."( Age-associated differences in cannabinoid-induced suppression of murine spleen, lymph node and thymus cell blastogenic responses.
Friedman, H; Klein, TW; Newton, C; Pross, S, 1987
)
0.27
" While excellent antiemetic control was achieved at the dosage 15 mg/m2, dysphoria was encountered at this dose level and we recommend that an initial dose of 5 mg/m2 which, if necessary, can be carefully increased to achieve maximum antiemetic benefit."( Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
Goldberg, D; Macdonald, JS; McCabe, M; Schein, PS; Smith, FP; Woolley, PV, 1988
)
0.27
" These results provide a preliminary indication that solid-state NMR spectroscopy is a useful technique for the investigation of drug polymorphs and drugs in their dosage forms."( Analysis of solid-state Carbon-13 NMR spectra of polymorphs (benoxaprofen and nabilone) and pseudopolymorphs (cefazolin).
Byrn, SR; Frye, J; Gray, G; Pfeiffer, RR, 1985
)
0.27
" Cannabinol (CBN) showed the same activity but required a dosage of approximately eight times that of THC to produce an equivalent effect."( The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.
Chesher, GB; Jackson, DM, 1985
)
0.27
" Nabilone dosage should be reduced to decrease the incidence and degree of adverse reactions while leaving the definite antiemetic activity unchanged."( Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy.
Niederle, N; Schmidt, CG; Schütte, J, 1986
)
0.27
" All subjects received two consecutive identical cycles of chemotherapy with the trial antiemetics given in accordance to a body weight-based dosage schedule beginning eight to 12 hours before treatment."( Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
Chan, HS; Correia, JA; MacLeod, SM, 1987
)
0.27
" Thus, a dosage and regimen sufficient to cause significant decreases in the activities of steroidogenic enzymes had little effect on succinate and lactate dehydrogenases in rat preovulatory follicles."( The in vivo effects of tetrahydrocannabinol on the activity of lactate and succinate dehydrogenases in rat preovulatory follicles.
Buono, JQ; Zoller, LC, 1987
)
0.27
"3 A second cannabis extract (II) with a different ratio of cannabinoids (also administered in dosage equivalent to 10 mg Delta(9)-THC/kg) failed to affect pentobarbitone anaesthesia in mice."( Interaction of cannabis and general anaesthetic agents in mice.
Chesher, GB; Jackson, DM; Starmer, GA, 1974
)
0.25
" A significant decrement was found following dosage at both levels, replicating earlier findings of temporal disintegration during cannabis intoxication."( Cannabis and temporal disintegration in experienced and naive subjects.
Casswell, S; Marks, DF, 1973
)
0.25
" An effect of dosage on response was observed with cannabis."( Cannabis and alcohol: effects on stimulated car driving.
Bech, P; Christiansen, J; Christrup, H; Nyboe, J; Rafaelsen, L; Rafaelsen, OJ, 1973
)
0.25
" Autoradiograms showing the distribution of (14)C-cannabinoid 2 h after dosing are presented."( Distribution of delta 9-tetrahydrocannabinol in the mouse.
Freudenthal, RI; Martin, J; Wall, ME, 1972
)
0.25
" A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM."( Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes.
Fleming, RM; Howlett, AC, 1984
)
0.27
" Following discrimination training subjects were tested for generalization to five dosage levels (5, 10, 15, 20, 25 mg/kg) of phenobarbital."( Assessment of drug state dimensionality via drug-drug training and stimulus generalization testing.
Akins, FR; Gouvier, WD; Trapold, MA, 1984
)
0.27
" The following precautions are suggested to minimize the risks of potentially harmful pharmacons: 1) all unnecessary medications should be avoided by nrusing mothers; 2) if medication is necessary during lactation, drug dosage should be controlled and the infant should be monitored for adverse symptoms; 3) drugs should be administered shortly after breastfeeding and the interval prolonged before the next feeding; and 4) if the infant must be fed soon after a potentially harmful drug has been taken by the mother, bottle feeding is recommended."( Maternal drug use: evaluation of risks to breast-fed infants.
Groziak, SM; Kirksey, A, 1984
)
0.27
" A dose-response relationship (5-100 mg/kg) for the hypothermic effect of delta 9-THC was seen."( The mechanism of action of delta 9-tetrahydrocannabinol on body temperature in mice.
Davies, JA; Graham, JD, 1980
)
0.26
"The cardiovascular effects of repeated dosing with delta-9-tetrahydrocannabinol (THC) were examined in chronically catheterized, conscious rhesus monkeys."( The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys.
Benowitz, NL; Fredericks, AB; Savanapridi, CY, 1981
)
0.26
" The dose-response curve in the range of 5-50 ng/mL (serum or blood) was linear on log-logit transformation and iterative weighted regression."( delta 9-Tetrahydrocannabinol by GLC-MS validated radioimmunoassays of hemolyzed blood or serum.
Goebelsmann, U; Grant, JD; Gross, SJ; Soares, JR; Yeager, EP,
)
0.13
" Thus, CBC alone at this dosage did not act like THC; moreover, it antagonized the effects of THC when the two were given in combination."( Perinatal exposure to cannabichromene and delta 9-tetrahydrocannabinol: separate and combined effects on viability of pups and on male reproductive system at maturity.
Davis, WM; Elsohly, MA; Hatoum, NS; Turner, CE, 1981
)
0.26
"5 days after dosing with THC."( Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man.
Bachman, J; Herning, RI; Hunt, CA; Jones, RT, 1981
)
0.26
" Four separate protocols are described which will determine optimal dosage of oral THC in adults and children receiving cyclic chemotherapy and adults receiving chronic chemotherapy or radiotherapy, and the optimal dose for smoked marihuana."( The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.
Dow, GJ; Meyers, FH,
)
0.13
" In addition to central nervous system stimulation, THC usually elicited depression; the qualitative character of the effect of the drug was dependent upon the dosage and the test system."( Electrophysiologic properties of the cannabinoids.
Karler, R; Turkanis, SA,
)
0.13
" In contrast, cannabidiol, over a wide dosage range, caused only depression."( Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat.
Karler, R; Turkanis, SA, 1981
)
0.26
" 2 There were highly significant interactions between drug dosage and Extraversion and Neuroticism scores, so that the direction and degree of response to the different doses of delta 9THC depended on the personality characteristics of the subjects."( The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man.
Ashton, H; Golding, J; Marsh, VR; Millman, JE; Thompson, JW, 1981
)
0.26
" Comparisons were made on the basis of dose-response relationships."( Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.
Morton, EC; Vaupel, DB, 1982
)
0.26
" In animals initially anesthetized with pentobarbital, delta-9-THC over a wide dosage range produced only an enhancement of the reflex, whereas in methohexital-treated animals only depression was elicited."( Influence of different barbiturate anesthetics on delta-9-tetrahydrocannabinol effects on spinal monosynaptic reflexes.
Karler, R; Turkanis, SA, 1983
)
0.27
"The purpose of the present study was to examine the dose-response relationship and the therapeutic time window for the synthetic nonpsychotropic cannabinoid (HU-211) as a neuroprotective agent in transient, severe forebrain ischemia in the rat."( HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats.
Adamchik, J; Bar-Joseph, A; Belayev, L; Biegon, A, 1995
)
0.29
" Mean daily energy intake was significantly elevated following chronic dosing by rectal suppository, but not oral capsule, relative to all acute dosing regimens except inhalation."( Cannabinoids and appetite stimulation.
Elsohly, MA; Engelman, K; Mattes, RD; Shaw, LM, 1994
)
0.29
" Task performance measures were not reliably influenced by marijuana smoke exposure within the dosing ranges examined."( Marijuana smoking: effects of varying puff volume and breathhold duration.
Azorlosa, JL; Greenwald, MK; Stitzer, ML, 1995
)
0.29
"With many drugs of abuse, humans and other species display a preference for higher doses (or more potent dosage forms) over lower doses (or less potent dosage forms)."( Preference for high- versus low-potency marijuana.
Burke, KA; Chait, LD, 1994
)
0.29
" The first was a double-blind, placebo-controlled, acute oral dosing trial, involving an age and gender stratified sample of 57 adults."( Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults.
Engelman, K; Mattes, RD; Shaw, LM, 1994
)
0.29
" Dose-response curves were generated for both delta 9-THC (i."( Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Martin, BR; Smith, PB; Welch, SP, 1994
)
0.29
" The statistical distribution of the drug concentrations compared with the self-reported consumption behaviour of the users may possibly lead to a better understanding of the relationship between drug dosage and corresponding concentrations in hair."( Concentrations of delta 9-tetrahydrocannabinol, cocaine and 6-monoacetylmorphine in hair of drug abusers.
Kauert, G; Röhrich, J, 1996
)
0.29
" In all studies, mean body weights of dosed male and female rats and mice were lower than controls but feed consumptions were similar."( Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice.
Braun, AG; Bucher, JR; Chan, PC; Haseman, JK; Sills, RC, 1996
)
0.29
"We have recently described the dose-response effect of anandamide (AEA), the N-amide derivative of arachidonic acid that acts as an endogenous ligand for the cannabinoid receptor, on extrapyramidal function."( Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
de Miguel, R; Fernández-Ruiz, JJ; García-Palomero, E; Ramos, JA; Romero, J, 1995
)
0.29
" A dosing interval of 1 h leads to a continuous "high", and recovery will last about 150 minutes after the last joint."( Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana.
Harder, S; Rietbrock, S, 1997
)
0.3
" Following training, substitution tests using a cumulative dosing procedure revealed that anandamide (0."( (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
Burkey, RT; Nation, JR, 1997
)
0.3
" Using a dosing regimen known to produce pharmacological and behavioral tolerance, mice were treated with Delta9-tetrahydrocannabinol (Delta9-THC) twice a day for 1 wk."( CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook, SA; Lowe, JA; Martin, BR, 1998
)
0.3
" Available prescription tracking data indicates that use remains within the therapeutic dosage range over time."( Abuse potential of dronabinol (Marinol).
Calhoun, SR; Galloway, GP; Smith, DE,
)
0.46
" A secondary goal was to determine the accuracy of Drug Recognition Examiners (DREs) in detecting if subjects were dosed with these drugs."( Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana.
Crouch, DJ; Heishman, SJ; Singleton, EG, 1998
)
0.3
"Controlled human dosing studies with drugs of abuse have revealed the importance of the chosen route of administration on the delivery of drugs to the bloodstream and to their site of action."( Recent discoveries in pharmacokinetics of drugs of abuse.
Cone, EJ, 1998
)
0.3
" The dose-response curves for oxymorphone and hydromorphone were shifted 5- and 12."( Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz, DL; Martin, ZL; Smith, FL; Welch, SP, 1999
)
0.3
" CT-3 was devoid of GI ulceration when administered with DMSO either acutely at doses below 100 mg/kg or chronically at a dosage of 30 mg/kg/day for 5 days."( 1',1'-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties.
Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Mir, GN; Neeleman, SD; Shahwan, TG; Taylor, J; Taylor, MS, 1999
)
0.3
" In this study, we performed a dose-response study of the effects of Delta(9)-tetrahydrocannabinol on movement."( Activational role of cannabinoids on movement.
Fernandez-Ruiz, JJ; Romero, J; Sañudo-Peña, MC; Seale, GE; Walker, JM, 2000
)
0.31
"We examined the effects of Delta 9-tetrahydrocannabinol (Delta 9-THC), (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide ((R)-methanandamide, AM 356), SR 141716, and d-amphetamine on fixed-ratio (FR) responding maintained by food in rats before and during daily dosing with Delta 9-THC."( Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.
Goutopoulos, A; Järbe, TU; Lamb, RJ; Lin, S; Makriyannis, A, 2000
)
0.31
"The time course for the development of tolerance to delta-9-tetrahydrocannabinol (Delta(9)-THC) was studied in an effort to determine the role that length of dosing may have in the onset and maintenance of tolerance."( Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.
Bass, CE; Martin, BR, 2000
)
0.31
" Moreover, cannabis increases the risk of head and neck cancer in a dose-response manner for frequency and duration of use."( [Cannabis and cancer].
Carriot, F; Sasco, AJ, 2000
)
0.31
" JTE-907 dosed orally inhibited carrageenin-induced mouse paw edema dose dependently."( In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Inaba, T; Iwamura, H; Kaya, T; Suzuki, H; Ueda, Y, 2001
)
0.31
" We suggest that the increase in phobic anxiety is mainly due to the fact that a single-dose treatment rules out the possibility of administering the dosage slowly."( Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
Emrich, HM; Jöbges, M; Koblenz, A; Kolbe, H; Müller-Vahl, KR; Schneider, U, 2001
)
0.31
"3 and 1 mg/kg) produced rightward shifts in the Delta9-THC dose-response curve for Delta9-THC-appropriate responding and for (R)-methanandamide-appropriate responding (surmountable antagonism)."( (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Järbe, TU; Lamb, RJ; Lin, S; Makriyannis, A, 2001
)
0.31
" to nude mice at a dosage several orders of magnitude below that which produces toxicity, inhibited the growth of subcutaneously implanted U87 human glioma cells modestly but significantly."( Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Burstein, S; Jang, T; Karim, P; Kubiatowski, T; Litofsky, NS; Pipia, G; Recht, LD; Rosetti, R; Ross, AH; Salmonsen, R; Zurier, R, 2001
)
0.31
" Intraperitoneal administration resulted in an "inverted U" dose-response curve at all time points, while all central doses resulted in increased intake early in the time course and the hyperphagic effects were of greater duration than those following peripheral administration."( Delta9-tetrahydrocannabinol stimulates palatable food intake in Lewis rats: effects of peripheral and central administration.
Koch, JE; Matthews, SM, 2001
)
0.31
" The first series of experiments was designed to determine if Delta(9)-THC-mediated changes in cerebral metabolism followed a clear dose-response relationship."( Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland, CS; Miller, MD; Porrino, LJ; Whitlow, CT, 2002
)
0.31
" These data indicate that participants' choice to self-administer marijuana was unaltered by the oral Delta(9)-THC dosing regimen used in the present investigation."( Effects of oral THC maintenance on smoked marijuana self-administration.
Fischman, MW; Foltin, RW; Haney, M; Hart, CL; Ward, AS, 2002
)
0.31
" The pharmacokinetics of THC with its prolonged storage in fat and its slow release result in variable and delayed pharmacological response, which precludes precise dosing to achieve timely therapeutic effects."( A molecular basis of the therapeutic and psychoactive properties of cannabis (delta9-tetrahydrocannabinol).
Cancro, R; Harvey, DJ; Nahas, G; Sutin, K; Turndorf, H, 2002
)
0.31
" Antinociceptive dose-response curves were constructed for spinal Delta(9)-THC and WIN 55,212-2 in prodynorphin knock-out mice and in wild-type littermates."( Dynorphin-independent spinal cannabinoid antinociception.
Gardell, LR; Lai, J; Ossipov, MH; Porreca, F; Vanderah, TW, 2002
)
0.31
" Three patients had transient hypotension and intoxication with rapid initial dosing of THC-containing CME."( A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.
Aram, J; House, H; Makela, P; Robson, P; Wade, DT, 2003
)
0.32
" After dose-response and therapeutic time window-finding experiments, the rats were injected with HU-210 (45 microg/kg IV) or vehicle 1 hour after PMCAO."( Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210.
Gai, N; Leker, RR; Mechoulam, R; Ovadia, H, 2003
)
0.32
" After responding stabilized, dose-response curves were determined for other drugs."( Retention of sequential drug discriminations under fixed-interval schedules for long time periods without training.
Li, M; McMillan, DE, 2003
)
0.32
" The present study evaluated sex differences in the effects of acute and repeated dosing with Delta(9)-tetrahydrocannabinol on locomotor activity in male and female Swiss Webster (CFW) mice."( Sex-dependent effects of delta 9-tetrahydrocannabinol on locomotor activity in mice.
Wiley, JL, 2003
)
0.32
" This open label prospective study investigated the safety, tolerability and analgesic benefit of oral Delta-9-tetrahydrocannabinol (THC) titrated to a maximal dosage of 25 mg/day in 8 consecutive patients with chronic refractory neuropathic pain."( Are oral cannabinoids safe and effective in refractory neuropathic pain?
Atlami, S; Attal, N; Bouhassira, D; Brasseur, L; Clermond-Gnamien, S; Guirimand, D, 2004
)
0.32
" In one group of rats, we studied (1) acquisition of heroin self-administration behavior using a continuous-reinforcement (fixed-ratio (FR) 1) schedule, (2) heroin dose-response relationships using an FR1/variable-dose schedule, and (3) reinforcing efficacy of heroin using a progressive-ratio schedule."( Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy: a self-administration study in rats.
Goldberg, SR; Panlilio, LV; Solinas, M, 2004
)
0.32
" Sativex is a sublingual spray on Cannabis extract basis, and is equipped with an electronic tool to facilitate accurate dosing and to prevent misuses."( [A novel analgesics made from Cannabis].
Szendrei, K, 2004
)
0.32
" Moreover, increasing doses of carbidopa significantly shifted the inhibitory dose-response effect of delta-9-THC in protecting shrews from 5-HTP-induced emesis to the left."( Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani, NA; Johnson, JC, 2004
)
0.32
" Regimens for the use of the sublingual spray emerged and a wide range of dosing requirements was observed."( Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
Miller, R; Newport, S; Notcutt, W; Phillips, C; Price, M; Sansom, C; Simmons, S, 2004
)
0.32
"8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session."( Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
George, MP; Gustafson, RA; Huestis, MA; Kim, I; Klette, KL; Levine, B; Moolchan, ET; Stout, PR, 2004
)
0.32
" However, heroin, but not SNC-80 or U50488, significantly shifted the dose-response curve for THC discrimination to the left."( Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Goldberg, SR; Solinas, M, 2005
)
0.33
" Although the basis for this unique pharmacology has not as yet been determined, it is possible that regional specificity of cannabinoid CB1 receptor downregulation and endocannabinoid release induced by repeated dosing with Delta9-tetrahydrocannabinol may play a role."( Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.
Dewey, WL; Razdan, RK; Smith, FL; Wiley, JL, 2005
)
0.33
" The cytotoxic effects of KM-233 against human glioma cells in vitro occur as early as two hours after administration, and dosing of KM-233 can be cycled without compromising cytotoxic efficacy and while improving safety."( Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006
)
0.33
" Patients self titrate their overall dose and pattern of dosing according to their response to and tolerance of the medicine."( Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes, MP, 2006
)
0.33
" Moreover, dose-response curves of the agonists showed that mu and CB1 receptors mediating inhibition of [3H]glutamate release display a non-additive interaction, whereas these receptors synergistically interact regarding their inhibitory control of [3H]GABA release."( Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
De Vries, TJ; Hogenboom, F; Schoffelmeer, AN; Wardeh, G, 2006
)
0.33
" The study participants chose the dosage of the study drug themselves (between 1 und 4 capsules/day, in the case of nabilone this corresponds to (1/4)-1 mg/day)."( [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial].
Hiermann, E; Pinsger, M; Pölz, W; Riederer, F; Schimetta, W; Volc, D, 2006
)
0.33
" There was a 10-day washout period between each dosing regimen."( Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.
Barnes, A; Elsohly, M; Gustafson, RA; Huestis, MA; Nebro, W; Smith, ML, 2006
)
0.33
" Plasma specimens were collected during and after each dosing condition."( Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Barnes, A; Goodwin, RS; Gustafson, RA; Huestis, MA; Moolchan, ET; Nebro, W, 2006
)
0.33
"The objectives of the present research investigations were to (i) elucidate the mechanism for the oxidative degradation of Delta(9)-tetrahydrocannabinol (THC) in polymer matrix systems prepared by a hot-melt fabrication procedure, and (ii) study the potential for controlling these mechanisms to reduce the degradation of THC in solid dosage formulations."( Polymeric systems for amorphous Delta9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability.
Elsohly, MA; Munjal, M; Repka, MA, 2006
)
0.33
"), given 60 min before the test, exhibited a dose-response anxiolytic effect evaluated in terms of increase in the percentage of total entries and time spent in the open and decrease of total entries and time spent in the closed arms."( 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats.
Braida, D; Limonta, V; Malabarba, L; Sala, M; Zani, A, 2007
)
0.34
" Although Delta(9)-THC dose-effect functions were more similar across age after repeated exposure, subchronic dosing produced greater change in the hypothermic and locomotor effects of Delta(9)-THC in adolescents, but less change in its antinociceptive effects."( Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats.
O'connell, MM; Tokarz, ME; Wiley, JL; Wright, MJ, 2007
)
0.34
" Additional experiments with THC employed a dosing regimen that increased the number of injections, controlled for behavioral tolerance, examined different aspects of behavior, and used a different species (Sprague-Dawley rats)."( Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine.
Lichtman, AH; Martin, BR; Varvel, SA, 2007
)
0.34
" Although preliminary in nature, the actual urinary elimination half-life of THCCOOH appears to be significantly shorter than its apparent or terminal half-life reported from single or multiple dosing of delta-9-tetrahydrocannabinol (THC)."( The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans.
Aderjan, R; Dietz, L; Glaz-Sandberg, A; Mikus, G; Nguyen, H; Skopp, G, 2007
)
0.34
" Time-course and dose-response experiments indicate that DARPP-32 phosphorylation is maximal 30 min following administration of 10mg/kg of THC."( Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.
Borgkvist, A; Fisone, G; Fuxe, K; Greengard, P; Marcellino, D, 2008
)
0.35
" No tolerance to the benefit of Sativex on pain or sleep, nor need for dosage increases have been noted in safety extension studies of up to four years, wherein 40-50% of subjects attained good or very good sleep quality, a key source of disability in chronic pain syndromes that may contribute to patients' quality of life."( Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
Guy, GW; Robson, PJ; Russo, EB, 2007
)
0.34
" On the basis of our previous studies in male rats the third experiment assessed the dose-response relationship for the effects of THC on spatial learning and memory in female animals."( Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats.
Cha, YM; Jones, KH; Kuhn, CM; Swartzwelder, HS; Wilson, WA, 2007
)
0.34
" Recent agency guidance suggests that these obstacles are not insurmountable, although cannabis herbal material ("medical marijuana") may present fatal uncertainties of quality control and dosage standardization."( The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.
Barkin, RL; McCarberg, BH,
)
0.13
" However, the relationship between receptor adaptation and tolerance is not well understood, and the dose-response relationship of THC-induced cannabinoid receptor adaptation is unknown."( Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.
Cassidy, MP; Collier, LM; Martin, BR; McKinney, DL; Selley, DE; Sim-Selley, LJ; Wiley, JL, 2008
)
0.35
" Repeated injections of morphine caused a rightward shift in the morphine dose-response curve on Day 3 (i."( Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.
Maher, L; Morgan, MM; Wilson, AR, 2008
)
0.35
" A major active 11-hydroxy metabolite is formed after both inhalation and oral dosing (20 and 100% of parent, respectively)."( [Delta-9-tetrahydrocannabinol pharmacokinetics].
Goullé, JP; Lacroix, C; Saussereau, E, 2008
)
0.35
" Here, we examined the effects of acute and repeated dosing with two antipsychotics, haloperidol and clozapine, and Delta(9)-tetrahydrocannabinol [Experiments 1 and 2, respectively] in adolescent rats of both sexes that differed in shipping status (i."( To breed or not to breed? Empirical evaluation of drug effects in adolescent rats.
Evans, RL; Wiley, JL, 2009
)
0.35
" On the demand side, more information is required on the question of cannabis dosage and volumes used by both occasional and regular users."( A review of the world cannabis situation.
Leggett, T, 2006
)
0.33
" Furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample sizes (n = 6-22), heterogeneous samples with regard to cannabis exposure (lumping users and nonusers), lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose-response data."( The effects of cannabinoids on serum cortisol and prolactin in humans.
Braley, G; Cooper, T; D'Souza, DC; Krystal, J; Perry, E; Pittman, B; Ranganathan, M, 2009
)
0.35
" Three hundred and eighteen tests (or test variants) were grouped in test clusters and functional domains, to allow their evaluation as a useful biomarker and to study their dose-response effects."( Biomarkers for the effects of cannabis and THC in healthy volunteers.
Ippel, AE; Moin, E; van Gerven, JM; Zuurman, L, 2009
)
0.35
" In mouse models, following chronic treatment with delta9-tetrahydrocannabinol (THC), administration of the selective cannabinoid CB1 receptor antagonist SR141716 (rimonabant) elicited varying behavioral responses, depending on mouse strain and dosing regimen."( Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.
Cowan, A; Huang, P; Liu-Chen, LY; Unterwald, EM, 2009
)
0.35
"Adult male rats were orally dosed with purified Delta9THC, synthetic Delta9THC, or Delta9THC-BDS, matched for Delta9THC content (0."( Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats.
Farrimond, JA; Hill, AJ; Whalley, BJ; Williams, CM, 2010
)
0.36
" FAAH(-/-) mice dosed subchronically with equi-active maximally effective doses of AEA or THC displayed greater rightward shifts in THC dose-effect curves for antinociception, catalepsy, and hypothermia than in AEA dose-effect curves."( FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
Abdullah, RA; Cravatt, BF; Falenski, KW; Lichtman, AH; Schlosburg, JE; Selley, DE; Sim-Selley, LJ; Smith, TH; Thorpe, AJ, 2010
)
0.36
" Only the former effect showed a linear dose-response relation."( Cannabis with high δ9-THC contents affects perception and visual selective attention acutely: an event-related potential study.
Böcker, KB; Gerritsen, J; Hunault, CC; Kenemans, JL; Kruidenier, M; Mensinga, TT, 2010
)
0.36
" We recommend a larger trial with a more prolonged treatment period and an option to slowly increase the dosage further."( A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury.
Casey, A; Ethans, K; Perry, D; Pooyania, S; Szturm, T, 2010
)
0.36
" THC caused locomotor depression in both male and female animals dosed during early adolescence but only in female animals dosed during late adolescence."( Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat.
Dow-Edwards, D; Harte, LC,
)
0.13
" The available literature also provides some evidence that regional structural changes are associated with cannabis use patterns (particularly cumulative dosage and frequency of use), as well as measures of psychopathology (e."( Structural MRI findings in long-term cannabis users: what do we know?
Lorenzetti, V; Lubman, DI; Solowij, N; Whittle, S; Yücel, M, 2010
)
0.36
"Sulphasalazine, THC and CBD proved beneficial in this model of colitis with the dose-response relationship for the phytocannabinoids showing a bell-shaped pattern on the majority of parameters (optimal THC and CBD dose, 10 mg."( The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.
Jamontt, JM; Molleman, A; Parsons, ME; Pertwee, RG, 2010
)
0.36
" Future research to establish optimal dosing regimens, and reduce the development of tolerance, is required."( Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study.
Bedi, G; Comer, SD; Foltin, RW; Gunderson, EW; Haney, M; Hart, CL; Rabkin, J; Vosburg, SK, 2010
)
0.63
" Tests assessed the dose-response functions of ∆⁹-THC and the time course for rimonabant in its ability to block the discriminative stimulus effects of ∆⁹-THC."( Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.
Gifford, RS; Järbe, TU; Makriyannis, A, 2010
)
0.36
" In addition, subjects smoked a THC cigarette (400 μg/kg) at 3 h post-onset of alcohol dosing during every alcohol condition."( Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users.
de Brouwer, M; Kauert, G; Moeller, MR; Ramaekers, JG; Theunissen, EL; Toennes, SW, 2011
)
0.37
" A low dose of the selective adenosine A(2A) receptor antagonist MSX-3 (1 mg/kg) caused downward shifts of THC and anandamide dose-response curves."( Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.
Ferré, S; Franco, R; Goldberg, SR; Justinová, Z; Mascia, P; Müller, CE; Quarta, D; Redhi, GH; Stroik, J; Yasar, S, 2011
)
0.37
"Nine cannabis smokers completed all 5 dosing sessions."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
" Reassessment and modulation of dosing and/or medications occurred at 3- and 6-month intervals."( An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy.
Bestard, JA; Toth, CC,
)
0.13
"We found a dose-response relationship between the amount of cannabis use and the odds for psychiatric hospitalization."( Association between cannabis and psychiatric hospitalization.
Boks, MP; Breetvelt, EJ; Groenwold, RH; Kahn, RS; Ophoff, RA; Schubart, CD; Sommer, IE; van Gastel, WA, 2011
)
0.37
" In an experimental mouse model of MS-related spasticity, Sativex dose-dependently improved hind limb flexion/stiffness and a dosage of 10 mg/kg was shown to be as effective as the most widely established anti-spasticity treatment baclofen (5 mg/kg)."( Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
Di Marzo, V, 2011
)
0.37
" THC unexpectedly produced a modest hyperthermic effect when administered alone, but in animals co-treated with both THC and MDMA, there was an attenuation of MDMA-induced hyperthermia on dosing days."( Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.
Ali, SF; Meyer, JS; Shen, EY, 2011
)
0.37
" Four of eight participants receiving rimonabant (none of two receiving placebo) had greater cortisol concentrations 2 hours after dosing (at 11:30) than at 08:00, while normal diurnal variation should have peak concentrations at 08:00."( CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.
Baumann, MH; Bonnet, D; Darwin, WD; Goodwin, RS; Gorelick, DA; Huestis, MA; Kelly, DL; Ortemann-Renon, C; Schroeder, JR; Schwilke, E; Schwope, DM, 2012
)
0.38
" Whereas ketamine produced progressive increases in activity with repeated administration in rats of both ages, MDMA increased, and then decreased, activity in the chronic dosing regimen in female adolescents only."( Locomotor activity changes in female adolescent and adult rats during repeated treatment with a cannabinoid or club drug.
Evans, RL; Grainger, DB; Nicholson, KL; Wiley, JL, 2011
)
0.37
" The CNS effects were assessed at baseline and up to 24 h after dosing using visual analogue mood scales for feeling 'stimulated', 'anxious', 'sedated' and 'down'."( Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia.
Annas, P; Baxendale, J; Kalliomäki, J; Karlsten, R; Philipp, A; Segerdahl, M, 2012
)
0.38
" • the pharmacokinetics of the various administration routes of cannabis and cannabis based medicines are variable and dosing is hard to regulate."( Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Beumer, TL; de Kam, ML; Freijer, JI; Karger, LB; Kleinloog, HD; Klumpers, LE; Lipplaa, A; van Gerven, JM; van Hasselt, JG, 2012
)
0.38
"Among the main disadvantages of currently available Δ(9) -tetrahydrocannabinol (THC) formulations are dosing difficulties due to poor pharmacokinetic characteristics."( Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Beumer, TL; de Kam, ML; Freijer, JI; Karger, LB; Kleinloog, HD; Klumpers, LE; Lipplaa, A; van Gerven, JM; van Hasselt, JG, 2012
)
0.38
" There is a clearly identified need for further research to isolate significant benefits from the medical application of cannabinoids and to establish dosage levels, appropriate delivery mechanisms and formulations, and to determine what role, if any, cannabinoids might play in legitimate medical applications."( Marijuana: modern medical chimaera.
Lamarine, RJ, 2012
)
0.38
" Secondary outcomes were to determine evidence of developing tolerance and to assess the long-term dosing profile of Sativex."( Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Collin, C; Notcutt, W; Serpell, MG, 2013
)
0.39
"1 mg/kg/infusion) generated a typical inverted U-shaped dose-response curve."( Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys.
France, CP; Koek, W; Li, JX, 2012
)
0.38
"5 h after dosing and analyzed for THC, CBD, cannabinol (CBN), and 11-nor-9-carboxy-THC (THCCOOH)."( Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Barnes, AJ; Goodwin, RS; Huestis, MA; Karschner, EL; Lee, D; Milman, G, 2013
)
0.39
" THCCOOH/THC ratios increased throughout each dosing session."( Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
Barnes, AJ; Goodwin, RS; Huestis, MA; Karschner, EL; Lee, D; Milman, G, 2013
)
0.39
" There was evidence of dose-proportionality in the single but not the multiple dosing data sets."( A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
Guy, GW; Stott, CG; White, L; Wilbraham, D; Wright, S, 2013
)
0.39
" This article will describe the pharmacology of cannabis, effects of various dosage formulations, therapeutics benefits and risks of cannabis for pain and muscle spasm, and safety concerns of medical cannabis use."( The pharmacologic and clinical effects of medical cannabis.
Borgelt, LM; Franson, KL; Nussbaum, AM; Wang, GS, 2013
)
0.39
"Neuropathic pain caused by chemotherapy limits dosing and duration of potentially life-saving anti-cancer treatment and impairs quality of life."( A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain.
Cesar-Rittenberg, P; Hohmann, AG; Lynch, ME, 2014
)
0.4
" However, despite their high clinical potential, only few dosage forms are available to date."( Preparation and characterization of Δ(9)-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines.
Aberturas, Mdel R; Di Marzo, V; Gil-Alegre, ME; Hernán Pérez de la Ossa, D; Ligresti, A; Molpeceres, J; Torres, AI, 2013
)
0.39
"7) ng/μg, much more consistent in various dosing conditions over time."( Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration.
Barnes, AJ; Bergamaschi, M; Huestis, MA; Lee, D; Mendu, DR; Milman, G; Murray, JA; Vandrey, R, 2013
)
0.39
" This within-subject, double-blind study was designed to develop a smoking procedure to obtain a marijuana dose-response function."( Marijuana's dose-dependent effects in daily marijuana smokers.
Cooper, ZD; Haney, M; Ramesh, D, 2013
)
0.39
"Oral THC dosing significantly affected OF THCCOOH but minimally contributed to THC OF concentrations; prior ad libitum smoking was the primary source of THC, CBD, and CBN."( Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
Anizan, S; Barnes, AJ; Huestis, MA; Lee, D; Mendu, DR; Milman, G; Murray, JA; Vandrey, R, 2013
)
0.39
" THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake."( Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Barnes, AJ; Bergamaschi, MM; Huestis, MA; Lee, D; Mendu, DR; Milman, G; Vandrey, R, 2014
)
0.91
" We hypothesized that when used for pain, dronabinol has psychoactive effects in a dose-response relationship, whose peak effects are comparable with smoking marijuana."( The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.
Edwards, RR; Issa, MA; Jamison, RN; Michna, E; Narang, S; Penetar, DM; Wasan, AD, 2014
)
0.93
" The mean dosage was 4 sprays/day."( Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Feneberg, W; Koehler, J; Meier, M; Pöllmann, W, 2014
)
0.4
" However, despite the accumulation of evidence about long-term cognitive damage due to cannabis use, it is difficult to find unequivocal results, arising from the existence of many variables such as large differences between cannabis users, frequency of use, dosage and endogenous brain compensation."( [Short-and long-term effects of cannabinoids on memory, cognition and mental illness].
Bart, Y; Eliasi, Y; Livneh, I; Monovich, E; Sagie, S, 2013
)
0.39
" On day 7, rats were challenged with vehicle or rimonabant, counterbalanced across dosing groups, and were assessed for withdrawal-related behaviors."( Evaluation of sex differences in cannabinoid dependence.
Antonazzo, KR; Craft, RM; Lefever, TW; Marusich, JA; Wiley, JL, 2014
)
0.4
" Oral fluid was tested prior to and immediately after dosing with either Sativex(®) or placebo at intervals up to 2h after the dose."( The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Allsop, DJ; Copeland, J; Fu, S; Lewis, J; Molnar, A, 2014
)
0.4
" SCH-442416 produced a significant shift to the right of the THC self-administration dose-response curves, consistent with antagonism of the reinforcing effects of THC."( Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on Δ9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys.
Ferré, S; Goldberg, SR; Justinová, Z; Redhi, GH, 2014
)
0.4
"We evaluated antiallodynic efficacy, possible tolerance, and cannabimimetic side effects of repeated dosing with a CB2-preferring agonist AM1710 in a model of chemotherapy-induced neuropathy produced by paclitaxel using CB1 knockout (CB1KO), CB2 knockout (CB2KO), and wild-type (WT) mice."( Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Cornett, BL; Deng, L; Guindon, J; Hohmann, AG; Mackie, K; Makriyannis, A, 2015
)
0.42
" Finally, a screening level risk assessment that combines the measured environmental concentrations (MECs) with dose-response data to estimate Hazard Quotients (HQs) for the compounds studied is also presented."( Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river waters, occurrence in tap water and potential environmental and human risk.
Barceló, D; González-Alonso, S; López de Alda, M; Mastroianni, N; Mendoza, A; Rodríguez-Gil, JL; Valcárcel, Y, 2014
)
0.4
" Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a "main stream" pharmacological treatment for neuropathic pain."( The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study.
Almog, S; Eisenberg, E; Ogintz, M, 2014
)
0.4
", Any Effect, Sedated), but did not substitute for the Δ(9)-THC discriminative stimulus or alter the Δ(9)-THC discrimination dose-response function."( Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.
Hays, LR; Kelly, TH; Lile, JA, 2014
)
0.4
" In early clinical research, the THC challenge test can be optimized through more accurate predictions of the dosing sequence and the wash-out between occasions in a crossover setting, which is mainly determined by the terminal half-life of the compound."( Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.
Beumer, TL; Cohen, AF; Freijer, J; Guan, Z; Heuberger, JA; Klumpers, L; Morrison, PD; Oyetayo, OO; van Gerven, JM, 2015
)
0.42
" We report here eight cases of infants who were brought to the emergency division due to acute consciousness failure after accidental ingestion of hashish, confirmed by urinary dosage of Δ9-tetrahydrocannabinol."( [Intoxication from accidental ingestion of cannabis: analysis of eight cases].
Akdhar, M; Manin, C; Patissier, C; Renoux, MC; Rosellini, D; Tambat, A; Tiprez, C; Wendremaire, P, 2015
)
0.42
"6 mg/kg) served as a discriminative stimulus in both genotypes, with similar THC dose-response curves between groups."( Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Vann, RE; Walentiny, DM; Wiley, JL, 2015
)
0.42
" In a crossover design, each participant was exposed to 4 single dosing sessions of placebo or to low (1% tetrahydrocannabinol [THC]), medium (4% THC), or high (7% THC) doses of cannabis."( Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.
Atkinson, JH; Gouaux, B; Marcotte, TD; Umlauf, A; Wallace, MS, 2015
)
0.42
" A gp120-expressing plasmid, pVRCgp120, or a vector plasmid, pVRC2000, was injected intramuscularly into mice, which were also dosed with THC orally."( Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.
Chen, W; Crawford, RB; Kaminski, NE; Kaplan, BL, 2015
)
0.42
"Ten 14-day cycles of Δ9-THC dosing and 5-CSRTT testing were employed, each comprised of 5-day Δ9-THC dosing (0."( Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats.
Irimia, C; Parsons, LH; Polis, IY; Stouffer, D, 2015
)
0.42
"Dose-dependent increases in motor impulsivity (premature responses) and behavioral disinhibition (perseverative responses) emerged following 5 cycles of Δ9-THC exposure that persisted for the remaining dosing and testing cycles."( Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats.
Irimia, C; Parsons, LH; Polis, IY; Stouffer, D, 2015
)
0.42
" The benign adverse event profile of this dosage allows study of whether higher doses are efficacious and equally well-tolerated."( Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.
Ahmed, AI; Feuth, T; Kramers, C; Olde Rikkert, MG; Rosenberg, PB; van den Elsen, GA; van der Marck, MA; Verkes, RJ, 2015
)
0.42
" The dosage of δ9-tetrahydrocannabinol (THC) suggests a recent cannabis consumption (THC 12."( Death following ingestion of methylone.
Barrios, L; Boels, D; Bouquie, R; Clement, R; Grison-Hernando, H; Monteil-Ganiere, C, 2016
)
0.43
" Meaningful symptomatic improvement was achieved within the recommended dosage limit of ≤12 sprays per day."( Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Dechant, KL; Meuth, SG; Vila, C, 2015
)
0.42
" With widening uses of this medication, we aim to explore its effects on metabolic parameters in long-term dosing and hypothesize that it will not affect major metabolic parameters."( A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial.
Bayman, L; Reichenbach, ZW; Rizvi-Toner, A; Schey, R; Sloan, J; Valestin, J, 2015
)
0.66
" These results have important implications for future dosing strategies and may limit the utility of dronabinol as a treatment for opioid withdrawal."( Safety of oral dronabinol during opioid withdrawal in humans.
Babalonis, S; Elayi, SC; Jicha, CJ; Lofwall, MR; Nuzzo, PA; Walsh, SL, 2015
)
0.99
"At the dosage used, nabilone was not potent enough to improve the patients' quality of life over placebo."( Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial.
Côté, M; Fortin, A; Trudel, M; Wang, C, 2016
)
0.43
" Oral THC did not reduce NPS in dementia, but was well tolerated by these vulnerable patients, supporting future higher dosing studies."( Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial.
Ahmed, AIA; Feuth, T; Olde Rikkert, MGM; van den Elsen, GAH; van der Marck, MA; Verkes, RJ, 2015
)
0.42
" Open-label studies performed to date with a focus on effectiveness have indicated that about one-half to two-thirds of patients initiated on THC:CBD oromucosal spray continue to derive benefit after 3 months' treatment at a mean dosage of 5-7 sprays/day."( Advances in the management of MS symptoms: real-life evidence.
Trojano, M, 2015
)
0.42
" Dose-response curves had inverted U shapes, with peak response rates occurring at a dose of 10 μg/kg/injection."( Self-administration of the anandamide transport inhibitor AM404 by squirrel monkeys.
Goldberg, SR; Justinova, Z; Makriyannis, A; Redhi, GH; Scherma, M; Schindler, CW; Vadivel, SK, 2016
)
0.43
" Due to differences in timing of puberty in males and females during the P29-38 period of THC treatment, we also dosed female rats between P21-30 (pre-puberty) and male rats between P39-48 (puberty)."( Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: The unique susceptibility of the prepubescent animal.
Black, R; Dow-Edwards, D; Hurd, YL; Michaelides, M; Silva, L,
)
0.13
" Stretch reflex responders were taking a significantly higher number of puffs, whereas no differences were found in the responders by the other scales, suggesting that a higher dosage would add benefit if tolerated."( The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Abbruzzese, G; Bandini, F; Canneva, S; Capello, E; Colombano, F; Currà, A; Fattapposta, F; Marinelli, L; Mori, L; Trompetto, C, 2016
)
0.43
"This study aimed to explore a dose-response relationship of delta-9-tetrahydrocannabinol (THC) in THC-naïve children after unintentional acute exposure and compare clinical outcomes with non-naïve children."( Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes.
Bashqoy, F; Borgelt, LM; Heizer, JW; Reiter, PD; Wang, GS, 2018
)
0.48
" No significant symptomatic effects were detected at the prescribed dosage and for a 12-week period."( A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
Alonso Arias, MA; Fernández Ruiz, J; Galve-Roperh, I; García Caldentey, J; García de Yébenes Prous, J; García de Yébenes, MJ; García Ribas, G; García-Bermejo, ML; Guzmán, M; López-Sendón Moreno, JL; Ortega-Gutierrez, S; Resel, E; Ruiz Romero, C; Sagredo, O; Tolón, RM; Trigo Cubillo, P; Valdeolivas, S, 2016
)
0.43
" After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later."( Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.
Chopda, GR; Gatley, SJ; Makriyannis, A; Parge, V; Paronis, CA; Thakur, GA, 2016
)
0.43
"Sativex was well-tolerated by all participants (average dosage 77."( Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.
Barnes, AJ; Fischer, B; George, TP; Huestis, MA; Le Foll, B; Quilty, L; Rehm, J; Selby, P; Soliman, A; Staios, G; Trigo, JM,
)
0.13
" Both studies used nabilone, a synthetic cannabinoid, with a bedtime dosage of 1 mg/day."( Cannabinoids for fibromyalgia.
Fitzcharles, MA; Häuser, W; Klose, P; Phillips, T; Walitt, B, 2016
)
0.43
" When administered as an escalating dosage scheme, side effects were rare and only consisted in vomiting and restlessness (one patient each)."( Effective treatment of spasticity using dronabinol in pediatric palliative care.
Balzer, S; Borkhardt, A; Gagnon, G; Hoell, JI; Janßen, G; Kuhlen, M; Oommen, PT, 2016
)
0.7
" THC:CBD mean dosage was 6 sprays/day."( Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Trojano, M; Vermersch, P, 2016
)
0.43
"A cumulative dosing THC discrimination procedure was utilized to evaluate sex differences in the discriminative stimulus effects of THC and three synthetic cannabinoids: CP47,497, WIN55,212-2, and JWH-018."( Comparison of the discriminative stimulus and response rate effects of
Craft, RM; Lefever, TW; Marusich, JA; Wiley, JL, 2017
)
0.46
" We lack valid data on the safety, efficacy, and dosing of artisanal preparations available from dispensaries in the 25 states and District of Columbia with MMJ programs and online sources of CBD and other cannabinoids."( Cannabinoids in treatment-resistant epilepsy: A review.
Devinsky, O; Gloss, D; O'Connell, BK, 2017
)
0.46
"1mg/kg/day, biphasic dose-response effects, the use of THCA for seizure prevention, the use of THC for seizure rescue, and the synergy of cannabinoids and terpenoids in artisanal preparations."( The current status of artisanal cannabis for the treatment of epilepsy in the United States.
Goldstein, B; Saneto, R; Sulak, D, 2017
)
0.46
" Both THC and THC-Val-HS were detected in the ocular tissues following multiple dosing of THC-Val-HS in conscious animals."( Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.
Adelli, GR; Bhagav, P; ElSohly, MA; Gul, W; Hingorani, T; Majumdar, S; Pettaway, S; Repka, MA; Taskar, P, 2017
)
0.46
" The risks that may be associated with cannabis use, particularly for sensitive subgroups such as pregnant women, are difficult to define because of a paucity of dose-response data and the recent increase in cannabis potency."( Cannabis use during pregnancy: Pharmacokinetics and effects on child development.
Burbacher, TM; Grant, KS; Isoherranen, N; Petroff, R; Stella, N, 2018
)
0.48
" Each underwent clinical evaluation, cannabis blood metabolite dosage (THC, 11-OH-THC, and THC-COOH) and genotyping of ABCB1 C3435T polymorphism."( ABCB1 C3435T polymorphism is associated with tetrahydrocannabinol blood levels in heavy cannabis users.
Benyamina, A; Blecha, L; Chaumette, B; Kebir, O; Lafaye, G; Laqueille, X; Mouaffak, F, 2018
)
0.48
", methods of administration (smoking, vaporisation, oral), and dosing recommendations."( Practical considerations in medical cannabis administration and dosing.
MacCallum, CA; Russo, EB, 2018
)
0.48
" Dose-response information for both efficacy and toxicity pertaining to medicinal cannabis is lacking."( Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.
Galettis, P; Lucas, CJ; Martin, JH; Reuter, SE; Schneider, J; Solowij, N; Song, S, 2018
)
0.48
"Chronic dronabinol dosing can reduce cannabis self-administration in daily cannabis users and suppress withdrawal symptoms."( The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Lee, DC; Schlienz, NJ; Stitzer, ML; Vandrey, R, 2018
)
1.22
" Mechanism-based PK and PD models are promising for improved predictive dosing performance for ill and comorbid patients."( Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.
Liu, Z; Martin, JH, 2018
)
0.48
" This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regimens based on information from these studies."( Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Cameron, M; Rice, J, 2018
)
0.48
"We aimed to assess the potential relationship between intrasubject 9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray plasma profiles and clinical effects elicited by subacute dosing in chronically treated patients with multiple sclerosis (MS)."( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V,
)
0.13
" No significant effect of cannabinoids dosing could be appreciated according to posturographic and motor tests."( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V,
)
0.13
" Although preliminary, they suggest that subacute dosing might elicit a subjective clinically significant effect on MS-related spasticity, paralleling cannabinoids measurable plasma concentrations."( Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin, M; Foschi, M; Lugaresi, A; Mancinelli, L; Mohamed, S; Perrone, A; Riva, R; Sabattini, L; Scandellari, C; Vacchiano, V,
)
0.13
"Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale."( Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
Kawohl, W; Pichler, EM; Roser, P; Seifritz, E, 2019
)
0.51
" Blood samples from orally dosed (10, 25 and 50 mg) THC brownies were added to validate the model."( Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Bernhard, W; Greif, R; Kleine-Brueggeney, M; Theiler, L; Wolowich, WR, 2019
)
0.51
" Also, due to the complex pharmacology of cannabinoids, interindividual genetic differences in the metabolisation of ∆9-tetrahydrocannabinol (THC), the individual structure and function of the cannabinoid receptors, as well as differences in receptor density and distribution, the dosage and frequency of application must be individually determined."( [Cannabis for medical purposes and its prescription].
Bussick, D; Eckert-Lill, C; Hörnig, M; Kiefer, A; Reimann, H, 2019
)
0.51
" Only 2 of 39 participants were able to give an exact dosage used in milligrams."( Marijuana use among patients with epilepsy at a tertiary care center.
Ernst, L; Kellogg, M; Kerr, A; Walston, V; Wong, VSS, 2019
)
0.51
"The results observed in this study are useful for guiding future pharmacokinetic studies of medicinal cannabinoids, and for development of dosing guidelines for medical use of cannabis in the 'real-world' setting."( Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Broyd, SJ; de Krey, P; Galettis, P; Greenwood, LM; Liu, Z; Martin, JH; Schneider, J; Solowij, N; Steigler, A; van Hell, H; Zhu, X, 2020
)
0.56
" There was considerable heterogeneity in dose, route of administration and THC:CBD ratio across studies and no clear dose-response profile emerged."( How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Curran, HV; Freeman, AM; Freeman, TP; Hindocha, C; Lees, R; Mokrysz, C; Petrilli, K; Saunders, R, 2019
)
0.51
"Palliative medicine physicians are challenged by lack of guidance regarding effectiveness and dosing of cannabis products in the setting of their emerging popularity."( Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet, BH; Johnson, PW; Kaur, JS; Lesser, ER, 2020
)
0.56
" THC pharmacokinetics are important for designing optimal dosing regimens, and physiologically-based pharmacokinetic (PBPK) models are used to predict a compound's actions in target organs."( Development of a Physiologically-Based Pharmacokinetic Model of Δ
Kaewworasut, P; Lohitnavy, M; Methaneethorn, J; Naosang, K; Poomsaidorn, C, 2020
)
0.56
" The model could describe THC concentration-time profiles in several dosing scenarios (i."( A Δ
Kaewworasut, P; Lohitnavy, M; Methaneethorn, J; Naosang, K; Poomsaidorn, C, 2020
)
0.56
" Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when the medication is co-administered with a high-fat meal."( Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.
Bialer, M; Perucca, E, 2020
)
0.56
" No changes in serum biochemistry analysis were observed following IH dosing compared to baseline values."( Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa).
Coetzee, JF; Curtis, A; Griffin, J; Kleinhenz, KE; Kleinhenz, MD; Lin, Z; Magnin, G; Martin, M; Montgomery, S, 2020
)
0.56
" This allows for simultaneously printing an individual dose and encapsulating information relevant to the end-users and other stakeholders in a single dosage unit, which is readable by a standard smartphone."( Data-enriched edible pharmaceuticals (DEEP) of medical cannabis by inkjet printing.
Bøtker, J; Cornett, C; Frokjaer, S; Genina, N; Hansen, H; Öblom, H; Rades, T; Rantanen, J, 2020
)
0.56
"Daily high dosing with THC compromised performance on a task of cognition, and reduced activity in adolescent primates, with tolerance developing within weeks."( Effects of daily Δ
Bergman, J; Charles, S; Eisold, JE; George, SR; Gumbert, AB; Kangas, BD; Madras, BK; Withey, SL, 2021
)
0.62
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, decision-making surrounding appropriate dosing of cannabis used for medical purposes is limited."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
"Due to a lack of published pharmacokinetic (PK) and/or pharmacodynamic (PD) data, informed physician and patient decision-making surrounding appropriate dosing of cannabis for medical purposes is limited."( Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.
Bonn-Miller, MO; Land, MH; MacNair, L; Mosesova, I; Peters, EN; Turcotte, C; Vandrey, R; Ware, MA, 2022
)
0.72
" In dose-response studies, adult, male CD1 mice were injected intraperitoneally with (1) CBD alone (0-96 mg/kg), (2) THC alone (0-6."( Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice.
Burnham, WM; Liu, J; Scott, BW, 2022
)
0.72
" FDA authorization for the commercial use of four cannabinoid-derived products, available as oral dosage forms is a significant progress already."( Delivering therapeutic cannabinoids via skin: Current state and future perspectives.
Chukwunyere, UI; Frempong, D; Mishra, D; Puri, A; Thakur, D; Tijani, AO, 2021
)
0.62
" Drug deliveries calculated as percent vehicle followed a prototypical inverted-U shaped dose-response curve for cannabinoids and heroin except for THC and JWH-018 (in males)."( Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates.
Cooper, ZD; Evans, SM; Foltin, RW, 2021
)
0.62
"Medicinal cannabis is generally well tolerated when dosed appropriately."( A primer on medicinal cannabis safety and potential adverse effects.
Arnold, JC, 2021
)
0.62
" Urine specimens were collected before and for 58 h after dosing on a residential research unit."( Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Bigelow, GE; Cone, EJ; Flegel, RR; Goffi, E; Kuntz, D; Mitchell, JM; Sholler, DJ; Spindle, TR; Vandrey, R; Winecker, RE, 2022
)
0.72
"Our model is a useful tool for predicting the pharmacokinetics of lenabasum and adjustments to its dosing in possible drug-drug interaction scenarios."( A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum.
Atamas, SP; Fu, Q; Jones, HM; Sun, G, 2021
)
0.62
"The analysis of each of the subjective effects showed significant differences between the placebo and the active cannabis dosed conditions."( Perceived effects of cannabis and changes in driving performance under the influence of cannabis.
Berka, C; Brown, TL; Burt, TS; Gaffney, GR; McGehee, D; Milavetz, G; Schmitt, R, 2021
)
0.62
" Changes in performance measures such as SDLP are better explained by dosing condition."( Perceived effects of cannabis and changes in driving performance under the influence of cannabis.
Berka, C; Brown, TL; Burt, TS; Gaffney, GR; McGehee, D; Milavetz, G; Schmitt, R, 2021
)
0.62
"Liquid chromatography/mass spectrometry analysis of THC and its major metabolites was conducted on blood plasma and brain tissue at 5, 30, 60, and 120 min following a 30-min aerosol dosing session."( Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats.
Castillo, E; Fowler, CD; Justeson, DN; Lallai, V; Mahler, SV; Manca, L; Martinez, MX; Piomelli, D; Ruiz, CM; Torrens, A, 2021
)
0.62
"These results provide a benchmark for dosing adolescent rats with aerosolized (or "vaped") THC, which could facilitate adoption by other labs of this potentially human-relevant THC exposure model to understand cannabis effects on the developing brain."( Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats.
Castillo, E; Fowler, CD; Justeson, DN; Lallai, V; Mahler, SV; Manca, L; Martinez, MX; Piomelli, D; Ruiz, CM; Torrens, A, 2021
)
0.62
" No significant trends were observed between THC dosing and average basal progesterone, anti-Müllerian hormone, prolactin, LH, or thyroid-stimulating hormone concentrations."( The effects of delta-9-tetrahydrocannabinol exposure on female menstrual cyclicity and reproductive health in rhesus macaques.
Boniface, ER; Borgelt, LM; Campbell, LR; Hanna, CB; Hedges, JC; Hennebold, JD; Lo, JO; Mahalingaiah, S; Naito, CS; Roberts, VHJ; Ryan, KS; Terrobias, JJD, 2021
)
0.62
" Either THC or CBR antagonists were compounded in an aqueous solution and dosed during the induction of DED."( Topical application of cannabinoid-ligands ameliorates experimental dry-eye disease.
Gehlsen, U; Maass, M; Musial, G; Stern, ME; Steven, P; Tran, BN, 2022
)
0.72
"We demonstrate that commercial CBD products, especially aqueous beverages, can show inconsistent labeling, vary largely from their label claims should they make them, and show lot-to-lot variability making dosing unpredictable."( Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Elder, EJ; Gidal, BE; Jones, KJ; Miller, OS, 2022
)
0.72
"In rhesus macaques, chronic exposure to THC resulted in significant dose-response testicular atrophy, increased serum gonadotropin levels, and decreased serum sex steroids, suggestive of primary testicular failure."( Chronic exposure to delta-9-tetrahydrocannabinol impacts testicular volume and male reproductive health in rhesus macaques.
Bash, JC; Boniface, ER; Burch, FC; Easley, CA; Hanna, CB; Hedges, JC; Jensen, JV; Lo, JO; Mahalingaiah, S; Mishler, EC; Roberts, VHJ; Terrobias, JJD, 2022
)
0.72
" Future research should focus on longer term symptom relief, including nausea-free intervals and dosing frequency; the risks of consumption of medical cannabis, especially among high-risk populations, such as pregnant women and children; and potential interactions between cannabis, conventional antiemetics, other medications, food, tobacco, alcohol, and street drugs among specific patient populations."( The Effectiveness of Common Cannabis Products for Treatment of Nausea.
Brockelman, F; Hall, B; Keeling, K; Li, X; Lopez, V; Orozco, J; Stith, SS; Vigil, JM, 2022
)
0.72
"Studies on the effective and safe therapeutic dosage of delta-9-tetrahydrocannabinol (THC) for the treatment of Alzheimer's disease (AD) have been sparse due to the concern about THC's psychotropic activity."( Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice.
Brown, B; Cai, J; Cao, C; Gordon, M; Hong, Y; Li, M; Lin, X; Morgan, D; Shen, N; Wang, Y; Yan, J; Zhang, X; Zhou, Q, 2022
)
0.72
" Subsequently, radiotelemetry was used to continuously measure body temperature and locomotor activity before (baseline), during, and after the 5-day dosing regimens."( Evidence for spontaneous cannabinoid withdrawal in mice.
Bergman, J; Iliopoulos-Tsoutsouvas, C; Makriyannis, A; Nikas, SP; Papanastasiou, I; Paronis, C, 2022
)
0.72
" The dosage over time did not change in patients older than 64; in younger patients, there was a non-significant increasing trend."( [Cannabinoids reduce opioid use in older patients with pain : Retrospective three-year analysis of data from a general practice].
Böhm, R; Gastmeier, A; Gastmeier, K; Herdegen, T; Rottmann, F, 2023
)
0.91
" Although formulations and dosing guidelines for clinicians do not formally exist at present, attention to tetrahydrocannabinol concentration and understanding of risks with inhalation can reduce risk."( Cannabis Use in Patients With Cancer: A Clinical Review.
Hajjar, ER; Handley, N; Worster, B, 2022
)
0.72
" We found that systemic administration of PIMSR dose-dependently inhibited cocaine self-administration under fixed-ratio (FR5), but not FR1, reinforcement, shifted the cocaine self-administration dose-response curve downward, decreased incentive motivation to seek cocaine under progressive-ratio reinforcement, and reduced cue-induced reinstatement of cocaine seeking."( Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research.
Bi, GH; Galaj, E; Gardner, EL; Hempel, B; Klein, B; Moore, A; Seltzman, HH; Xi, ZX, 2022
)
0.72
" Compounds exhibiting cross-reactivity were then tested to create dose-response curves to calculate the percent cross-reactivity."( Determination of Cross-Reactivity of Contemporary Cannabinoids with THC Direct Immunoassay (ELISA) in Whole Blood.
Mathews, CM; Midthun, KM; Moody, MT; Ringel, MM, 2022
)
0.72
" Of major concern is the rising CCE impacting exponential cannabinoid genotoxic dose-response relationships."( European Epidemiological Patterns of Cannabis- and Substance-Related Body Wall Congenital Anomalies: Geospatiotemporal and Causal Inferential Study.
Hulse, GK; Reece, AS, 2022
)
0.72
" Finally, we investigated the dose-response relationship between THC and key brain substrates."( Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis.
Bhattacharyya, S; Blest-Hopley, G; Bossong, MG; Davies, C; Gunasekera, B; Radua, J; Ramsey, NF; Veronese, M, 2022
)
0.72
" Identifying appropriate solvents in which THC is stable as well as adequately solubilized is crucial in developing topical dosage forms."( Effect of Lipid Vehicles on Solubility, Stability, and Topical Permeation of Delta-9-Tetrahydrocannabinol.
Dave, M; Ellis, I; Murthy, R; Murthy, SN; Rangappa, S; Shankar, VK; Shettar, A, 2022
)
0.72
" Both isomers caused graded dose-response effects on euphoria, blurred vision, mental confusion and lethargy, although Δ8-THC was at least 25 % less potent."( Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis.
Busardò, FP; Di Giorgi, A; Huestis, MA; La Maida, N; Pichini, S, 2022
)
0.72
" The optimal type, concentration, ratio, and dosage form of cannabinoids in the treatment of insomnia symptoms needs further clarification."( Updates in the use of cannabis for insomnia.
Earl, DC; Proano, M, 2022
)
0.72
" Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations."( Cannabis dosing and administration for sleep: a systematic review.
Boerkoel, P; Cullen, K; Hawkins, M; Lai, WW; Malas, A; Roesler, J; Velzeboer, R, 2022
)
0.72
", dosage >12 sprays per day and/or not administered primarily for treatment of spasticity."( Effects of Sativex
Dykukha, I; Essner, U; Penner, IK; Raithel, LM; Schreiber, H, 2022
)
0.72
"3 mg/kg) produced the same degree of rightward shift in the dose-response curves for heroin- and THC-induced antinociception, respectively."( Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates.
Ding, H; Kiguchi, N; Kishioka, S; Ko, MC; Mabry, KM, 2023
)
0.91
" Given the exponential cannabinoid genotoxicity dose-response relationship results provide a powerful stimulus to constrain community cannabinoid exposure including protection of the food chain to preserve the genome and epigenome of coming generations."( Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study.
Hulse, GK; Reece, AS, 2022
)
0.72
" However, most use a mixture of CBD and the psychoactive, tetrahydrocannabinol (THC), and/or use variable dosing that is not consistent between individual patients."( Role of Cannabidiol for Improvement of the Quality of Life in Cancer Patients: Potential and Challenges.
Green, R; Khalil, R; Mohapatra, S; Mohapatra, SS, 2022
)
0.72
" First, we determined the analgesic effect of CBD and BCP individually by establishing dose-response studies."( Cannabidiol and Beta-Caryophyllene in Combination: A Therapeutic Functional Interaction.
Benamar, K; Blanton, H; Duong, J; Yin, L, 2022
)
0.72
" Data were analyzed using the SAS GLM Select procedure, using stepwise selection, with subjective effects, dosing condition (placebo vs."( Perceived effects of cannabis: Generalizability of changes in driving performance.
Berka, C; Brown, TL; Burt, TS; Gaffney, G; McGehee, D; Milavetz, G; Schmitt, R, 2022
)
0.72
" Dosing condition and "stoned" were perfectly consistent; "high" and "sedated" contained 1 mismatch; and "anxious," "good drug effect" and "restless" contained 3 or more mismatches."( Perceived effects of cannabis: Generalizability of changes in driving performance.
Berka, C; Brown, TL; Burt, TS; Gaffney, G; McGehee, D; Milavetz, G; Schmitt, R, 2022
)
0.72
"The goal of pharmacokinetic (PK) studies is to provide a basis for appropriate dosing regimens with novel therapeutic agents."( A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals.
Schwark, WS; Wakshlag, JJ, 2023
)
0.91
"A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST)."( Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B, 2023
)
0.91
" To better understand the factors affecting THC PK and dose-response relationships, future studies should incorporate a wide range of doses, multiple routes of administration, and different formulations relevant to typical community use."( Variable Delta-9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics After Cannabis Smoking in Regular Users.
Capparelli, EV; Fitzgerald, RL; Grant, I; Liyanage, M; Marcotte, TD; Momper, JD; Nikanjam, M; Suhandynata, RT, 2023
)
0.91
"2) days, with dosage escalating to twice per day."( Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Adkins, M; Bainbridge, J; Domen, CH; Klawitter, J; Leehey, MA; Liu, Y; Rajkovic, S; Sempio, C; Sillau, S, 2023
)
0.91
" A systematic pharmacokinetic study was performed to determine whether there are differences in the pharmacokinetic parameters and systemic exposure of CBD after oral dosing as an isolate, broad-spectrum, or full-spectrum product."( Comparative Pharmacokinetics of Commercially Available Cannabidiol Isolate, Broad-Spectrum, and Full-Spectrum Products.
Berthold, EC; Chiang, YH; Kamble, SH; Kanumuri, SRR; Kuntz, MA; McCurdy, CR; McMahon, LR; Senetra, AS; Sharma, A, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
hallucinogenDrugs capable of inducing illusions, hallucinations, delusions, paranoid ideations and other alterations of mood and thinking.
cannabinoid receptor agonistAn agonist that binds to and activates cannabinoid receptors.
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
benzochromene
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
phytocannabinoidA class of cannabinoid which are C21 terpenophenolic compounds isolated primarily from Cannabis sativa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
CBD synthetic pathway08
Metabolism of tetrahydrocannabinol (THC)25

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency23.87230.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency23.28810.000221.22318,912.5098AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency24.78660.000214.376460.0339AID720691; AID720692; AID720719
pregnane X nuclear receptorHomo sapiens (human)Potency7.94330.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.96440.000229.305416,493.5996AID743069; AID743078; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency30.10650.001019.414170.9645AID743094
aryl hydrocarbon receptorHomo sapiens (human)Potency8.69060.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency23.71010.001723.839378.1014AID743083
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency14.56680.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency28.60080.002319.595674.0614AID651631; AID720552
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.49150.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency33.49150.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)43.60000.00020.59827.0000AID1781163
L-lactate dehydrogenase A chainHomo sapiens (human)Ki14.00000.05003.76508.5000AID1782666
Fatty acid-binding protein, liverMus musculus (house mouse)Ki1.00000.02100.34832.0000AID1802031
Cannabinoid receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.21800.00020.660910.0000AID49003
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki0.04680.00020.566510.0000AID1137821; AID1287159; AID1709174; AID238320; AID238758; AID49144; AID49492; AID49662; AID497598; AID537503
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)0.00280.00010.275310.0000AID636834
Cannabinoid receptor 1Homo sapiens (human)Ki0.02950.00010.50779.6000AID1127482; AID1186019; AID1230030; AID1333350; AID1546674; AID1630814; AID1692636; AID1781159; AID299500; AID406791; AID459553; AID49314; AID49315; AID49684; AID49687; AID646621; AID714693; AID750731
Cannabinoid receptor 2 Homo sapiens (human)IC50 (µMol)0.00950.00081.58409.8000AID636835
Cannabinoid receptor 2 Homo sapiens (human)Ki0.03660.00000.415610.0000AID1127483; AID1186020; AID1230031; AID1333351; AID1630815; AID1692637; AID1709176; AID1781160; AID238759; AID299499; AID326577; AID406790; AID459824; AID497599; AID49832; AID49843; AID49845; AID49846; AID537504; AID646624; AID714692; AID750728
Cannabinoid receptor 1Mus musculus (house mouse)Ki0.04050.00060.72467.2000AID299504; AID49469
Cannabinoid receptor 2Mus musculus (house mouse)Ki0.03030.00020.07970.7943AID1709175; AID299503; AID49846
Lysophosphatidylserine lipase ABHD12Homo sapiens (human)IC50 (µMol)11.60000.08000.16820.1905AID1781166
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)100.00000.00091.126810.0000AID1781164
Monoacylglycerol lipase ABHD6Homo sapiens (human)IC50 (µMol)48.20000.01320.03000.0480AID1781165
Cannabinoid receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.21800.00210.30900.8200AID49003
Cannabinoid receptor 2Rattus norvegicus (Norway rat)Ki0.04600.02000.22060.9120AID49144
G-protein coupled receptor 55Homo sapiens (human)IC50 (µMol)14.20000.64000.64000.6400AID750737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)18.93330.00203.519610.0000AID1215086; AID1215087; AID1215094
Glutamate receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.19950.00411.89638.7000AID257800
Glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.19950.00411.62517.6000AID257800
Glutamate receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)0.19950.00411.17063.5000AID257800
Glutamate receptor 4Rattus norvegicus (Norway rat)EC50 (µMol)0.19950.00411.13393.5000AID257800
Cannabinoid receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.07380.00020.19211.9953AID257800; AID49474
Cannabinoid receptor 1Homo sapiens (human)EC50 (µMol)0.04580.00010.12752.2400AID1186023; AID1781161; AID646622
Glycine receptor subunit alpha-1Homo sapiens (human)EC50 (µMol)1.30000.32001.45774.2000AID1203550
Cannabinoid receptor 2 Homo sapiens (human)EC50 (µMol)0.00860.00030.15173.2800AID1186021; AID1781162; AID406792
D(3) dopamine receptorHomo sapiens (human)EC50 (µMol)0.01020.00010.02470.6690AID1441146
Cannabinoid receptor 2Mus musculus (house mouse)EC50 (µMol)0.00730.00730.15460.7040AID1573480
N-arachidonyl glycine receptorHomo sapiens (human)EC50 (µMol)4.61000.02001.55804.6100AID750732
Transient receptor potential cation channel subfamily A member 1Rattus norvegicus (Norway rat)EC50 (µMol)0.23000.06002.22238.4000AID482146
G-protein coupled receptor 55Homo sapiens (human)EC50 (µMol)10.00000.00200.66622.0100AID1725633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)Activity10.00000.09908.019810.0000AID500219
Cannabinoid receptor 1Homo sapiens (human)Log Ki0.00160.00030.00190.0036AID49325
Cannabinoid receptor 2 Homo sapiens (human)Log Ki0.00160.00050.00200.0035AID49851
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (298)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
lactate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
glycolytic processL-lactate dehydrogenase A chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
CD8-positive, alpha-beta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
CD8-positive, gamma-delta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of leukocyte chemotaxisN-arachidonyl glycine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionN-arachidonyl glycine receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionN-arachidonyl glycine receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
phosphatidylserine catabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
adult walking behaviorLysophosphatidylserine lipase ABHD12Homo sapiens (human)
phospholipid catabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
response to auditory stimulusLysophosphatidylserine lipase ABHD12Homo sapiens (human)
arachidonic acid metabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
acylglycerol catabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
glycerophospholipid catabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
regulation of inflammatory responseLysophosphatidylserine lipase ABHD12Homo sapiens (human)
monoacylglycerol catabolic processLysophosphatidylserine lipase ABHD12Homo sapiens (human)
macromolecule depalmitoylationLysophosphatidylserine lipase ABHD12Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
phospholipid catabolic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
arachidonic acid metabolic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
negative regulation of cell migrationMonoacylglycerol lipase ABHD6Homo sapiens (human)
acylglycerol catabolic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
positive regulation of lipid biosynthetic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
monoacylglycerol catabolic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
long-term synaptic depressionMonoacylglycerol lipase ABHD6Homo sapiens (human)
regulation of retrograde trans-synaptic signaling by endocanabinoidMonoacylglycerol lipase ABHD6Homo sapiens (human)
negative regulation of cold-induced thermogenesisMonoacylglycerol lipase ABHD6Homo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoacylglycerol lipase ABHD6Homo sapiens (human)
lysobisphosphatidic acid metabolic processMonoacylglycerol lipase ABHD6Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
activation of phospholipase C activityG-protein coupled receptor 55Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 55Homo sapiens (human)
cannabinoid signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
bone resorptionG-protein coupled receptor 55Homo sapiens (human)
negative regulation of osteoclast differentiationG-protein coupled receptor 55Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled receptor 55Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
L-lactate dehydrogenase activityL-lactate dehydrogenase A chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
cadherin bindingL-lactate dehydrogenase A chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityN-arachidonyl glycine receptorHomo sapiens (human)
phospholipase activityLysophosphatidylserine lipase ABHD12Homo sapiens (human)
lysophospholipase activityLysophosphatidylserine lipase ABHD12Homo sapiens (human)
palmitoyl-(protein) hydrolase activityLysophosphatidylserine lipase ABHD12Homo sapiens (human)
acylglycerol lipase activityLysophosphatidylserine lipase ABHD12Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
phospholipase activityMonoacylglycerol lipase ABHD6Homo sapiens (human)
protein bindingMonoacylglycerol lipase ABHD6Homo sapiens (human)
acylglycerol lipase activityMonoacylglycerol lipase ABHD6Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 55Homo sapiens (human)
cannabinoid receptor activityG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (60)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
nucleusL-lactate dehydrogenase A chainHomo sapiens (human)
cytosolL-lactate dehydrogenase A chainHomo sapiens (human)
membraneL-lactate dehydrogenase A chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase A chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase A chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase A chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
membraneN-arachidonyl glycine receptorHomo sapiens (human)
cytoplasmic vesicle membraneN-arachidonyl glycine receptorHomo sapiens (human)
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
endoplasmic reticulum membraneLysophosphatidylserine lipase ABHD12Homo sapiens (human)
plasma membraneLysophosphatidylserine lipase ABHD12Homo sapiens (human)
membraneLysophosphatidylserine lipase ABHD12Homo sapiens (human)
dendrite cytoplasmLysophosphatidylserine lipase ABHD12Homo sapiens (human)
AMPA glutamate receptor complexLysophosphatidylserine lipase ABHD12Homo sapiens (human)
endoplasmic reticulum membraneLysophosphatidylserine lipase ABHD12Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
lysosomal membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
plasma membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
late endosome membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
mitochondrial membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
postsynaptic membraneMonoacylglycerol lipase ABHD6Homo sapiens (human)
glutamatergic synapseMonoacylglycerol lipase ABHD6Homo sapiens (human)
GABA-ergic synapseMonoacylglycerol lipase ABHD6Homo sapiens (human)
AMPA glutamate receptor complexMonoacylglycerol lipase ABHD6Homo sapiens (human)
mitochondrionMonoacylglycerol lipase ABHD6Homo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (390)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346701Human CB1 receptor (Cannabinoid receptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1346728Human CB2 receptor (Cannabinoid receptors)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID1346556Human TRPA1 (Transient Receptor Potential channels)2004Nature, Jan-15, Volume: 427, Issue:6971
Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1.
AID1346814Human GPR18 (GPR18, GPR55 and GPR119)2012British journal of pharmacology, Apr, Volume: 165, Issue:8
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
AID1346701Human CB1 receptor (Cannabinoid receptors)1995Molecular pharmacology, Sep, Volume: 48, Issue:3
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1346814Human GPR18 (GPR18, GPR55 and GPR119)2012British journal of pharmacology, Apr, Volume: 165, Issue:8
So what do we call GPR18 now?
AID1346728Human CB2 receptor (Cannabinoid receptors)1995Molecular pharmacology, Sep, Volume: 48, Issue:3
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1346564Rat TRPV2 (Transient Receptor Potential channels)2008The Journal of neuroscience : the official journal of the Society for Neuroscience, Jun-11, Volume: 28, Issue:24
TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Dec, Volume: 152, Issue:7
The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996The Journal of biological chemistry, Apr-26, Volume: 271, Issue:17
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID714717Hypothermic activity in iv dosed Harlan ICR mouse assessed as change in rectal temperature at 30 mins2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1131388CNS activity in po dosed rat assessed as increase in latency to kill by muricidal rat test1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 2. Synthesis and central nervous system activities of some B-ring homocannabinoid derivatives and related lactones.
AID137780Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 100 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID167501Number of rabbits convulsed at 0.9 mg/kg, iv out of 9 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID497600Ratio of Ki for CB1 receptor in Sprague-Dawley rat brain cortex membranes to Ki for human CB2 receptor2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.
AID1524906Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1333351Agonist activity at CB2 receptor (unknown origin)2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
AID193536The compound was tested for decreasing motor activity in rat at a dose of 10 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1782666Non-competitive inhibition of human LDHA assessed as reduction in lactate production using pyruvate as substrate in presence of NADH by Lineweaver-Burk plot analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
Cannabichromene and Δ
AID1149115Antianxiety activity in albino BALB/cJ mouse assessed as reduction in footshock-induced fighting behavior at 10 mg/kg, po after 30 to 90 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID137784Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 50 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID362541Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1199B after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID177668Effective Dose when administered at a dose of 0.94 mg/kg in rats1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids.
AID49846Binding affinity was determined for Cannabinoid receptor 22000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.
AID49845Binding affinity towards Cannabinoid receptor 2 using CP-55940 as radioligand in HEK293 EBNA cells2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.
AID132312The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 7.5 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID128385Tested for the ability to alter the spontaneous activity in mice at 10.0 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1149144Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1230030Displacement of [3H]CP55940 from full length human recombinant CB1 receptor expressed in HEK293 cells after 90 mins by scintillation counting analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID406791Displacement of [3H]CP-55940 from human CB1 receptor2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Novel benzimidazole derivatives as selective CB2 agonists.
AID128392Tested for the ability to alter the spontaneous activity in mice at 7.5 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID137781Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 150 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID257800Displacement of [35S]GTP-gamma-S from rat cerebellar CB1 receptor2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
AID714693Displacement of [3H]CP55940 from CB1 receptor2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID139354Tail-flick latency was determined at a concentration of 50 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID646622Agonist activity at human CB1 receptor expressed in HEK293 EBNA cells by [35S]GTPgamma binding assay2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1149133Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 10 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1132947Toxicity in ip dosed Wistar rat assessed as tachycardia1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID159813Effective dose injected to pigeons in drug discrimination test at a given period of 1.5 hours1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
A novel probe for the cannabinoid receptor.
AID1725631Antagonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as inhibition of THC-induced beta arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1149190Increase in pepsin concentration in Sprague-Dawley rat at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1230031Displacement of [3H]CP55940 from full length human recombinant CB2 receptor expressed in HEK293 cells after 90 mins by scintillation counting analysis2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1230034Neurobehavioral effect on Swiss Webster mouse assessed as locomotor activity measured as total number of interruptions at 20 mg/kg, ip monitored for 30 mins (Rvb = 2091 +/- 209.3 No_unit) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1133176Ratio of delta9 THC Ki to compound Ki for mouse brain synaptosomal acyl-CoA:lysophosphatidylcholine acyltransferase using substrate [32P]lysophosphatidylcholine and oleoyl-CoA1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID49492Binding affinity for Cannabinoid receptor 1 using African green monkey (COS-7) cells transfected with the cDNA of rat brain synaptosomal membrane preparations.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID1133174Antihemolytic potency against hypotonic lysis-induced erythrocytes (unknown origin) assessed as stabilization1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID1573536Ratio of EC50 for C-terminally prolink-tagged mouse CB2 receptor expressed in CHOK1 cells harboring beta-galactosidase enzyme fused beta-arrestin assessed as increase in beta-arrestin recruitment to EC50 for mouse CB2 receptor expressed in HEK293 cells as2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1781167In vivo agonist activity at CB1R in BALB/c mouse assessed as induction of hypothermia at 50 mg/kg, ip measured after 1 hr by rectal measurement method
AID299504Binding affinity to mouse CB1 receptor2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1630815Binding affinity to CB2 receptor (unknown origin)
AID132617Tested for the concentration for the inhibition of spontaneous activity (SA).1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
AID1524910Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1211514Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1524904Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1692636Displacement of [3H]CP-55,940 from human CB1 receptor expressed in CHO cells incubated for 1 hr by liquid scintillation spectrometry2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID133443Compound was evaluated for the maximum possible effect in tail-flick test in mice at dose 1 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID646624Binding affinity to human CB2 receptor2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID49469Binding affinity for Cannabinoid receptor 1 in absence of phenylmethylsulfonyl fluoride (PMSF)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID1133175Molar volume, Vm of the compound at zero temperature1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID1150009Analgesic activity in po dosed Sprague-Dawley rat by tail flick assay1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1781170In vivo agonist activity at CB1R in BALB/c mouse assessed as induction of analgesia at 50 mg/kg, ip measured after 1 hr by hot plate test
AID1524909Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID133450Analgesic activity was determined by mouse hot plate (HP), 1 hour postdose.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
A cannabinoid derived prototypical analgesic.
AID49832Ability to bind with Cannabinoid receptor 2 using [H]CP-55940 as radioligand from cloned human receptor preparation1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
AID49687Compound was evaluated for Pharmacological response in the Cannabinoid receptor 11996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
AID114296Antinociception as measured from the tail - flick response (TF), in mice1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID128387Tested for the ability to alter the spontaneous activity in mice at 2.5 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID1151041Antinociceptive activity in sc dosed male white mouse by hot plate test1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
(-)-3-Isothujone, a small nonnitrogenous molecule with antinociceptive activity in mice.
AID714940Induction of catalepsy in iv dosed Harlan ICR mouse at 40 mins measured for 5 mins by ring immobility test2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID139358Evaluated for hypothermic activity in mice at a dose of 0 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1230047Neurobehavioral effect on Swiss Webster mouse assessed as hot plate latency time at 40 mg/kg, ip (Rvb = 8.32 +/- 2.20 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1230037Neurobehavioral effect on Swiss Webster mouse assessed as catalepsy latency time at 10 mg/kg, ip (Rvb = 2.1 +/- 0.60 secs) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID293905Effect on behavioral activity in mouse assessed as rectal temperature by tetrad test2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.
AID1230045Neurobehavioral effect on Swiss Webster mouse assessed as hot plate latency time at 10 mg/kg, ip (Rvb = 8.32 +/- 2.20 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1137822Displacement of [3H]CP55940 from mouse brain CB2 receptor expressed in HEK293 cells2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
C-ring cannabinoid lactones: a novel cannabinergic chemotype.
AID1127484Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1333350Agonist activity at CB1 receptor (unknown origin)2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
AID130663Evaluated for catalepsy activity in mice and percentage immobility was determined at a concentration of 0.3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID139359Evaluated for hypothermic activity in mice at a dose of 0 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1230035Neurobehavioral effect on Swiss Webster mouse assessed as locomotor activity measured as total number of interruptions at 40 mg/kg, ip monitored for 30 mins (Rvb = 2091 +/- 209.3 No_unit) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID180354The compound was tested for analgesic activity using (RTF) tail-flick test in rat1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID139360Evaluated for hypothermic activity in mice at a dose of 0.3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1781168In vivo agonist activity at CB1R in BALB/c mouse assessed as catalepsy like behaviour at 50 mg/kg, ip measured after 1 hr by bar test
AID646627Aqueous solubility of the compound at pH 7.42012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID1630814Binding affinity to CB1 receptor (unknown origin)
AID130665Evaluated for catalepsy activity in mice and percentage immobility was determined at a concentration of 3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID167339Number of rabbits convulsed at 0.05 mg/kg, iv out of 14 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1781159Displacement of [3H]CP55940 from human CB1 receptor transfected in CHO cells measured for 1.5 hrs by liquid scintillation counting analysis
AID132466The compound was tested for analgesic activity using writhing (W) test in mouse1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID139350Tail-flick latency was determined at a concentration of 30 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID49474Effective concentration for inhibition of Cannabinoid receptor 1-mediated adenylyl cyclase activity using African green monkey (COS-7) cells transfected with the cDNA of rat CB1 receptor1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID1524903Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID56263Cardiovascular effect for percentage change in heart rate in anesthetized dogs after 1 mg/kg iv dose1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID1149132Antipsychotic activity in rat assessed as reduction of methamphetamine-induced hyperactivity at 5 mg/kg, po administered prior to methamphetamine challenge relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID133442Compound was evaluated for the maximum possible effect in tail-flick test in mice at dose 0.3 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID113708Inhibition of spontaneous activity (SA) in mice1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID1524905Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1709176Displacement of [3H]CP55940 from human CB2 receptor expressed in HEK293 cell membrane by scintillation counting method2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID193376Percentage decrease in systolic blood pressure (heart rate) after 4 hr at 100 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID636834Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells after 90 mins2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Cannabinomimetic lipid from a marine cyanobacterium.
AID57835Tested for Maximal behavioral effect(overt behavior) in dogs, activity is expressed as av score at a dose of 0.2 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID714692Binding affinity to human CB2 receptor by filtration assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1149103Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing administered 30 mins prior to acetic acid challenge measured after 5 mins for 20 mins1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID238321Binding affinity for cannabinoid receptor 22005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1200343Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1230049Neurobehavioral effect on Swiss Webster mouse assessed as decrease in rectal temperature at 10 mg/kg, ip (Rvb = 0.58 +/- 0.26 degC) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1782665Inhibition of human LDHB assessed as reduction in lactate production using pyruvate as substrate at 10 uM in presence of NADH by spectrophotometric analysis relative to control2021Journal of natural products, 05-28, Volume: 84, Issue:5
Cannabichromene and Δ
AID1186020Displacement of [3H]CP55940 from human cannabinoid CB2 receptor expressed in CHO-K1 cells by liquid scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1150011Antianxiety activity in albino BALB/cJ mouse assessed as decrease in foot shock-induced fighting behavior at 5 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID362545Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID127747Tested for the ability to change in rectal temperature in mice at 5.0 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID636835Displacement of [3H]CP55940 from human recombinant CB2 receptor expressed in HEK293 cells after 90 mins2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Cannabinomimetic lipid from a marine cyanobacterium.
AID1131392CNS activity in po dosed mouse assessed as decrease in early exploratory behavior in activity cage1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 2. Synthesis and central nervous system activities of some B-ring homocannabinoid derivatives and related lactones.
AID1149139Antidepressant activity in mouse assessed as potentiation of DOPA-induced effect at 5 mg/kg, po administered 4 hrs prior to DOPA challenge1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID49694Inhibitory activity of 1 uM against human Cannabinoid receptor 2-mediated adenylyl cyclase using African green monkey (COS-7) cells transfected with the cDNA of human CB2 receptor1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID130662Evaluated for catalepsy activity in mice and percentage immobility was determined at a concentration of 0 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1441146Agonist activity at recombinant human CB1 receptor expressed in CHO-K1 cells assessed as increase in cAMP accumulation after 20 mins by HTRF assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolas
AID1725632Antagonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as inhibition of THC-induced beta arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relative to control2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1149164Hypnotic activity in cat assessed as increase in non-REM sleep time at 1 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID326577Displacement of [3H]CP-55940 from human cloned CB2 receptor2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID127837Compound was evaluated in vivo for Pharmacology response in the mouse model Antinociception (as tail flick, TF)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
AID1781165Inhibition of human ABHD6 transfected in HEK293 cells using 2-OG as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by liquid scintillation spectroscopy
AID139355Tail-flick latency was determined at a concentration of 6 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID406790Displacement of [3H]CP-55940 from human CB2 receptor2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Novel benzimidazole derivatives as selective CB2 agonists.
AID125659The compound was evaluated for the rating of psychotropic effects in rhesus monkey at a dose of 0.1 mg/Kg; value is (++) stupor, ataxia, suppression of motor activity, full ptosis1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Stereochemical requirements for cannabinoid activity.
AID482146Agonist activity at rat TRPA1 channel expressed in HEK293 cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1127482Binding affinity to human CB1 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1781163Inhibition of FAAH (unknown origin) in human U-937 cells using [ethanolamine-1-3H]AEA as substrate preincubated for 30 mins followed by substrate addition measured after 15 mins by liquid scintillation spectroscopy
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID139348Tail-flick latency was determined at a concentration of 150 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1709174Displacement of [3H]CP55940 from rat brain CB1 receptor by scintillation counting method2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID243030Ratio of the binding affinity towards CB1 receptor to that of CB2 receptor2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
AID362546Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID49481Concentration of compound required to inhibit 50% of [3H]WIN-55212 binding to Cannabinoid receptor 1 in rat cerebellum membranes.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.
AID132618Tested for the concentration that shows hypothermia as changes in rectal temperature (RT).1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
AID1287159Displacement of [3H]HU-243 from CB1 receptor in Sprague-Dawley rat brain incubated for 90 mins2016European journal of medicinal chemistry, Apr-13, Volume: 112Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
AID500219Agonist activity at TRPA12005Nature chemical biology, Jul, Volume: 1, Issue:2
Sensing with TRP channels.
AID1830990Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF542021Bioorganic & medicinal chemistry letters, 12-15, Volume: 54THC shows activity against cultured Plasmodium falciparum.
AID750731Displacement of [3H]-CP55,940 from human CB1 receptor transfected in CHOK1 cells2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID139346Tail-flick latency was determined at a concentration of 100 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1573483Inverse agonist activity at C-terminally prolink-tagged mouse CB2 receptor expressed in CHOK1 cells harboring beta-galactosidase enzyme fused beta-arrestin assessed as increase in beta-arrestin recruitment after 90 mins by chemiluminescent assay relative 2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID326576Displacement of [3H]CP-55940 from CB1 receptor in Sprague-Dawley rat brain membrane2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID137782Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 3 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1901239Hypothermic effect in in female Sprague-Dawley rat model assessed as reduction in body temperature at 10 to 30 mg/kg after 30 to 360 mins2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID49843Binding affinity to Cannabinoid receptor 2 using African green monkey (COS-7) cells Chinese hamster ovary(CHO) cells transfected with the cDNA of human CB21997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID137777Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 0 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID133451Analgesic activity was determined by mouse phenylbenzoquinone (PBQ) induced writhing, 1 hour postdose.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
A cannabinoid derived prototypical analgesic.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1524914Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID125658The compound was evaluated for the rating of psychotropic effects in rhesus monkey at a dose of 0.05 mg/Kg; value is (-) No change1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Stereochemical requirements for cannabinoid activity.
AID159812Effective Dose when administered in pigeons1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids.
AID1546674Binding affinity to human CB1 receptor2020Journal of natural products, 01-24, Volume: 83, Issue:1
Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal
AID238759Binding affinity to displace [3H]CP-55940 from cloned human CB2 receptor2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
AID1573480Inverse agonist activity at mouse CB2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-mediated cAMP accumulation after 5 mins by fluorescence assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1725633Agonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID167487Number of rabbits convulsed at 0.1 mg/kg, iv out of 10 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID243998Inhibitory potency against fatty acid amide hydrolase activity in mouse brain microsomes in presence of 58 uM anandamide at 160 uM2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID129979Compound was evaluated for inhibition of spontaneous activity at 5-15 min in mouse when administered intravenously1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist.
AID1133173Inhibition of mouse brain synaptosomal Lysophosphatidylcholine acyltransferase using substrate [32P]lysophosphatidylcholine and oleoyl-CoA1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Molar volume relationships and the specific inhibition of a synaptosomal enzyme by psychoactive cannabinoids.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID714707Antinociceptive activity in iv dosed Harlan ICR mouse assessed as latency to heat-induced tail flicking at 20 mins2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID714690Selectivity ratio of Ki for CB1 receptor to Ki for human CB2 receptor2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID1230033Neurobehavioral effect on Swiss Webster mouse assessed as locomotor activity measured as total number of interruptions at 10 mg/kg, ip monitored for 30 mins (Rvb = 2091 +/- 209.3 No_unit) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1150017Antianxiety activity in po dosed beagle-like dog assessed as minimum dose required to produce moderate ataxia1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID362543Antibacterial activity against tetracycline-resistant Staphylococcus aureus XU212 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1131391CNS activity in rat assessed as decrease in septal-lesioned-induced hyperactivity at 10 mg/kg, po by septal-lesioned rat test1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Cannabinoids. 2. Synthesis and central nervous system activities of some B-ring homocannabinoid derivatives and related lactones.
AID133452Analgesic activity was determined by mouse tail flick (TF), 1 hour postdose.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
A cannabinoid derived prototypical analgesic.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID139366Evaluated for hypothermic activity in mice at a dose of 150 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID362544Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1149141Anticonvulsant activity in po dosed mouse assessed as dose required to protect 80% of animal measured after 1 to 4 hrs by audiogenic seizure test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1573481Inverse agonist activity at mouse CB2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-mediated cAMP accumulation after 5 mins by fluorescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1524912Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1147838Effect on overt behavior in dog assessed as prostration at 4 to 10 mg/kg, iv1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties.
AID1149196Increase in pepsin output in Sprague-Dawley rat at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149118Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 5 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID132307The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 5 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID299511Analgesic activity against formalin-induced acute pain in po dosed mouse2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1781160Displacement of [3H]CP55940 from human CB2 receptor transfected in CHO cells measured for 1.5 hrs by liquid scintillation counting analysis
AID1149201Antidiarrheal activity in Charles River rat assessed as inhibition of castor oil-induced diarrhea by measuring protected animals at 0.5 mg/kg, po administered 1 hr prior to castor oil challenge measured after 1 hr relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1203550Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID139368Evaluated for hypothermic activity in mice at a dose of 30 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1524913Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID362542Antibacterial activity against macrolide-resistant Staphylococcus aureus RN4220 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID193538The compound was tested for decreasing motor activity in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID167507Number of rabbits convulsed at 10 mg/kg, iv out of 1 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1692637Displacement of [3H]CP-55,940 from human CB2 receptor expressed in CHO cells incubated for 1 hr by liquid scintillation spectrometry2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID1137821Displacement of [3H]CP55940 from rat brain CB1 receptor2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
C-ring cannabinoid lactones: a novel cannabinergic chemotype.
AID137783Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 30 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID646623Agonist activity at human CB1 receptor expressed in HEK293 EBNA cells by [35S]GTPgamma binding assay relative to Win55,212-22012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID750737Antagonist activity at human GPR55 transfected in CHO cells assessed as inhibition of LPI-induced beta-arrestin recruitment incubated 60 mins prior to LPI addition by beta-arrestin translocation assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID537505Selectivity ratio of IC50 for CB1 receptor in Sprague-Dawley rat brain membranes to IC50 for human CB2 receptor2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.
AID1524911Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID193371Percentage decrease in systolic blood pressure (heart rate) after 24 hr at 100 mg/kg administered perorally in rats1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New antihypertensive cannabinoids.
AID1149157Hypnotic activity in cat assessed as increase in total sleep time at 4 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID57833Tested for Maximal behavioral effect(overt behavior) in dogs, activity is expressed as av score at a dose of 0.1 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID138344Concentration required to inhibit electrically induced contractions in isolated mouse vas deferens preparation in vitro1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.
AID1186019Displacement of [3H]CP55940 from human cannabinoid CB1 receptor expressed in CHO-K1 cells by liquid scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1149105Analgesic activity in po dosed Sprague-Dawley rat after 15 to 90 mins by tail flick test1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID140546The compound was tested for activity to decrease fighting in mouse at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID49314Binding affinity towards Cannabinoid receptor 1 using CP-55940 as radioligand in HEK293 EBNA cells2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.
AID139367Evaluated for hypothermic activity in mice at a dose of 3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1453021Competitive inhibition of human liver microsomes CYP1 expressed in supersomes coexpressing NADPH-CYP reductase using 7-Ethoxyresorufin as substrate measured every 5 mins for 30 mins in presence of NADPH by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID165405Capability to induce convulsions in tetrahydrocannabinol-seizure susceptible (THC-SS) rabbit1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID1149178Antisecretory activity in Sprague-Dawley rat assessed as decrease in acidity at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1524907Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1149145Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 10 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID112372The compound was tested in vivo for hypothermic activity in mice1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID1781166Inhibition of human ABHD12 transfected in HEK293 cells using 2-OG as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by liquid scintillation spectroscopy
AID195166The compound was tested for hyperexcitability in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1211515Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis in presence of O-20502012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID406792Agonist activity at cloned human CB2 receptor in Sf9 cells assessed as stimulation of [35S]GTPgammaS binding assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Novel benzimidazole derivatives as selective CB2 agonists.
AID137767Evaluated for reduction in spontaneous locomotor activity in mice at a dose of 0.3 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID222820Compound was evaluated for the cataleptic effect in the mouse at the dose 40 mg/kg1992Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities.
AID133444Compound was evaluated for the maximum possible effect in tail-flick test in mice at dose 2.5 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID130143Spontaneous activity in mice at a dose 0.3 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID132616Tested for the concentration for antinociception as measured by the tail-flick response (TF).1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
AID159815Effective dose injected to pigeons in drug discrimination test at a given period of 9.0 hours1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
A novel probe for the cannabinoid receptor.
AID646621Displacement of [3H]-CP55,940 from human CB1 receptor expressed in HEK293 cells2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID299509Analgesic activity against formalin-induced acute pain in iv dosed mouse2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1524902Cytotoxicity against human OVCAR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID1149156Hypnotic activity in cat assessed as increase in total sleep time at 1 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1230050Neurobehavioral effect on Swiss Webster mouse assessed as decrease in rectal temperature at 20 mg/kg, ip (Rvb = 0.58 +/- 0.26 degC) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID114230Ring immobility (RI) in mice1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID127743Tested for the ability to change in rectal temperature in mice at 10.0 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID112348Hypothermia as measured from changes in rectal (RT) in mice1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain.
AID130141Compound was evaluated for production of ring immobility at 90 min in mouse when administered intravenously1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist.
AID132301The difference between the preinjection and postinjection (60 min) temperatures in mice was evaluated at a dose 2.5 mg/kg1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol.
AID56262Cardiovascular effect for percentage change in blood pressure in anesthetized dogs after 1 mg/kg iv dose1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID112374The compound was tested in vivo for locomotor activity in mice1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID1149131Antianxiety activity in po dosed dog assessed as ataxia administered as single dose measured up to 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID125661The compound was evaluated for the rating of psychotropic effects in rhesus monkey at a dose of 0.25 mg/Kg; value is (++) stupor, ataxia, suppression of motor activity, full ptosis1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Stereochemical requirements for cannabinoid activity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID49003The compound was tested in vitro for binding activity against THC cannabinoid receptor site, using 3H-CP-55940 as the radioligand1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID127744Tested for the ability to change in rectal temperature in mice at 2.5 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID1150010Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1127494Antinociceptive activity against iv dosed ICR mouse measured at 20 mins by tail flick test2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID299510Analgesic activity against formalin-induced inflammatory pain in iv dosed mouse2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1149129Antianxiety activity in po dosed rhesus monkey assessed as antiagressive behavior measured every hour post dosing1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID139364Evaluated for hypothermic activity in mice at a dose of 100 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID646683Ratio of drug uptake in brain to plasma of Sprague-Dawley rat at 1 mg/kg, sc2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AID167338Number of rabbits convulsed at 0.01 mg/kg, iv out of 4 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID195165The compound was tested for hyperexcitability in rat at a dose of 20 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1186023Partial agonist activity at human cannabinoid CB1 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1230038Neurobehavioral effect on Swiss Webster mouse assessed as catalepsy latency time at 20 mg/kg, ip (Rvb = 2.1 +/- 0.60 secs) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID139349Tail-flick latency was determined at a concentration of 3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1830992Inhibition of Beta-hematin in Plasmodium falciparum cells assessed as hemozoin formation after 32 hrs by NP40 detergent-mediated assay2021Bioorganic & medicinal chemistry letters, 12-15, Volume: 54THC shows activity against cultured Plasmodium falciparum.
AID497599Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHO cells after 1 hr by liquid scintillation spectrometry analysis2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.
AID112376The compound was tested in vivo for ring immobility in mice1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID1230046Neurobehavioral effect on Swiss Webster mouse assessed as hot plate latency time at 20 mg/kg, ip (Rvb = 8.32 +/- 2.20 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID459824Displacement of [3H]CP-55940 from CB2 receptor2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.
AID1149142Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 25 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID159814Effective dose injected to pigeons in drug discrimination test at a given period of 4.5 hours1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
A novel probe for the cannabinoid receptor.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID137785Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 6 mg/Kg1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID299505Half life in rat at 2 mg/kg, iv and 30 mg/kg, po2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1230051Neurobehavioral effect on Swiss Webster mouse assessed as decrease in rectal temperature at 40 mg/kg, ip (Rvb = 0.58 +/- 0.26 degC) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID299503Binding affinity to mouse CB2 receptor2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID1781169In vivo agonist activity at CB1R in BALB/c mouse assessed as induction of hypolocomotion at 50 mg/kg, ip measured after 1 hr by rotarod test
AID185351Analgesic activity was determined by rat tail clamp assay(RTC), 2 hour postdose.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
A cannabinoid derived prototypical analgesic.
AID49315Binding affinity was determined for Cannabinoid receptor 12000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.
AID238320Binding affinity for cannabinoid receptor 12005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1150008Antidepressant activity in mouse assessed as potentiation of (+/-)Dopa-induced motor responses at 5 mg/kg, po challenged with Dopa after 4 hrs compound treatment1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID537503Displacement of [3H]CP-55940 from CB1 receptor in Sprague-Dawley rat brain membranes after 1 hr by liquid scintillation spectrophotometry2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.
AID1524916Inhibition of Wnt/beta-catenin signaling pathway in human HepG2 cells assessed as reduction in TCF-dependent beta-catenin mediated transcription at 20 to 40 uM incubated for 24 hrs by Topflash reporter assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID193540The compound was tested for decreasing motor activity in rat at a dose of 5 mg/Kg1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
New azacannabinoids highly active in the central nervous system.
AID1230039Neurobehavioral effect on Swiss Webster mouse assessed as catalepsy latency time at 40 mg/kg, ip (Rvb = 2.1 +/- 0.60 secs) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1132948Analgesic activity in po dosed mouse by hot plate test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1150015Antianxiety activity in Long-Evens rat assessed as decrease in motor activity at 10 mg/kg, po by tranquilizer activity test1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1127483Binding affinity to human CB2 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1149165Hypnotic activity in cat assessed as decrease in non-REM sleep time at 4 mg/kg administered orally through diet measured for 12 hrs by EEG analysis1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1149218Acute toxicity in po dosed mouse1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1203551Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID750728Displacement of [3H]-CP55,940 from human CB2 receptor transfected in CHOK1 cells2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID326578Selectivity for human cloned CB2 receptor over Sprague Dawley rat brain membrane CB1 receptor2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID1562903Displacement of [3H]JWH-018 from CB1R/CB2R in Wistar rat brain membranes after 60 mins by liquid scintillation analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors.
AID1150019Antipsychotic activity in Long-Evens rat assessed as reduction in methamphetamine-induced hyperactivity at 5 mg/kg, po1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID185350Analgesic activity was determined by rat flinch jump (FJ), 2 hour postdose.1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
A cannabinoid derived prototypical analgesic.
AID1132949Analgesic activity in po dosed mouse by anti-writhing test1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Drugs derived from cannabinoids. 7. Tachycardia and analgesia structure-activity relationships in delta9-tetrahydrocannabinol and some synthetic analogues.
AID1709175Displacement of [3H]CP55940 from mouse CB2 receptor expressed in HEK293 cell membrane by scintillation counting method2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID1150024Sedative-hypnotic activity in cat assessed as change in total sleep time at 1 mg/kg, po after 12 hrs1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID537504Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHO cells after 1 hr by liquid scintillation spectrophotometry2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.
AID1524908Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID139372Evaluated for hypothermic activity in mice at a dose of 50 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID167494Number of rabbits convulsed at 0.5 mg/kg, iv out of 20 rabbits tested1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
AID137779Evaluated for reduction in spontaneous locomotor activity in mice, at a dose of 0 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1781164Inhibition of MAGL (unknown origin) in human U-937 cells using [ethanolamine-1-3H]AEA as substrate preincubated for 30 mins followed by substrate addition measured after 15 mins by liquid scintillation spectroscopy
AID1230043Neurobehavioral effect on Swiss Webster mouse assessed as tail-flick latency time at 40 mg/kg, ip (Rvb = 0.84 +/- 3.58 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1725634Agonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relative to control2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID49144Compound was evaluated for the competitive inhibition of [3H]3-(1,1-Dimethyl-heptyl)-9-hydroxymethyl-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1-ol to cannabinoid receptor from synaptosomal membranes of rat whole brain1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
A novel probe for the cannabinoid receptor.
AID1149183Antisecretory activity in Sprague-Dawley rat assessed as decrease in acid output at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1590131Inhibition of LPS-induced PGE2 production in mouse J774 cells at 10 uM incubated for 24 hrs by enzyme immunoassay relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Eicosanoid mediation of cannabinoid actions.
AID1830991Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K12021Bioorganic & medicinal chemistry letters, 12-15, Volume: 54THC shows activity against cultured Plasmodium falciparum.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID132619Tested for the concentration that shows ring immobility (RI).1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
AID49856Compound was evaluated for its ability to displace specifically bound [3H]CP-55940 from a Cannabinoid receptor 2 enriched mouse spleen preparation.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
AID714694Locomotor activity in iv dosed Harlan ICR mouse from 5 to 15 mins by spontaneous locomotor activity test2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
AID49851Binding affinity towards cloned human cannabinoid receptor 22000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1590138Reduction in intraocular pressure in rabbit applied topically relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Eicosanoid mediation of cannabinoid actions.
AID238758Binding affinity to displace [3H]CP-55940 from CB1 receptor of rat brain2005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
AID139373Evaluated for hypothermic activity in mice at a dose of 6 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID127838Compound was evaluated in vivo for Pharmacology response in the mouse model Hypothermia (as rectal temperature, RT)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
AID49325Binding affinity towards cloned human Cannabinoid receptor 12000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1230042Neurobehavioral effect on Swiss Webster mouse assessed as tail-flick latency time at 20 mg/kg, ip (Rvb = 0.84 +/- 3.58 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1781162Partial agonist activity at human CB2 receptor transfected in CHO cells incubated for 90 mins by scintillation counting based [35S]GTP-gamma-S-binding assay
AID127281Compound was tested for activity in rhesus monkey behavioral test; Active1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
The importance of the orientation of the C9 substituent to cannabinoid activity.
AID1203549Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
AID750732Agonist activity at human GPR18 transfected in CHO cells after 90 mins by beta-arrestin translocation assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID112375The compound was tested in vivo for locomotor stimulus in rats1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID127839Compound was evaluated in vivo for Pharmacology response in the mouse model Spontaneous Activity1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
AID1524901Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain.
AID57836Tested for Maximal behavioral effect(overt behavior) in dogs, activity is expressed as av score at a dose of 0.4 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID459553Displacement of [3H]CP-55940 from CB1 receptor2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.
AID1781161Partial agonist activity at human CB1 receptor transfected in CHO cells incubated for 90 mins by scintillation counting based [35S]GTP-gamma-S-binding assay
AID1901237Antinociceptive activity against female Sprague-Dawley rat model of thermal-induced nociception at 0.01 to 10 mg/kg measured after 30 to 360 mins by tail flick test2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID130672Evaluated for catalepsy activity in mice and percentage immobility was determined at a concentration of 6 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID139342Tail-flick latency was determined at a concentration of 0.3 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID293909Effect on behavioral activity in intrathecally dosed mouse assessed as tail flick by tetrad test2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.
AID130142Compound was evaluated for reduction of rectal temperature at 60 min in mouse when administered intravenously1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID130667Evaluated for catalepsy activity in mice and percentage immobility was determined at a concentration of 30 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID128390Tested for the ability to alter the spontaneous activity in mice at 5.0 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID299500Binding affinity to human CB1 receptor2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1230041Neurobehavioral effect on Swiss Webster mouse assessed as tail-flick latency time at 10 mg/kg, ip (Rvb = 0.84 +/- 3.58 %) by mouse tetrad assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
AID1149121Antianxiety activity in Long-Evans rat assessed as reduction in motor activity at 20 mg/kg, po after 2 hrs relative to vehicle-treated control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID1186021Partial agonist activity at human cannabinoid CB2 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID129980Compound was evaluated for inhibition of tail-flick response at 20 min in mouse when administered intravenously1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and pharmacological properties of 11-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol: a high-affinity cannabinoid agonist.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID293904Effect on behavioral activity in mouse assessed as tail flick by tetrad test2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.
AID116116The compound was tested in vivo for tail-flick latency in mice1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.
AID1149143Antihypertensive activity in spontaneously hypertensive rat model assessed as reduction in blood pressure at 25 mg/kg, po after 24 hrs1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID497598Displacement of [3H]CP-55940 from CB1 receptor in Sprague-Dawley rat brain cortex membranes2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.
AID49663Compound was evaluated for its ability to displace specifically bound [3H]CP-55940 from a Cannabinoid receptor 1 enriched rat brain microsome preparation.1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
AID49662Binding to Cannabinoid receptor 1 using African green monkey (COS-7) cells transfected with the cDNA of rat CB1.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.
AID127749Tested for the ability to change in rectal temperature in mice at 7.5 mg/kg1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
3'-Hydroxy- and (+/-)-3',11-dihydroxy-delta 9-tetrahydrocannabinol: biologically active metabolites of delta 9-tetrahydrocannabinol.
AID293903Effect on behavioral activity in mouse assessed as spontaneous activity by tetrad test2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1211513Displacement of [3H]CP-55,940 from CB1 receptor in B6SJL mouse brain membrane after 90 mins by liquid scintillation spectrophotometric analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID299499Binding affinity to human CB2 receptor2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
AID49327Ratio of binding affinity towards cannabinoid receptor-1 (CB1) to that of cannabinoid receptor-2 (CB2)2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.
AID139341Tail-flick latency was determined at a concentration of 0 ug/Kg administered intraventricularly1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1149173Increase in volume in Sprague-Dawley rat at 50 mg/kg, po administered 30 mins prior to pylorus ligation measured after 4 hrs relative to control1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Drugs derived from cannabinoids. 5. delta6a,10a-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID49684Evaluated for its binding affinity towards Cannabinoid receptor 1 (CB1)1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
AID139340Tail-flick latency was determined at a concentration of 0 mg/Kg.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
AID1802031FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7,801)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902251 (28.86)18.7374
1990's837 (10.73)18.2507
2000's1432 (18.36)29.6817
2010's1999 (25.62)24.3611
2020's1282 (16.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.20 (24.57)
Research Supply Index9.12 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index148.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (80.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials785 (9.45%)5.53%
Reviews831 (10.00%)6.00%
Case Studies201 (2.42%)4.05%
Observational46 (0.55%)0.25%
Other6,444 (77.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (194)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of N-acetylcysteine on the Acute Cognitive Effects of Delta-9-Tetrahydrocannabinol [NCT02335060]Early Phase 15 participants (Actual)Interventional2014-05-02Terminated(stopped due to Feasibility pilot was completed)
Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans [NCT01180374]Early Phase 127 participants (Actual)Interventional2010-02-01Completed
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans [NCT02781519]Phase 1100 participants (Anticipated)Interventional2015-06-30Recruiting
Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study [NCT03008005]Phase 446 participants (Actual)Interventional2017-06-01Completed
A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (∆-9-THC) in Patients With Fibromyalgia [NCT01149018]80 participants (Anticipated)Interventional2010-06-30Recruiting
Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD) [NCT02759185]Phase 280 participants (Actual)Interventional2017-01-02Completed
The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain; a Randomized, Double Blinded, Placebo-controlled, Experiment [NCT01562483]Phase 236 participants (Actual)Interventional2012-10-31Completed
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus [NCT03093402]Phase 2109 participants (Actual)Interventional2017-12-21Completed
Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS): the Role of Sleep and Pain Phenotype [NCT05269628]Phase 2166 participants (Anticipated)Interventional2022-03-25Recruiting
The Roles of Endocannabinoids in Insulin Secretion and Action [NCT01517100]Phase 145 participants (Actual)Interventional2012-01-05Completed
Title A Pilot Trial to Evaluate Syndros in Decreasing Opioid Requirement in Patients With Bone Metastases From Breast Cancer [NCT03661892]Early Phase 114 participants (Actual)Interventional2018-12-19Completed
"A Randomized Double Blind Placebo Controlled Proof of Concept Study to Evaluate Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults With Tourette Syndrome (Entourage)" [NCT03651726]Phase 260 participants (Anticipated)Interventional2018-08-31Not yet recruiting
Dose-Titration Study to Evaluate the Opioid-Sparing Effect of Dronabinol When Coadministered With Opioid Analgesics to Chronic Pain Patients [NCT03766269]Phase 2280 participants (Anticipated)Interventional2018-12-01Recruiting
The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking [NCT02112292]10 participants (Actual)Interventional2014-04-30Completed
A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects With Obstructive Sleep Apnoea Who Are Intolerant, Non-Compliant, or Naïve to Positive Airway Pressure [NCT06146101]Phase 2/Phase 3560 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Randomised Four-Period Cross-Over Phase I Study to Assess Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs in Healthy Volunteers [NCT05857384]Phase 1116 participants (Anticipated)Interventional2023-09-08Recruiting
Effects of Cannabidiol and Tetrahydrocannabinol on the Microbiome, Endocannabinoids, and Neuroinflammation in HIV [NCT05514899]Phase 2100 participants (Anticipated)Interventional2023-07-15Recruiting
The Safety, Tolerability, and Analgesic Efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain [NCT01318369]Phase 224 participants (Actual)Interventional2011-10-31Completed
Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder [NCT03206463]Phase 12 participants (Actual)Interventional2017-08-01Terminated(stopped due to Feasibility pilot was completed)
A Double-Blind, Placebo-Controlled Study of Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors [NCT03530800]Phase 2/Phase 350 participants (Actual)Interventional2018-10-01Completed
Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia [NCT01302340]Phase 222 participants (Actual)Interventional2011-09-30Completed
Effect of Tetrahydrocannabinol (THC) on Sleep in Humans [NCT03560934]Early Phase 118 participants (Actual)Interventional2018-09-01Active, not recruiting
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic [NCT03984214]Phase 3104 participants (Anticipated)Interventional2019-12-16Recruiting
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I [NCT02811939]Phase 113 participants (Actual)Interventional2016-04-07Completed
The Effects of Δ⁹-Tetrahydrocannabinol on the Retrieval of Emotional Memories [NCT03471585]Early Phase 124 participants (Actual)Interventional2017-02-15Completed
Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial [NCT05335252]Phase 330 participants (Anticipated)Interventional2022-06-28Recruiting
Activation of the Endocannabinoid System and Cognition (Effekte Einer Akuten Aktivierung Des Cannabinoid-Systems Auf Kognitive Funktionen) [NCT05226351]180 participants (Anticipated)Interventional2022-03-01Recruiting
The Effect of Dronabinol on the Acquisition and Consolidation of Trauma-Associated Memories [NCT04871269]291 participants (Anticipated)Interventional2021-05-01Recruiting
An Electrophysiological Examination of CB1 and NMDA Receptors in Humans [NCT04199468]Phase 121 participants (Anticipated)Interventional2019-09-24Active, not recruiting
Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain [NCT00959218]Phase 3240 participants (Actual)Interventional2007-06-30Completed
A Comparative Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions [NCT01380457]Phase 169 participants (Actual)Interventional2006-01-31Completed
Examining the Efficacy of a Therapeutic Combination of Dronabinol (Synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Tourette Syndrome [NCT03066193]Phase 217 participants (Actual)Interventional2017-02-01Completed
Investigation of Cannabis for Chronic Pain and Palliative Care [NCT02683018]Phase 10 participants (Actual)InterventionalWithdrawn(stopped due to funding)
Investigation of Cannabis for Pain and Inflammation in Lung Cancer [NCT02675842]Phase 10 participants (Actual)InterventionalWithdrawn(stopped due to funding)
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans [NCT06058702]Phase 1215 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain. [NCT05351801]Phase 221 participants (Actual)Interventional2023-06-21Active, not recruiting
A Randomized Controlled Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain [NCT02460692]Phase 2131 participants (Actual)Interventional2016-12-31Completed
A Phase I, Single Center Crossover Study, Evaluating the Pharmacokinetic Profile and Safety of Self-emulsified THC/CBD Powder Compared With Equivalent Dose of THC/CBD Oil, Orally Administered. [NCT06149988]Phase 114 participants (Anticipated)Interventional2023-08-27Recruiting
Evaluation of Oral THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women [NCT05067387]Phase 122 participants (Anticipated)Interventional2024-04-30Not yet recruiting
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II [NCT04704271]Phase 1100 participants (Anticipated)Interventional2019-10-09Recruiting
Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function [NCT02291562]20 participants (Actual)Interventional2014-07-31Completed
Effects of Marijuana on Memory-Related Neurochemistry and Neural Response [NCT04855526]Early Phase 19 participants (Anticipated)Interventional2022-04-01Not yet recruiting
Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure [NCT05261321]Phase 120 participants (Anticipated)Interventional2022-10-15Recruiting
Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) [NCT02291536]20 participants (Actual)Interventional2014-02-28Completed
Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation [NCT05239390]Phase 220 participants (Anticipated)Interventional2021-12-29Recruiting
The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects [NCT03907163]24 participants (Actual)Interventional2018-07-02Completed
Using Imaging to Assess Effects of THC on Brain Activity [NCT03655717]316 participants (Actual)Interventional2018-11-05Completed
An Open Label ,Phase I, 2-way Crossover Study Evaluating the Pharmacokinetics of Prana P1 THC Activated Capsules [NCT03744091]Phase 113 participants (Actual)Interventional2018-07-16Active, not recruiting
Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD) [NCT02517424]Phase 26 participants (Actual)Interventional2017-02-07Completed
Sex- and AGE-dependent Effects of Smoked and Oral Delta-9-THC [NCT05865470]Phase 1103 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function [NCT02492074]Phase 160 participants (Anticipated)Interventional2020-06-30Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence [NCT01020019]Phase 2/Phase 3156 participants (Actual)Interventional2010-01-31Completed
Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study [NCT00623376]Phase 20 participants Interventional2007-07-31Completed
Investigating the Acute Effects of THC on Functional Brain Systems [NCT00628706]Phase 112 participants (Anticipated)Interventional2008-04-30Completed
Dronabinol Interactions in Humans [NCT00842985]Early Phase 153 participants (Actual)Interventional2008-09-30Completed
Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS) [NCT00812851]24 participants (Actual)Interventional2005-04-30Completed
The Effects of Dronabinol in Opioid-Related Outcomes [NCT04025359]Early Phase 136 participants (Anticipated)Interventional2019-05-31Recruiting
Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations [NCT03191084]Early Phase 126 participants (Actual)Interventional2017-12-01Completed
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone [NCT02576912]Phase 138 participants (Actual)Interventional2015-02-28Completed
Probing the Cannabinoid System in Individuals With a Family History of Psychosis [NCT02102113]Early Phase 121 participants (Anticipated)Interventional2014-01-31Active, not recruiting
A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels [NCT04231643]Early Phase 1144 participants (Anticipated)Interventional2021-09-01Recruiting
Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Pilot Study, Followed by an Open-Label Extension Phase [NCT03337503]Phase 4160 participants (Anticipated)Interventional2018-01-29Recruiting
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System, Cognition and Neuronal Oscillations [NCT02487381]Phase 160 participants (Anticipated)Interventional2015-04-30Completed
Investigating the Effect of Dronabinol on Post-surgical Pain [NCT04099355]Early Phase 10 participants (Actual)Interventional2025-09-01Withdrawn(stopped due to Funding not obtained)
Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia [NCT04155008]Phase 41 participants (Actual)Interventional2021-03-01Terminated(stopped due to The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled.)
A Single-dose, Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users [NCT02094599]Phase 143 participants (Actual)Interventional2014-02-28Completed
Modulation of ∆9-tetrahydrocannabinol Acute Psychoactive Effects by Ranging Doses of Cannabidiol in Healthy, Occasional Cannabis Users: a Controlled, Triple Blind, Randomized, Cross-over Study [NCT06099379]Phase 1/Phase 2100 participants (Anticipated)Interventional2023-11-15Not yet recruiting
Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease [NCT02792257]Phase 2160 participants (Anticipated)Interventional2017-03-01Recruiting
Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol? [NCT04851392]48 participants (Actual)Interventional2019-03-11Completed
Pharmacokinetic and Pharmacodynamic Evaluation of 3 Standard Formulations of Δ9-THC in Healthy Volunteers and Post-chemotherapy Patients in Colombia [NCT05272865]Phase 1/Phase 2334 participants (Anticipated)Interventional2023-08-15Not yet recruiting
Effects of Perioperative Dronabinol Use in Total Knee Arthroplasty [NCT04734080]Phase 4114 participants (Actual)Interventional2021-03-01Active, not recruiting
A Prospective, Randomized, Double Blind Trial Comparing Dronabinol to a Placebo in the Management of Post-operative Pain in Total Joint Arthroplasty [NCT04298528]Phase 3460 participants (Anticipated)Interventional2020-02-05Recruiting
Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain [NCT02569073]Phase 40 participants (Actual)Interventional2017-06-21Withdrawn(stopped due to Funding)
Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults [NCT03944954]Early Phase 150 participants (Anticipated)Interventional2017-07-15Recruiting
A Phase II Double-Blind Placebo-Controlled Trial of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal [NCT00480441]Phase 261 participants (Actual)Interventional2006-08-31Completed
Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Pilot, Randomized, Double-blind, Placebo-controlled, Crossover, Dose-ranging Trial [NCT05427630]Phase 220 participants (Anticipated)Interventional2023-02-15Enrolling by invitation
Determining the Combined Effects of THC and Alcohol on Driving Performance [NCT03555968]Phase 40 participants (Actual)Interventional2021-07-31Withdrawn(stopped due to Logistical issues)
Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC [NCT05287256]Phase 170 participants (Anticipated)Interventional2022-05-23Recruiting
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Efficacy Study of Oral Dronabinol Alone and in Combination With Ondansetron Versus Ondansetron Alone in Subjects With Delayed Chemotherapy-Induced Nausea and Vomiting [NCT00642512]Phase 364 participants (Actual)Interventional2003-07-31Completed
Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD [NCT00965809]Phase 470 participants (Anticipated)Interventional2009-10-31Active, not recruiting
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee [NCT04992624]Phase 2200 participants (Anticipated)Interventional2022-02-22Recruiting
Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia [NCT05742698]Phase 245 participants (Anticipated)Interventional2023-03-07Active, not recruiting
Cannabinoid Analgesia for Medical Abortion: A Randomized Controlled Trial [NCT03604341]Phase 472 participants (Actual)Interventional2018-11-01Completed
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans [NCT04920539]Phase 140 participants (Anticipated)Interventional2022-02-08Recruiting
Safety of Acute and Repeated Doses of Natural Medical Marijuana Products and Effects on Subjective and Physiological Responses to Stress and Pain [NCT04226690]Phase 124 participants (Actual)Interventional2022-11-15Active, not recruiting
An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Treatment, Four-Period, Crossover Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. [NCT02325011]Phase 114 participants (Actual)Interventional2014-11-30Completed
The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia [NCT02608931]Phase 20 participants (Actual)Interventional2015-11-30Withdrawn(stopped due to Unable to begin study with drug provider)
An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions [NCT02604992]54 participants (Actual)Interventional2015-11-30Completed
Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study [NCT00682929]Phase 1/Phase 241 participants (Actual)Interventional2004-04-14Terminated(stopped due to Unable to complete subject recruitment)
Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa [NCT00760695]Phase 324 participants (Actual)Interventional2008-10-31Completed
Smoked Marijuana Discrimination and Marijuana Choice in Humans: A Laboratory Mode [NCT00943930]29 participants (Actual)Observational2009-04-30Completed
Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects [NCT01591629]Early Phase 16 participants (Actual)Interventional2011-11-04Completed
Pharmacogenetics of Cannabinoid Response [NCT00678730]Early Phase 172 participants (Actual)Interventional2007-08-23Completed
A Randomized, Double-Blind, Placebo-Controlled, Multiple Crossover N-of-1 Study Design of the Use of Medicinal Cannabis Oil-Based Extracts for Symptom Management in Cancer Patients [NCT03948074]Phase 2150 participants (Anticipated)Interventional2021-02-01Recruiting
An Open-Label Study of Dronabinol, a Cannabinoid Agonist, for Obsessive Compulsive Disorder and the Obsessive-Compulsive Spectrum Disorders Trichotillomania and Pathological Skin Picking [NCT01093976]Phase 214 participants (Actual)Interventional2010-04-30Completed
Open-Label 4-Period Dose-Escalation Safety and Efficacy Study of AD313 in Participants With Obstructive Sleep Apnea [NCT05101122]Phase 1/Phase 215 participants (Actual)Interventional2021-10-19Completed
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers [NCT00743119]Phase 234 participants (Actual)Interventional2008-06-30Completed
Evaluation of Smoked THC and CBD in Oral Fluid, Pharmacokinetics, and Subjective and Neurocognitive Effects in Men and Women [NCT05037487]Phase 122 participants (Anticipated)Interventional2022-09-01Recruiting
Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations II [NCT05115513]Phase 132 participants (Anticipated)Interventional2022-08-25Active, not recruiting
Dronabinol On the Pain Experience (DOPE): a Pragmatic Randomized Clinical Trial [NCT05820685]Phase 4664 participants (Anticipated)Interventional2023-07-27Recruiting
A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas [NCT00314808]Phase 133 participants (Actual)Interventional2006-04-30Completed
Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease [NCT03978156]Phase 16 participants (Actual)Interventional2019-07-26Terminated(stopped due to Covid-19. Relocation of trainee/investigator. Covid-19.)
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study [NCT04605393]36 participants (Actual)Interventional2021-01-01Completed
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? [NCT01964404]Phase 1261 participants (Actual)Interventional2014-07-31Completed
A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting [NCT00642499]Phase 2103 participants (Actual)Interventional2003-08-31Completed
Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs [NCT04201197]Phase 122 participants (Actual)Interventional2020-11-10Completed
A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of a Cannabis-Infused Oil For Treatment of Insomnia in Major Depression [NCT05041647]Phase 260 participants (Anticipated)Interventional2023-08-28Recruiting
Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome [NCT01253408]Phase 236 participants (Actual)Interventional2009-09-30Completed
Cannabinoid Modulation of Pain [NCT01595620]Early Phase 16 participants (Actual)Interventional2011-11-09Completed
A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma [NCT05629702]Phase 2234 participants (Anticipated)Interventional2023-02-03Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis [NCT03451045]Phase 2447 participants (Actual)Interventional2017-12-22Completed
Dronabinol Naltrexone Treatment for Opioid Dependence [NCT01024335]Phase 2/Phase 360 participants (Actual)Interventional2010-01-31Completed
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design [NCT01551511]Phase 229 participants (Actual)Interventional2012-10-31Completed
Cannabinoid Control of Fear Extinction Neural Circuits in Humans [NCT02472847]Phase 485 participants (Actual)Interventional2012-05-31Completed
Effects of a Cannabis Extract as Anaesthetic Premedication on Postoperative Pain, Nausea-vomiting and Perioperative Anxiety [NCT02283281]Phase 2/Phase 3200 participants (Anticipated)Interventional2015-05-31Recruiting
A Mobile Prototype for a Field Sobriety Test for Cannabis [NCT03804840]Early Phase 148 participants (Actual)Interventional2017-03-01Completed
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC): Effectiveness, Side Effects and Neurobiological Changes [NCT03215940]Early Phase 175 participants (Anticipated)Interventional2018-02-01Recruiting
[NCT01598207]Phase 413 participants (Actual)Interventional2011-02-28Completed
A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol [NCT02485158]28 participants (Actual)Interventional2013-07-31Completed
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache [NCT00123201]Phase 20 participants Interventional2005-09-30Completed
Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers [NCT00438139]Phase 16 participants Interventional2007-03-31Terminated
A Randomized Controlled Clinical Trial of Dronabinol (Marinol) vs Placebo as Add-on Therapy For Patients on Opioids for Chronic Pain [NCT00153192]Phase 2/Phase 330 participants Interventional2001-04-30Completed
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes [NCT01832766]Phase 1/Phase 213 participants (Actual)Interventional2005-06-30Terminated(stopped due to Unable to find subjects with schizophrenia that were using only cannabis)
Cue Reactivity Model for Assessing Pharmacologic Intervention in Treatment of Cannabis Use Disorders (Study 2) [NCT00218504]20 participants (Anticipated)Observational2005-12-31Completed
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain [NCT05052541]Phase 3157 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Analgesic and Appetite-stimulating Effects of Cannabigerol Administered Alone and in Combination With Delta-9-tetrahydrocannabinol [NCT04859296]Phase 120 participants (Anticipated)Interventional2023-02-15Recruiting
THC and Marijuana--Effects in Individuals With HIV/AIDS [NCT00079560]Phase 1/Phase 230 participants (Actual)Interventional2001-12-31Completed
The Analgesic Efficacy of Perioperative Δ9-THC (Namisol®) in Patients Undergoing Major Abdominal Surgery: A Randomized, Double Blinded, Placebo-controlled, Parallel Design [NCT01790555]Phase 240 participants (Anticipated)Interventional2013-07-31Recruiting
Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy [NCT00553059]Phase 362 participants (Actual)Interventional2008-05-31Completed
Acute Effects of Smoked Marijuana on Decision Making, as Assessed by a Modified Gambling Task, in Experienced Marijuana Users [NCT00373399]Phase 136 participants (Actual)Interventional2006-05-31Completed
Effects of Combined Alcohol and Cannabis on Young Drivers' Simulated Driving [NCT03106363]Early Phase 185 participants (Actual)Interventional2017-07-04Completed
Efficacy of Inhaled Cannabis Versus Placebo for the Acute Treatment of Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Trial [NCT04360044]Phase 292 participants (Actual)Interventional2020-11-20Completed
Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects [NCT02054754]Phase 140 participants (Actual)Interventional2014-01-31Completed
A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study [NCT00316563]Phase 280 participants (Anticipated)Interventional2006-08-31Completed
Effect of Estradiol and Cortisol on Marinol Metabolism [NCT04374773]Phase 412 participants (Anticipated)Interventional2020-10-19Active, not recruiting
Phase II, Double Blind, Randomized, Placebo Controlled Trial of Dronabinol for the Treatment of Cervical Dystonia [NCT00418925]Phase 238 participants (Anticipated)Interventional2006-09-30Recruiting
A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease [NCT01502046]Phase 225 participants (Actual)Interventional2011-09-30Completed
Investigation of the Effects of Cannabis on the Immune-genome in People With HIV [NCT06034314]Phase 1160 participants (Anticipated)Interventional2023-09-21Recruiting
Safety and Tolerability of Oral Namisol®, a Tablet Containing Delta-9-Tetrahydrocannabinol, in Elderly Subjects: A Randomized Controlled Trial [NCT01740960]Phase 112 participants (Actual)Interventional2012-08-31Completed
Prevention of Postoperative Nausea and Vomiting in Surgical Patients [NCT00757822]216 participants (Actual)Interventional2009-12-31Completed
Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse [NCT00373503]Phase 28 participants (Actual)Interventional2005-08-31Completed
Sativex Associated With Behavioral-relapse Prevention Strategy as Treatment for Cannabis Dependence [NCT01747850]Phase 245 participants (Actual)Interventional2013-03-31Completed
The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial: A Pilot Study [NCT06175273]Phase 2/Phase 345 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Abuse Potential of Sativex in Subjects With a History of Recreational Marijuana Use [NCT01323569]Phase 158 participants (Actual)Interventional2008-02-29Completed
A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions [NCT01448772]Phase 188 participants (Actual)Interventional2011-10-31Completed
Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers [NCT00490269]Phase 112 participants (Actual)Interventional2006-10-31Completed
Neuroscience of Marijuana Impaired Driving [NCT02757313]Phase 162 participants (Actual)Interventional2016-10-31Completed
Effects of Dronabinol (Oral THC) on Cannabis Use [NCT01394185]Phase 1/Phase 225 participants (Actual)Interventional2011-02-28Completed
Impacts of THC Potency of Cannabis Concentrates and THC Metabolism on Cognitive Impairment in Young Adults [NCT06077292]110 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy [NCT05672342]Early Phase 1120 participants (Anticipated)Interventional2023-12-06Not yet recruiting
The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis [NCT03172741]Phase 2/Phase 30 participants (Actual)Interventional2017-01-31Withdrawn(stopped due to Did not pursue study)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis [NCT03813160]Phase 3176 participants (Actual)Interventional2018-12-17Completed
Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb [NCT00377468]Phase 2100 participants (Anticipated)Interventional2006-09-30Recruiting
Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults [NCT05906511]Early Phase 130 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Randomized, Double Blind Clinical Trial to Study the Effect of Cannabidiol (CBD) 133mg + Cannabigerol (CBG) 66mg + Tetrahydrocannabinol (THC) 4mg a Day as Adjunctive Therapy in the Treatment of Chronic Migraine - CAMTREA TRIAL [NCT04989413]Phase 4110 participants (Anticipated)Interventional2022-10-18Recruiting
Impact of Dronabinol on Post-operative Pain After Lumbar Fusion for Degenerative Disorders of the Spine [NCT04346407]Phase 490 participants (Anticipated)Interventional2020-09-01Enrolling by invitation
Cannabis Use, Cognition, and the Endocannabinoid System in HIV [NCT04883255]Early Phase 1138 participants (Anticipated)Interventional2023-05-03Recruiting
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I [NCT02709954]Phase 140 participants (Anticipated)Interventional2016-03-31Active, not recruiting
Effects of Fixed or Self-Titrated Dosages of Sativex on Cannabis Users [NCT01748799]16 participants (Actual)Interventional2013-02-28Completed
Single-site, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Dronabinol for the Treatment of Agitation in Outpatient With Dementia [NCT05612711]Phase 250 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Brain-Behavior Markers of Reward and Drug Effects in Young Adults [NCT04512365]Early Phase 180 participants (Anticipated)Interventional2021-03-16Recruiting
Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study [NCT04080427]Phase 1100 participants (Anticipated)Interventional2021-04-15Recruiting
Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia [NCT01608217]Phase 250 participants (Actual)Interventional2012-06-30Completed
Randomized, Controlled Cross-over Comparison of Cannabinoid to Oral Opioid for Postoperative Photorefractive Keratectomy Pain Control [NCT05477875]Phase 235 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome [NCT00000737]Phase 156 participants InterventionalCompleted
The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development [NCT00362089]208 participants (Actual)Interventional2006-06-30Completed
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia [NCT01598896]Phase 2/Phase 312 participants (Actual)Interventional2012-05-31Terminated(stopped due to low enrollment due to limited resources)
Acute and Residual Effects of Cannabis on Young Drivers' Performance of Driving-related Skills [NCT01592409]99 participants (Actual)Interventional2012-07-31Completed
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoid Combination (Δ9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD) In 1:1 Ratio) [NCT01893424]Phase 112 participants (Actual)Interventional2013-08-31Completed
A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy. [NCT00530764]Phase 2360 participants (Actual)Interventional2007-11-30Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction [NCT00217971]Phase 2156 participants (Actual)Interventional2005-03-31Completed
A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET). [NCT03805750]Phase 1/Phase 27 participants (Actual)Interventional2019-01-22Completed
The Pharmacokinetics of Oral Tetrahydrocannabinol and Cannabidiol Across the Spectrum of Glomerular Filtration Rate: a PharmacoKinetic Study [NCT05742724]Phase 124 participants (Anticipated)Interventional2023-01-11Recruiting
Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial [NCT01755091]Phase 275 participants (Actual)Interventional2013-02-28Completed
The Effect of Prescription Medications in Marijuana Users [NCT00893074]Phase 1/Phase 224 participants (Actual)Interventional2009-04-30Completed
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment [NCT00946348]Phase 112 participants (Actual)Interventional2009-12-31Completed
Age-Related Effects of THC [NCT04294966]Early Phase 124 participants (Actual)Interventional2020-03-10Completed
Dronabinol for the Reduction of Chronic Pain and Inflammation in People With Sickle Cell Disease [NCT05519111]Phase 260 participants (Anticipated)Interventional2022-10-01Recruiting
Differential Female Response to Δ9-tetrahydrocannabinol (THC): The Influence of Estradiol [NCT03809546]Early Phase 160 participants (Actual)Interventional2018-11-06Completed
Study on the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Diarrhea-Predominant Irritable Bowel Syndrome [NCT01786109]Phase 275 participants (Actual)Interventional2009-09-30Completed
Behavioral and Physiological Effects of delta9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) [NCT03832816]Phase 10 participants (Actual)Interventional2019-12-31Withdrawn(stopped due to cancellation of funding contract)
Marijuana's Impact on Alcohol Motivation and Consumption [NCT02983773]Phase 2131 participants (Actual)Interventional2017-01-23Completed
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I [NCT02811510]Phase 140 participants (Anticipated)Interventional2016-06-30Recruiting
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III [NCT02710331]Phase 140 participants (Anticipated)Interventional2016-03-31Active, not recruiting
The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary [NCT04596826]Phase 2100 participants (Anticipated)Interventional2020-11-11Recruiting
Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides [NCT02310347]18 participants (Actual)Interventional2014-12-31Active, not recruiting
CBD/THC Solution as a Pharmacological Strategy for Patients With Fibromyalgia. Single-center, Double-blind, Randomized, Placebo-controlled Clinical Trial Protocol (FibroCann) [NCT05283161]Phase 2/Phase 340 participants (Anticipated)Interventional2022-04-15Not yet recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis [NCT03398837]Phase 3365 participants (Actual)Interventional2017-12-18Terminated(stopped due to Sponsor terminated open-label extension)
A Single Centre Randomized Controlled Trial To Evaluate Dronabinol For Acute Pain Management In Adults With Traumatic Injury [NCT03928015]Phase 20 participants (Actual)Interventional2019-10-01Withdrawn(stopped due to This trial did not enroll subjects. After initial approval we procured an appropriate placebo. Before IRB the amendment was approved, the COVID-19 pandemic placed a hold on all non-essential research activity at the enrolling hospital.)
Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder [NCT02069366]86 participants (Actual)Interventional2014-11-30Completed
The Impact of Medical Cannabis on Pain and Inflammation in People Living With HIV [NCT05554146]100 participants (Anticipated)Interventional2022-10-28Recruiting
Dialysis Symptom Control-Pruritus Outcome Trial: A Randomized Blinded Placebo Controlled Crossover Trial [NCT05180968]Phase 314 participants (Actual)Interventional2022-08-02Completed
Phase I Pre-pilot Open-label Clinical Trial of Nabilone for Severe Behavioural Problems (Aggression) in Adults With Intellectual and Developmental Disabilities [NCT05273320]Phase 130 participants (Anticipated)Interventional2022-03-17Recruiting
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition [NCT02404688]Phase 140 participants (Anticipated)Interventional2015-12-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00217971 (1) [back to overview]Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial
NCT00314808 (5) [back to overview]Mean Change From Baseline in Quality of Life -- FLIE
NCT00314808 (5) [back to overview]Mean Change From Baseline in Quality of Life -- FACT-Br
NCT00314808 (5) [back to overview]Unacceptable Toxicity Rate
NCT00314808 (5) [back to overview]Tolerability Rate
NCT00314808 (5) [back to overview]Mean Change From Baseline in Quality of Life -- MMSE
NCT00373399 (1) [back to overview]Change From Baseline in Iowa Gambling Task Scores [Objective Measure of Decision Making]
NCT00480441 (2) [back to overview]Physiological Changes in Response to Cue-induced Craving.
NCT00480441 (2) [back to overview]Tolerability of Treatment
NCT00490269 (1) [back to overview]Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects.
NCT00530764 (9) [back to overview]Change in Patient Global Impression of Change - PGIC
NCT00530764 (9) [back to overview]Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline
NCT00530764 (9) [back to overview]Change in Sleep Disruption NRS
NCT00530764 (9) [back to overview]Change in Montgomery Asberg Depression Rating Scale (MADRS)
NCT00530764 (9) [back to overview]Change in Mean Daily NRS Pain Score (Worst Pain).
NCT00530764 (9) [back to overview]Change in Mean Daily NRS Pain Score (Average Pain).
NCT00530764 (9) [back to overview]Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)
NCT00530764 (9) [back to overview]Change in Cumulative Average Pain Response Curves
NCT00530764 (9) [back to overview]Change in Brief Pain Inventory - Short Form (BPI-SF)
NCT00553059 (7) [back to overview]Number of Participants With Vomiting for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Total Protection in the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Nausea for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Complete Response for the Acute, Delayed, and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants With Complete Protection for the Acute, Delayed, and Overall Periods
NCT00553059 (7) [back to overview]Number of Participants Received Rescue Medication in the Acute, Delayed and Overall Periods
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Expanded Disability Status Score (EDSS)
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Bowel and Bladder
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Brainstem
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Cerebellar
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Cerebral
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Pyramidal
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Sensory
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Functional System Score - Vision
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Modified Ashworth Score (MAS)
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Paced Auditory Serial Addition Test (PASAT) Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in the Rate of Torque Increase, Extension
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in the Rate of Torque Increase, Flexion
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in 25 Foot Walk Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in 9 Hole Peg Test (Dominant Hand) Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in 9 Hole Peg Test (Non- Dominant Hand) Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Ambulation Index (AI) Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Expanded Disability Status Score (EDSS)
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Bowel and Bladder
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Brainstem
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Cerebellar
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Cerebral
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Pyramidal
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Sensory
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Functional System Score - Vision
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Modified Ashworth Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in Paced Auditory Serial Addition Test (PASAT) Score
NCT00682929 (54) [back to overview]Change From Week 0 to Week 7 in the Rate of Torque Increase, Flexion
NCT00682929 (54) [back to overview]Change From Week 0 to Week3 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score
NCT00682929 (54) [back to overview]LIDO Machine Score - Rate of Torque Increase, Extension
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in 25 Foot Walk Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in 9 Hole Peg Test (Dominant Hand) Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in 9 Hole Peg Test (Non- Dominant Hand) Time
NCT00682929 (54) [back to overview]Change From Week 0 to Week 3 in Ambulation Index (AI) Score
NCT00743119 (1) [back to overview]Pain Tolerance
NCT00757822 (8) [back to overview]Post-Operative Care Unit Length of Stay (Min)
NCT00757822 (8) [back to overview]Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery
NCT00757822 (8) [back to overview]Incidence of Postoperative Nausea and Vomiting
NCT00757822 (8) [back to overview]Patient Satisfaction 2: Willingness to Pay Extra Money for Post-Operative Nausea and Vomiting (PONV) Preventive Medication
NCT00757822 (8) [back to overview]Post-operative Antiemetic Use
NCT00757822 (8) [back to overview]Post-Surgery Hospital Admissions (All Cause) After Out-patient Abdominal Procedure
NCT00757822 (8) [back to overview]Patient Satisfaction: Willingness to Take Pre-operative Medication for Post-operative Nausea and/or Vomiting
NCT00757822 (8) [back to overview]Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale
NCT00842985 (1) [back to overview]CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing
NCT00893074 (3) [back to overview]Peak Effect of Marijuana Withdrawal
NCT00893074 (3) [back to overview]Heart Rate
NCT00893074 (3) [back to overview]"Subjective Drug Effect After Smoked Marijuana"
NCT00946348 (1) [back to overview]fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC).
NCT01020019 (1) [back to overview]21 Days of Consecutive Abstinence as Measured by the Time-line Followback.
NCT01024335 (2) [back to overview]Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .
NCT01024335 (2) [back to overview]Retention
NCT01093976 (1) [back to overview]Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score
NCT01253408 (6) [back to overview]Ascending Colon Emptying T 1/2
NCT01253408 (6) [back to overview]Colonic Filling at 6 Hours
NCT01253408 (6) [back to overview]Colonic Transit Geometric Center at 24 Hours
NCT01253408 (6) [back to overview]Gastric Emptying Half-Time (t1/2)
NCT01253408 (6) [back to overview]Colonic Transit Geometric Center
NCT01253408 (6) [back to overview]Gastric Emptying at 2 and 4 Hours
NCT01394185 (2) [back to overview]Marijuana Self-administration - Progressive Ratio
NCT01394185 (2) [back to overview]Marijuana Self-administration - Drug Vs Money Choice
NCT01592409 (1) [back to overview]Psychomotor Impairment (Driving)
NCT01598207 (7) [back to overview]Frequency of Chest Pain Episodes
NCT01598207 (7) [back to overview]Frequency of Chest Pain in Treatment Group vs Baseline
NCT01598207 (7) [back to overview]Sensory Thresholds for First Sensation
NCT01598207 (7) [back to overview]Duration of Chest Pain Episodes
NCT01598207 (7) [back to overview]Intensity of Chest Pain Episodes
NCT01598207 (7) [back to overview]Sensory Thresholds for Discomfort
NCT01598207 (7) [back to overview]Sensory Thresholds for Pain
NCT01598896 (4) [back to overview]Change in Craving Symptoms From Baseline at 14 Weeks
NCT01598896 (4) [back to overview]Change in Craving Symptoms From Baseline at 10 Weeks
NCT01598896 (4) [back to overview]Change From Baseline in Cannabis Use at 14 Weeks
NCT01598896 (4) [back to overview]Change From Baseline in Cannabis Use at 10 Weeks
NCT01747850 (5) [back to overview]Tolerability
NCT01747850 (5) [back to overview]Withdrawal
NCT01747850 (5) [back to overview]Cannabis Use (in Days)
NCT01747850 (5) [back to overview]Cannabis Craving
NCT01747850 (5) [back to overview]Cannabis Use (Grams)
NCT01748799 (3) [back to overview]Feasibility
NCT01748799 (3) [back to overview]Tolerability of Sativex in Persons That Are Cannabis Dependent
NCT01748799 (3) [back to overview]Cannabis Withdrawal
NCT01755091 (5) [back to overview]Adverse Events (AEs)
NCT01755091 (5) [back to overview]Change in Apnea/Hypopnea Index (AHI)
NCT01755091 (5) [back to overview]Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)
NCT01755091 (5) [back to overview]Change in Epworth Sleepiness Scale (ESS)
NCT01755091 (5) [back to overview]Change in Desaturation Time (DT)
NCT01786109 (8) [back to overview]Postprandial Colonic Motility Index
NCT01786109 (8) [back to overview]Post-Treatment Overall Sensory Rating in Response to 16, 24, 32, and 40 mm Hg Distensions
NCT01786109 (8) [back to overview]Postprandial Change in Colonic Tone
NCT01786109 (8) [back to overview]Post-treatment Sensory Threshold for First Sensation
NCT01786109 (8) [back to overview]Post-treatment Sensory Threshold for First Perception of Pain
NCT01786109 (8) [back to overview]Fasting Colonic Tone
NCT01786109 (8) [back to overview]Post-Treatment Sensory Threshold for First Perception of Gas
NCT01786109 (8) [back to overview]Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)
NCT01832766 (3) [back to overview]P50 Auditory Evoked Potential
NCT01832766 (3) [back to overview]California Verbal Learning Test Change at 2 Hours From Baseline
NCT01832766 (3) [back to overview]Brief Psychiatric Rating Scale Change From Baseline at 1 Hour
NCT02054754 (2) [back to overview]Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters
NCT02054754 (2) [back to overview]Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose
NCT02069366 (3) [back to overview]Brain Measures
NCT02069366 (3) [back to overview]Expectancy Ratings
NCT02069366 (3) [back to overview]Subjective Units of Distress (SUDS)
NCT02460692 (17) [back to overview]Beck Depression Inventory II
NCT02460692 (17) [back to overview]Driving Simulation (Car Following)
NCT02460692 (17) [back to overview]Wechsler Adult Intelligence Scale-III Digit Symbol Test
NCT02460692 (17) [back to overview]Repeated Measures Recommended Minimal Dataset (NIH Task Force on Chronic Low Back Pain)
NCT02460692 (17) [back to overview]Profile of Mood States
NCT02460692 (17) [back to overview]Numerical Pain Intensity
NCT02460692 (17) [back to overview]Locally Developed Psychoactive Effect Scale - Good Drug Effect
NCT02460692 (17) [back to overview]Locally Developed Psychoactive Effect Scale - High
NCT02460692 (17) [back to overview]Marijuana Subscale (M-scale) of the Addiction Research Center Inventory
NCT02460692 (17) [back to overview]Hopkins Verbal Learning Test
NCT02460692 (17) [back to overview]Cold Pressor Test - Pain Tolerance
NCT02460692 (17) [back to overview]Neuropathic Pain Scale
NCT02460692 (17) [back to overview]Grooved Pegboard Test - Dominant Hand
NCT02460692 (17) [back to overview]Driving Simulation (Lane Tracking)
NCT02460692 (17) [back to overview]Cold Pressor Test - Pain Sensitivity
NCT02460692 (17) [back to overview]Cannabis Withdrawal Scale - Withdrawal Intensity
NCT02460692 (17) [back to overview]Cannabis Withdrawal Scale - Negative Impact of Withdrawal
NCT02472847 (1) [back to overview]BOLD Signal Measured by Functional Magnetic Resonance Imaging (fMRI)
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration
NCT02759185 (9) [back to overview]Actigraph Change in Sleep Efficiency
NCT02759185 (9) [back to overview]Change in PTSD Checklist (PCL-5) From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]Stage 1 Primary Endpoint CAPS-5 Total Severity Scores (Visit 5)
NCT02759185 (9) [back to overview]Change in Inventory of Psychosocial Functioning (IPF) From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]Change in Inventory of Depression and Anxiety (IDAS) Social Anxiety Total Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]Change in Inventory of Depression and Anxiety (IDAS) General Depression Total Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]Change in Insomnia Severity Index (ISI) Scores From Baseline to Stage 1 Primary Endpoint
NCT02759185 (9) [back to overview]Change in CAPS-5 Total Severity Scores From Baseline to Stage 1 Primary Endpoint (Visit 5)
NCT02759185 (9) [back to overview]Baseline CAPS-5 Total Severity Score
NCT03008005 (2) [back to overview]Brain Measures
NCT03008005 (2) [back to overview]Expectancy Ratings
NCT03066193 (1) [back to overview]Changes in Tic Severity
NCT03093402 (38) [back to overview]Number of BILAG-2004 Disease Flares
NCT03093402 (38) [back to overview]Number of BILAG-2004 Disease Flares
NCT03093402 (38) [back to overview]Number of BILAG-2004 Disease Flares
NCT03093402 (38) [back to overview]Number of BILAG-2004 Disease Flares
NCT03093402 (38) [back to overview]Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)
NCT03093402 (38) [back to overview]Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)
NCT03093402 (38) [back to overview]Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)
NCT03093402 (38) [back to overview]Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)
NCT03093402 (38) [back to overview]Percentage of Participants as Responders Using the SLE Responder Index (SRI)
NCT03093402 (38) [back to overview]Percentage of Participants Who Had 100% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits
NCT03093402 (38) [back to overview]Percentage of Participants Who Had at Least 30% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits
NCT03093402 (38) [back to overview]Percentage of Participants Who Had at Least 50% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits
NCT03093402 (38) [back to overview]Percentage of Participants Who Had at Least 75% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits Score
NCT03093402 (38) [back to overview]Percentage of Participants With Increased Scores From Baseline on ARCI-M
NCT03093402 (38) [back to overview]Percentage of Participants With Presence of Arthritis in SELENA-SLEDAI
NCT03093402 (38) [back to overview]Change From Baseline in Physician Assessed Swollen Joint Count
NCT03093402 (38) [back to overview]Number of Grade 3 or Higher Treatment-emergent Adverse Events (TEAE) Related to Study Product
NCT03093402 (38) [back to overview]Number of Treatment Emergent Events With Elevated Liver Tests
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS-29 Short Form Score - Physical Function T-score
NCT03093402 (38) [back to overview]Number of Treatment Emergent Intolerability Events
NCT03093402 (38) [back to overview]Number of Treatment Emergent QTc Prolongation Events
NCT03093402 (38) [back to overview]Percentage of Participants Indicating Clinical Benefit in Treatment Satisfaction
NCT03093402 (38) [back to overview]Percentage of Participants With Improvement From Baseline in Arthritis in BILAG-2004
NCT03093402 (38) [back to overview]Percentage of Physicians Indicating Participant Clinical Benefit in Treatment Satisfaction
NCT03093402 (38) [back to overview]Change From Baseline in Lupus Disease Activity - SELENA-SLEDAI Score
NCT03093402 (38) [back to overview]Change From Baseline in Lupus Disease Activity - Total BILAG-2004 Score
NCT03093402 (38) [back to overview]Change From Baseline in Lupus Disease Activity -Physician's Global Assessment (PGA) Score
NCT03093402 (38) [back to overview]Change From Baseline in Lupus Disease Activity- Patient Global Assessment Score
NCT03093402 (38) [back to overview]Change From Baseline in Physician Assessed Tender Joint Count
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Anxiety T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Depression T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Fatigue T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Pain Intensity
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Pain Interference T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Sleep Disturbance T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS - Social Role Satisfaction T-Score
NCT03093402 (38) [back to overview]Change in Baseline in PROMIS Cognitive Function T-Score
NCT03093402 (38) [back to overview]Improvement in the Maximum Daily NRS-Pain Score at Day 84
NCT03451045 (6) [back to overview]Time to First New Pulmonary Exacerbation (PEx)
NCT03451045 (6) [back to overview]Pulmonary Exacerbation (PEx) Rate Over 28 Weeks
NCT03451045 (6) [back to overview]Pulmonary Exacerbation (PEx) Rate
NCT03451045 (6) [back to overview]Pulmonary Exacerbation (PEx)
NCT03451045 (6) [back to overview]FEV1 % Predicted
NCT03451045 (6) [back to overview]CFQ-R Respiratory Symptom Domain
NCT03530800 (2) [back to overview]Skin Picking Symptom Assessment Scale (SP-SAS)
NCT03530800 (2) [back to overview]NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS)
NCT03604341 (1) [back to overview]Maximum Self-reported Pain Score on a Numeric Rating Scale
NCT03655717 (2) [back to overview]Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans During Resting State.
NCT03655717 (2) [back to overview]Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans of Patients Completing the N-back Task.
NCT03805750 (7) [back to overview]Accelerometry-based Assessment of Tremor Severity
NCT03805750 (7) [back to overview]Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)
NCT03805750 (7) [back to overview]Digital Spirography
NCT03805750 (7) [back to overview]Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
NCT03805750 (7) [back to overview]Number of Participants With New Study-related Electrocardiogram (EKG) Abnormalities
NCT03805750 (7) [back to overview]Number of Participants Reporting Adverse Events Based on Common Terminology Criteria
NCT03805750 (7) [back to overview]Global Impression of Change
NCT04201197 (10) [back to overview]Peak Change From Baseline Number of Correct Trials on Paced Auditory Serial Addition Task (PASAT)
NCT04201197 (10) [back to overview]Peak Change From Baseline Cognitive Performance as Assessed by the Divided Attention Task
NCT04201197 (10) [back to overview]Peak Change From Baseline Beats Per Minute for Heart Rate (HR)
NCT04201197 (10) [back to overview]Omeprazole AUC in Plasma
NCT04201197 (10) [back to overview]Number of Correct Trials on the Digit Symbol Substitution Task (DSST)
NCT04201197 (10) [back to overview]Midazolam AUC in Plasma
NCT04201197 (10) [back to overview]Losartan Area Under the Curve (AUC) in Plasma
NCT04201197 (10) [back to overview]Drug Effect Questionnaire (DEQ) - Peak Score for Feel Drug Effect
NCT04201197 (10) [back to overview]Dextromethorphan AUC in Plasma
NCT04201197 (10) [back to overview]Caffeine AUC in Plasma
NCT04294966 (1) [back to overview]Change From Baseline in Profile of Mood States (POMS)
NCT05101122 (1) [back to overview]Apnea-Hypopnea Index (AHI)4% Events Per Hour

Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial

Timeline Followback self report data was collected. This daily report was used to assess the proportion of patients abstinent during weeks 7 and 8 of the clinical trial. (NCT00217971)
Timeframe: weeks 7 and 8

Interventionparticipants (Number)
Dronabinol14
Placebo12

[back to top]

Mean Change From Baseline in Quality of Life -- FLIE

The mean change from baseline in quality of life as measured by the Functional Living Index Emesis (FLIE) scale during the first 24 and 72 hours of cycle 1. Change at 24 hours was computed as the 24 hour FLIE assessment minus the baseline assessment; whereas, change at 72 hours was computed as the 72 hour FLIE assessment minus the baseline assessment. The FLIE consists of 18 items for nausea and appetite on a 7-point scale. The effect of nausea and vomiting is measured by physical activity, social, and emotional function. Higher scores indicate less difficulty and interference with nausea and vomiting. Scores for the two subscales (nausea and vomiting) range between 0 and 54. (NCT00314808)
Timeframe: baseline, 24 hours, and 72 hours

Interventionunits on a scale (Mean)
Nausea at 24 hoursNausea at 72 hoursEmesis at 24 hoursEmesis at 72 hours
Dronabinol-13.07-4.18-10.96-3.50

[back to top]

Mean Change From Baseline in Quality of Life -- FACT-Br

The mean change between baseline and post-treatment in quality of life as measured by the Functional Assessment of Cancer Therapy-Brain (FACT-Br), where change is computed as quality of life at 2 months minus quality of life at baseline. The FACT-Br instrument consists of 54 items to assess physical(PWB), social and family (SWB), emotional (EWB), functional well-being (FWB), and additional brain cancer specific concerns (AC). Using a 5-point Likert type scale, responses to individual items range from 0 (not at all) to 4 (Very Much) with higher scores indicating better quality of life. PWB, SWB, and FWB are the sum of 7 items and have a possible range between 0 and 28. EWB ranges between 0 and 24, and is the sum of 6 items. AC is the sum of 19 items, and ranges between 0 and 76. (NCT00314808)
Timeframe: baseline and 2 months

Interventionunits on a scale (Mean)
Physical Well-Being (N=19)Social Well-Being (N=19)Emotional Well-Being (N=19)Functional Well-Being (N=19)Additional Concerns (N=11)
Dronabinol1.680.471.582.261.77

[back to top]

Unacceptable Toxicity Rate

Percentage of participants who experience one or more adverse events attributable to Dronabinol of the following types or grades: ≥Grade 3 non-hematologic, ≥Grade 2 hepatic/metabolic or ≥Grade 4 neuro toxicities (NCT00314808)
Timeframe: 2 months

Interventionpercentage of participants (Number)
Dronabinol0

[back to top]

Tolerability Rate

Percentage of participants where the 2 cycles of Dronabinol is tolerable. The treatment regimen is considered intolerable if (1) at least two adverse events of the following types that are attributed to Dronabinol during the 2 cycles of treatment occur: ≥Grade 3 non-hematologic, ≥Grade 2 hepatic/metabolic or ≥Grade 4 neuro toxicities, or (2) Dronabinol treatment is terminated early due to adverse events (NCT00314808)
Timeframe: Two months

Interventionpercentage of participants (Number)
Dronabinol60

[back to top]

Mean Change From Baseline in Quality of Life -- MMSE

The mean change between baseline and post-treatment in quality of life as measured by the Mini Mental Status Exam (MMSE). Change is computed as the MMSE level at month 2 minus MMSE level at baseline. MMSE is an 11-item questionnaire used to measure global cognitive status with scores ranging from 0 to 30; higher scores are an indication of greater cognitive function. (NCT00314808)
Timeframe: baseline and 2 months

Interventionunits on a scale (Mean)
Dronabinol1.41

[back to top]

Change From Baseline in Iowa Gambling Task Scores [Objective Measure of Decision Making]

"A modified version of the Gambling Task (Bechara et al., 1994) was used. Four decks of cards (A-D) were displayed on a computer screen. Volunteers were told that the objective of the game was to win as much money as possible. They were also told that the game entailed a series of card selections from any of the decks, one card at a time, and that they should select cards until instructed to stop. The task was stopped after 100 card selections or after 5 min had elapsed. Data indicate change from baseline in mean number of cards selected from advantageous decks minus number of cards selected from disadvantageous decks as a function of drug condition. Higher numbers indicate better decision making regarding advantageous cards.~Planned comparisons using single degrees of freedom, generated by a two-tailed repeated measures analysis of variance (ANOVA), were used to examine the effects of THC concentration (0% vs. 1.8%, 0% vs. 3.9%, and 1.8% vs. 3.9%) on task performance." (NCT00373399)
Timeframe: 3 weeks

Interventionmean number of cards (Mean)
Inactive Marijuana (0%THC)3.7
Low Dose Marijuana (1.8% THC)10.1
High Dose Marijuana (3.9% THC)4.4

[back to top]

Physiological Changes in Response to Cue-induced Craving.

Functional MRI brain response to cannabis vs neutral cues. Higher T values represent increased blood flow in response to cues. (NCT00480441)
Timeframe: Baseline functional mri (fMRI), (prior to randomization)

InterventionT value (Number)
All Participants5.65

[back to top]

Tolerability of Treatment

Reports of side effects leading to discontinuation of treatment were examined in all participants. (NCT00480441)
Timeframe: baseline to two years

Interventionparticipants (Number)
Placebo/Dronabinol0

[back to top]

Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects.

Does dronabinol (when given during smoking of a marijuana cigarette) show changes in the number of participants that experience cardiovascular effects of smoked marijuana or has any other combination side effects. (NCT00490269)
Timeframe: Day 9 and 10

Interventionparticipants (Number)
Dronabinol6
Placebo6

[back to top]

Change in Patient Global Impression of Change - PGIC

"A 7-point Likert-type scale was used, with the question: 'Please assess the status of your pain due to cancer since entry into the study using the scale below' with the markers very much improved, much improved, slightly improved, no change, slightly worse, much worse or very much worse. At Visit 2 (Baseline) patients wrote a brief description of their pain caused by cancer which was used at Week 5 to aid their memory regarding their symptoms at study start. For each of above markers the number of participants were reported." (NCT00530764)
Timeframe: End of Week 5

,,,
InterventionParticipants (Number)
Very much improvedMuch improvedSlightly improvedNo changeSlightly worseMuch worseVery much worse
Placebo9162817110
Sativex High Dose Group6202513612
Sativex Low Dose Group10241913310
Sativex Medium Dose Group6192613502

[back to top]

Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline

"A positive 30% pain response is defined as a reduction of at least 30% in the mean NRS average pain score from baseline to week 5 (last 3 days). The patient was asked on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. The average pain NRS was completed at the same time each day, i.e. bedtime in the evening." (NCT00530764)
Timeframe: 5 Weeks: Baseline (first 3 days) - Week 5 (last 3 days)

InterventionParticipants (Number)
Sativex High Dose Group22
Sativex Medium Dose Group26
Sativex Low Dose Group30
Placebo24

[back to top]

Change in Sleep Disruption NRS

"The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night? where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline." (NCT00530764)
Timeframe: 5 Weeks: Baseline - End of Treatment (Last 3 days of Week 5)

InterventionPoints on scale (Mean)
Sativex High Dose Group-0.7
Sativex Medium Dose Group-0.9
Sativex Low Dose Group-1.5
Placebo-0.8

[back to top]

Change in Montgomery Asberg Depression Rating Scale (MADRS)

The MADRS comprises of 10 questions that are completed by the patient to determine their depression level. The MADRS was completed at Visit 2 (Baseline) prior to receiving the study drug and at Visit 4 (Week 5 or premature termination). Each item is scored on a 0-6 scale , where 0=no sadness to 6=extreme and continuous gloom and despondency, and the MADRS score is the sum of the 10 item scores (range 0-60). The higher the score the more severe the depression. (NCT00530764)
Timeframe: Baseline and End of Treatment (Week 5 or premature termination)

InterventionScore on scale (Mean)
Sativex High Dose Group-0.4
Sativex Medium Dose Group-1.0
Sativex Low Dose Group-1.1
Placebo-2.9

[back to top]

Change in Mean Daily NRS Pain Score (Worst Pain).

"The worst pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked on a scale of '0 to 10', please indicate the number that best describes your worst pain in the last 24 hours where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in worst pain score from baseline." (NCT00530764)
Timeframe: 5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)

InterventionPoints on scale (Mean)
Sativex High Dose-1.0
Sativex Medium Dose-1.2
Sativex Low Dose-1.6
Placebo-0.9

[back to top]

Change in Mean Daily NRS Pain Score (Average Pain).

"The average pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline." (NCT00530764)
Timeframe: 5 Weeks: Baseline (first 3 days) - End of Treatment (last 3 days of week 5)

InterventionPoints on scale (Mean)
Sativex High Dose-0.9
Sativex Medium Dose-1.2
Sativex Low Dose-1.6
Placebo-0.8

[back to top]

Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)

The PAC-QoL questionnaire consists of 28 questions divided into the following areas: 4 questions on physical discomfort, 8 questions on psychosocial discomfort, 11 questions on worries/concerns and 5 questions on satisfaction. The PAC-QoL was completed at baseline and then at the end of treatment. An overall score (range 0-4) was calculated at each visit and the difference determined. A positive difference in score represents an improvement. (NCT00530764)
Timeframe: Baseline (Visit 2) and End of Treatment (Week 5 or premature termination)

InterventionScore on scale (Mean)
Sativex High Dose Group0.0
Sativex Medium Dose Group-0.1
Sativex Low Dose Group0.0
Placebo-0.1

[back to top]

Change in Cumulative Average Pain Response Curves

"The cumulative response to treatment is the percentage changes from baseline in the mean NRS pain score as defined as the 30% response.~The pain NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer." (NCT00530764)
Timeframe: Baseline to end of treatment (Week 5)

InterventionPercent Change (Median)
Sativex High Dose Group-13
Sativex Medium Dose Group-20
Sativex Low Dose Group-20
Placebo-10

[back to top]

Change in Brief Pain Inventory - Short Form (BPI-SF)

The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). the minimum value is zero and maximum is 10. A higher score represents a poor outcome. (NCT00530764)
Timeframe: Baseline (Visit 2) and End of Treatment (End of Week 5 or premature termination)

InterventionScore on scale (Mean)
Sativex High Dose Group-1.0
Sativex Medium Dose Group-1.5
Sativex Low Dose Group-1.3
Placebo-1.0

[back to top]

Number of Participants With Vomiting for the Acute, Delayed and Overall Periods

Number of Participants with Vomiting Acute, Delayed and Overall. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol61019
Placebo3919

[back to top]

Number of Participants With Total Protection in the Acute, Delayed and Overall Periods

Total protection is defined as no vomiting, no rescue therapy, and no nausea as indicated by responses to the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. Data to be recorded in the study diary during the 5-day study period. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221111
Placebo1455

[back to top]

Number of Participants With Nausea for the Acute, Delayed and Overall Periods

Number of Participants with Nausea for the Acute, Delayed and Overall Periods. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol81911
Placebo15235

[back to top]

Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods

Number of Participants With Nausea and Vomiting for the Acute, Delayed and Overall Periods. Evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol4715
Placebo2810

[back to top]

Number of Participants With Complete Response for the Acute, Delayed, and Overall Periods

Complete response is defined as vomiting episodes with rescue medication evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: Up to 5 days (first 5 days following first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221415
Placebo191312

[back to top]

Number of Participants With Complete Protection for the Acute, Delayed, and Overall Periods

Complete Protection is no vomiting, no rescue therapy, and no nausea evaluated for the acute (0-24 hour), delayed (24-120 hour), and overall (0-120 hour) periods as indicated by responses to the Daily Assessment of Nausea and Vomiting questionnaire. The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. (NCT00553059)
Timeframe: Up to 5 days (first 5 days following first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedOverall
Dronabinol221414
Placebo18109

[back to top]

Number of Participants Received Rescue Medication in the Acute, Delayed and Overall Periods

The assessment measures in detail the occurrence, duration, and severity of post-chemotherapy nausea and emesis using a 10-point Likert-type scale ranging from 0 (none) to 10 (as bad as it could be) if nausea or vomiting is present. The first section asks the patient to record presence and severity of nausea during the last 24 hours. The second section asks the patient to record vomiting episodes during the last 24 hours. The third section asks if the patient took medication for nausea or vomiting during the last 24 hours and asks how useful the treatment for nausea or vomiting was. The fourth section screens for toxicity by asking about side effects and problems experienced during the last 24 hours. Use of rescue antiemetic medication and adverse events also assessed and documented. (NCT00553059)
Timeframe: 5 Days (first 5 days of the first cycle of chemotherapy)

,
InterventionParticipants (Count of Participants)
AcuteDelayedResponse
Dronabinol31110
Placebo51512

[back to top]

Change From Week 0 to Week 3 in Expanded Disability Status Score (EDSS)

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The total EDSS score ranges from 0 to 10, in 0.5 unit increments. A score of 0 is the lowest (normal neurological exam) and 10 is the highest (death due to MS). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.0833
2) Oral THC0.0909
3) Placebo-0.2727

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Bowel and Bladder

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Bowel and Bladder score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (loss of bowel and bladder function). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.1667
2) Oral THC0.0
3) Placebo-0.2727

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Brainstem

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Brainstem score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (inability to swallow or speak). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.1667
2) Oral THC-0.0909
3) Placebo0.2727

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Cerebellar

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Cerebellar score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (unable to perform coordinated movements due to ataxia). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.50
2) Oral THC-0.20
3) Placebo-0.0909

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Cerebral

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Cerebral score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (dementia). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. Fatigue did not contribute to this FS score or the EDSS total score. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.50
2) Oral THC0.0
3) Placebo-0.3636

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Pyramidal

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Pyramidal score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (tetraplegia (grade 0 or 1 in all muscle groups of upper and lower limbs). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.3333
2) Oral THC-0.1818
3) Placebo0

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Sensory

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Sensory score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (sensation essentially lost below the head). Higher values indicate more impaired function. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.1667
2) Oral THC0.0
3) Placebo-0.1818

[back to top]

Change From Week 0 to Week 3 in Functional System Score - Vision

"The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Vision score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (grade 5 plus maximal visual acuity of better eye of 20/60 (0.3) or less).~Higher values indicate more impaired vision. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in vision and correlates to a better outcome." (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.1667
2) Oral THC-0.3000
3) Placebo-1.0

[back to top]

Change From Week 0 to Week 3 in Modified Ashworth Score (MAS)

The Modified Ashworth scale measures resistance during passive soft-tissue stretching. Spasticity is graded on a scale of 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). The highest score (flexion or extension), for the lower extremities only, was used for each subject. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates a decrease in spasticity and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on scale (Mean)
1) Inhaled Cannabis-0.333
2) Oral THC0
3) Placebo-0.4545

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score

The Bladder Control Scale is a 4-item scale developed to assess the impact of multiple sclerosis on bladder function. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-22. The scale is set up so that a higher score indicates greater bladder control problems. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in bladder control and correlates to a better outcome. A positive result indicates a decrease in bladder control and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.500
2) Oral THC-0.700
3) Placebo-2.1818

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score

The Bowel Control Scale is a 5-item scale developed to assess the impact of multiple sclerosis on bowel function. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-26. The scale is set up so that a higher score indicates greater bowel control problems. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in bowel control and correlates to a better outcome. A positive result indicates a decrease in bowel control and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.7143
2) Oral THC-1.000
3) Placebo0.7778

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score

The Impact of Visual Impairment Scale is a 5-item scale developed to assess the extent to which activities dependent on vision are affected by MS-related visual problems. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-15. The scale is set up so that a higher score indicates greater impact of visual problems on daily activities. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of visual problems on daily activities and correlates to a better outcome. A positive result indicates an increase in the impact of visual problems on daily activities and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.2857
2) Oral THC0.5556
3) Placebo0.00

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score

The Mental Health Inventory (MHI) is an 18-item scale developed as a measure of overall emotional functioning. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-100. The scale is set up so that a higher score indicates better mental health. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A positive result indicates an improvement in mental health and correlates to a better outcome. A negative result indicates decrease in mental health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-14.8148
2) Oral THC4.6296
3) Placebo4.6667

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score

The Modified Social Support Scale is an 18-item scale developed as a measure of perceived social support. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-100. The scale is set up so that a higher score indicates greater perceived support. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A positive result indicates an improvement in perceived support and correlates to a better outcome. A negative result indicates a decrease in perceived support and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-6.3988
2) Oral THC0.2604
3) Placebo7.1875

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score

The Pain Effects Scale is a 6-item scale developed to assess the effects of pain on behavior and mood. It is a part of the MS Quality of Life Inventory. The scale is measured from 6-30. The scale is set up so that a higher score indicates a greater impact of pain on a patient's mood and behavior. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of pain on mood and behavior and correlates to a better outcome. A positive result indicates an increase in the impact of pain on mood and behavior and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-1.0
2) Oral THC-2.20
3) Placebo-2.5455

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score

The Perceived Deficits Scale is a 20-item scale developed to assess the patient's perceived cognitive deficits. It is composed of four 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-80. The scale is set up so that a higher score indicates greater perceived cognitive impairment. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates a decrease in the perception of cognitive impairment. A positive result indicates an increase in the perception of cognitive impairment. Since patient perceptions of cognitive impairment may not correlate with objective measures of cognitive impairment, the results should be interpreted with caution. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-3.2857
2) Oral THC3.000
3) Placebo-6.600

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score

"The Sexual Satisfaction Scale is a 4-item scale developed to assess the impact of multiple sclerosis on sexual function and satisfaction. It is a part of the MS Quality of Life Inventory. The scale is measured from 4-24. The scale is set up so that a higher score indicates greater problems with sexual satisfaction. Subjects that answered No to the question, Do you have a relationship with one primary partner, did not complete the scale. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in sexual satisfaction and correlates to a better outcome. A positive result indicates a decrease in sexual satisfaction and correlates to a worse outcome." (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-4.250
2) Oral THC0.6667
3) Placebo-0.7778

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component Score

The SF-36 is a 36-item scale developed as a generic health status measure. It is a part of the MS Quality of Life Inventory. It can be reported as 2 summary scales - the Physical and Mental components. The scale is measured from 0 -100. The scale is set up so that a higher score indicates better health. The change was calculated by taking the Week 3 score and subtracting the Week 0. A positive result indicates an improvement in mental health status and correlates to a better outcome. A negative result indicates a decline in mental health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.7606
2) Oral THC-4.3820
3) Placebo2.9471

[back to top]

Change From Week 0 to Week 3 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score

The SF-36 is a 36-item scale developed as a generic health status measure. It is a part of the MS Quality of Life Inventory. It can be reported as 2 summary scales - the Physical and Mental components. The scale is measured from 0 -100. The scale is set up so that a higher score indicates better health. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A positive result indicates an improvement in health status and correlates to a better outcome. A negative result indicates a decline in health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis2.5734
2) Oral THC4.3401
3) Placebo1.2656

[back to top]

Change From Week 0 to Week 3 in Paced Auditory Serial Addition Test (PASAT) Score

The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability; The test is presented via recording on a CD to control the rate of stimulus presentation. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The test score is the number of correct sums given (out of a possible 60) in each trial. There are 2 test forms, A and B. The forms were alternated and at least 1 practice test (10 sums) was performed prior to each trial. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates an improvement in performance and correlates with a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionnumber correct (Mean)
1) Inhaled Cannabis-3.7143
2) Oral THC0.3636
3) Placebo2.5455

[back to top]

Change From Week 0 to Week 3 in the Rate of Torque Increase, Extension

A modified servo-controlled torque motor system (Lido WorkSet II) was designed for this study to analyze the resistance to passive movement of the knee. It determines the amount of torque required to move the knee joint (without voluntary resistance) at high velocities (up to 200 degrees per second) and at slow velocities (as low as 10 degrees per second). The slow displacement torque is a measure of the passive resistance to movement (from the connective tissue and the non-contracting muscle) and the rapid displacement torques are the sum of the passive and active (involuntary) resistance. The active (involuntary) resistance is the result of the stretch reflex and correlates well with the clinical assessment of spasticity. The change was calculated by taking the value at Week 3 and subtracting the value at Week 0. A negative result indicates a decrease in the torque measured and correlates to a decrease in spasticity and a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventiondegrees/second (Mean)
1) Inhaled Cannabis0.0004
2) Oral THC-0.0310
3) Placebo0.0105

[back to top]

Change From Week 0 to Week 3 in the Rate of Torque Increase, Flexion

A modified servo-controlled torque motor system (Lido WorkSet II) was designed for this study to analyze the resistance to passive movement of the knee. It determines the amount of torque required to move the knee joint (without voluntary resistance) at high velocities (up to 200 degrees per second) and at slow velocities (as low as 10 degrees per second). The slow displacement torque is a measure of the passive resistance to movement (from the connective tissue and the non-contracting muscle) and the rapid displacement torques are the sum of the passive and active (involuntary) resistance. The active (involuntary) resistance is the result of the stretch reflex and correlates well with the clinical assessment of spasticity. The change was calculated by taking the value at Week 3 and subtracting the value at Week 0. A negative result indicates a decrease in the torque measured and correlates to a decrease in spasticity and a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventiondegrees/second (Mean)
1) Inhaled Cannabis0.0018
2) Oral THC-0.0121
3) Placebo0.0007

[back to top]

Change From Week 0 to Week 7 in 25 Foot Walk Time

The Timed 25 Foot Walk is a quantitative measure of lower extremity function. The patient is instructed to walk on a marked 25-foot course, as quickly and as safely as possible. The patient is allowed to use his/her typical walking aid, if applicable. The task is completed twice and the average time of the two trials was used for this outcome measure. The change was calculated by taking the Week 7 time and subtracting the Week 0 time. A negative result indicates an improvement in walking ability and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionseconds (Mean)
1) Inhaled Cannabis-2.6000
2) Oral THC3.3667
3) Placebo2.2773

[back to top]

Change From Week 0 to Week 7 in 9 Hole Peg Test (Dominant Hand) Time

"The 9 hold peg test is a quantitative measure of upper extremity (arm and hand function). Patients are instructed to fill an 9 hole peg board with 1 peg at a time and then immediately remove the pegs, 1 at a time. The dominant hand is tested twice and the average time was used for this outcome measure. The change was calculated by taking the Week 7 time and subtracting the Week 0 time.~A negative result indicates an improvement in arm and hand function and correlates with a better outcome." (NCT00682929)
Timeframe: Week 0, Week 7

Interventionseconds (Mean)
1) Inhaled Cannabis5.6714
2) Oral THC1.4756
3) Placebo-0.4991

[back to top]

Change From Week 0 to Week 7 in 9 Hole Peg Test (Non- Dominant Hand) Time

"The 9 hold peg test is a quantitative measure of upper extremity (arm and hand function). Patients are instructed to fill an 9 hole peg board with 1 peg at a time and then immediately remove the pegs, 1 at a time. The dominant hand is tested twice and the average time was used for this outcome measure. The change was calculated by taking the Week 7 time and subtracting the Week 0 time.~A negative result indicates an improvement in arm and hand function and correlates with a better outcome." (NCT00682929)
Timeframe: Week 0, Week 7

Interventionseconds (Mean)
1) Inhaled Cannabis-2.1083
2) Oral THC-3.9556
3) Placebo0.5530

[back to top]

Change From Week 0 to Week 7 in Ambulation Index (AI) Score

The AI is a 9-point rating scale used to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. Scores range from 0 (asymptomatic, fully active) to 9 (restricted to wheelchair, unable to transfer self independently). Lower scores represent a better outcome for MS patients. For this study, the AI score was based on the results of the 25 Foot Walk test, also performed at the study visit. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result for this outcome indicates an improvement in ambulation and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.1429
2) Oral THC0.4444
3) Placebo0.3333

[back to top]

Change From Week 0 to Week 7 in Expanded Disability Status Score (EDSS)

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The total EDSS score ranges from 0 to 10, in 0.5 unit increments. A score of 0 is the lowest (normal neurological exam) and 10 is the highest (death due to MS). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.0714
2) Oral THC0.0
3) Placebo-0.2083

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Bowel and Bladder

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Bowel and Bladder score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (loss of bowel and bladder function). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.5714
2) Oral THC0.2500
3) Placebo-0.3333

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Brainstem

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Brainstem score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (inability to swallow or speak). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.1429
2) Oral THC0.6250
3) Placebo0.1667

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Cerebellar

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Cerebellar score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (unable to perform coordinated movements due to ataxia). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.5714
2) Oral THC-0.7500
3) Placebo0.0

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Cerebral

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Cerebral score is determined by a 6-point scale, with 0 being the lowest (normal) and 5 being the highest (dementia). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. Fatigue did not contribute to this FS score or the EDSS total score. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.4286
2) Oral THC0.0
3) Placebo-0.2500

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Pyramidal

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Pyramidal score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (tetraplegia (grade 0 or 1 in all muscle groups of upper and lower limbs). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.4286
2) Oral THC-0.5000
3) Placebo0.0833

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Sensory

The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Sensory score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (sensation essentially lost below the head). Higher values indicate more impaired function. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in function and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.0
2) Oral THC-0.1250
3) Placebo-0.3333

[back to top]

Change From Week 0 to Week 7 in Functional System Score - Vision

"The EDSS is a method of quantifying disability in MS patients and monitoring changes in the level of disability over time. The EDSS quantifies disability in 7 functional systems (FS): visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral, and includes a measure of ambulation. Neurostatus version 10/2002 was used for this study. The FS Vision score is determined by a 7-point scale, with 0 being the lowest (normal) and 6 being the highest (grade 5 plus maximal visual acuity of better eye of 20/60 (0.3) or less).~Higher values indicate more impaired vision. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in vision and correlates to a better outcome." (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.1429
2) Oral THC-0.3750
3) Placebo-0.6667

[back to top]

Change From Week 0 to Week 7 in Modified Ashworth Score

The Modified Ashworth scale measures resistance during passive soft-tissue stretching. Spasticity is graded on a scale of 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension). The highest score (flexion or extension), for the lower extremities only, was used for each subject. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates a decrease in spasticity and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis1.1429
2) Oral THC-0.3750
3) Placebo-0.2500

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bladder Control Scale Score

The Bladder Control Scale is a 4-item scale developed to assess the impact of multiple sclerosis on bladder function. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-22. The scale is set up so that a higher score indicates greater bladder control problems. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in bladder control and correlates to a better outcome. A positive result indicates a decrease in bladder control and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.8571
2) Oral THC-1.8889
3) Placebo-2.500

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Bowel Control Scale Score

The Bowel Control Scale is a 5-item scale developed to assess the impact of multiple sclerosis on bowel function. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-26. The scale is set up so that a higher score indicates greater bowel control problems. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in bowel control and correlates to a better outcome. A positive result indicates a decrease in bowel control and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.7143
2) Oral THC0.2222
3) Placebo0.4545

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Impact of Visual Impairment Scale Score

The Impact of Visual Impairment Scale is a 5-item scale developed to assess the extent to which activities dependent on vision are affected by MS-related visual problems. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-15. The scale is set up so that a higher score indicates greater impact of visual problems on daily activities. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of visual problems on daily activities and correlates to a better outcome. A positive result indicates an increase in the impact of visual problems on daily activities and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0.5714
2) Oral THC0.2500
3) Placebo-0.7500

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Mental Health Inventory Scale Score

The Mental Health Inventory (MHI) is an 18-item scale developed as a measure of overall emotional functioning. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-100. The scale is set up so that a higher score indicates better mental health. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A positive result indicates an improvement in mental health and correlates to a better outcome. A negative result indicates decrease in mental health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-8.8889
2) Oral THC-1.1111
3) Placebo-8.7037

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score

The Modified Fatigue Index is a 21-item scale developed to assess the perceived impact of fatigue on daily activities. It is a part of the MS Quality of Life Inventory. The scale is measured from 0 - 84. The scale is set up so that a higher score indicates a greater impact of fatigue on a patient's daily activities. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of fatigue on daily activities and correlates to a better outcome. A positive result indicates an increase in the impact of fatigue on daily activities and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-15.50
2) Oral THC1.3333
3) Placebo-11.0909

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Modified Social Support Scale Score

The Modified Social Support Scale is an 18-item scale developed as a measure of perceived social support. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-100. The scale is set up so that a higher score indicates greater perceived support. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A positive result indicates an improvement in perceived support and correlates to a better outcome. A negative result indicates a decrease in perceived support and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis2.2693
2) Oral THC-4.8177
3) Placebo-1.4915

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Pain Effects Scale Score

The Pain Effects Scale is a 6-item scale developed to assess the effects of pain on behavior and mood. It is a part of the MS Quality of Life Inventory. The scale is measured from 6-30. The scale is set up so that a higher score indicates a greater impact of pain on a patient's mood and behavior. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of pain on mood and behavior and correlates to a better outcome. A positive result indicates an increase in the impact of pain on mood and behavior and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-2.5714
2) Oral THC-2.4444
3) Placebo-2.500

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Perceived Deficits Scale Score

The Perceived Deficits Scale is a 20-item scale developed to assess the patient's perceived cognitive deficits. It is composed of four 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization. It is a part of the MS Quality of Life Inventory. The total score is measured from 0-80. The scale is set up so that a higher score indicates greater perceived cognitive impairment. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates a decrease in the perception of cognitive impairment. A positive result indicates an increase in the perception of cognitive impairment. Since patient perceptions of cognitive impairment may not correlate with objective measures of cognitive impairment, the results should be interpreted with caution. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-4.8571
2) Oral THC4.3750
3) Placebo-2.0909

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - Sexual Satisfaction Scale Score

"The Sexual Satisfaction Scale is a 4-item scale developed to assess the impact of multiple sclerosis on sexual function and satisfaction. It is a part of the MS Quality of Life Inventory. The scale is measured from 4-24. The scale is set up so that a higher score indicates greater problems with sexual satisfaction. Subjects that answered No to the question, Do you have a relationship with one primary partner, did not complete the scale. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in sexual satisfaction and correlates to a better outcome. A positive result indicates a decrease in sexual satisfaction and correlates to a worse outcome." (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-3.750
2) Oral THC0.1667
3) Placebo2.5556

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Mental Component

The SF-36 is a 36-item scale developed as a generic health status measure. It is a part of the MS Quality of Life Inventory. It can be reported as 2 summary scales - the Physical and Mental components. The scale is measured from 0 -100. The scale is set up so that a higher score indicates better health. The change was calculated by taking the Week 3 score and subtracting the Week 0. A positive result indicates an improvement in mental health status and correlates to a better outcome. A negative result indicates a decline in mental health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis5.7328
2) Oral THC-2.0820
3) Placebo1.6035

[back to top]

Change From Week 0 to Week 7 in MS Quality of Life Inventory (MSQLI) - SF-36 Physical Component Score

The SF-36 is a 36-item scale developed as a generic health status measure. It is a part of the MS Quality of Life Inventory. It can be reported as 2 summary scales - the Physical and Mental components. The scale is measured from 0 -100. The scale is set up so that a higher score indicates better health. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A positive result indicates an improvement in health status and correlates to a better outcome. A negative result indicates a decline in health and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-0.8695
2) Oral THC1.0957
3) Placebo-0.8803

[back to top]

Change From Week 0 to Week 7 in Paced Auditory Serial Addition Test (PASAT) Score

The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability; The test is presented via recording on a CD to control the rate of stimulus presentation. Single digits are presented every 3 seconds and the patient must add each new digit to the one immediately prior to it. The test score is the number of correct sums given (out of a possible 60) in each trial. There are 2 test forms, A and B. The forms were alternated and at least 1 practice test (10 sums) was performed prior to each trial. The change was calculated by taking the Week 7 score and subtracting the Week 0 score. A negative result indicates an improvement in performance and correlates with a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventionnumber correct (Mean)
1) Inhaled Cannabis2.0
2) Oral THC0.1111
3) Placebo7.9167

[back to top]

Change From Week 0 to Week 7 in the Rate of Torque Increase, Flexion

A modified servo-controlled torque motor system (Lido WorkSet II) was designed for this study to analyze the resistance to passive movement of the knee. It determines the amount of torque required to move the knee joint (without voluntary resistance) at high velocities (up to 200 degrees per second) and at slow velocities (as low as 10 degrees per second). The slow displacement torque is a measure of the passive resistance to movement (from the connective tissue and the non-contracting muscle) and the rapid displacement torques are the sum of the passive and active (involuntary) resistance. The active (involuntary) resistance is the result of the stretch reflex and correlates well with the clinical assessment of spasticity. The change was calculated by taking the value at Week 7 and subtracting the value at Week 0. A negative result indicates a decrease in the torque measured and correlates to a decrease in spasticity and a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventiondegrees/second (Mean)
1) Inhaled Cannabis-0.0013
2) Oral THC-0.0015
3) Placebo0.0043

[back to top]

Change From Week 0 to Week3 in MS Quality of Life Inventory (MSQLI) - Modified Fatigue Index Score

The Modified Fatigue Index is a 21-item scale developed to assess the perceived impact of fatigue on daily activities. It is a part of the MS Quality of Life Inventory. The scale is measured from 0-84. The scale is set up so that a higher score indicates a greater impact of fatigue on a patient's daily activities. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result indicates a decrease in the impact of fatigue on daily activities and correlates to a better outcome. A positive result indicates an increase in the impact of fatigue on daily activities and correlates to a worse outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis-11.3333
2) Oral THC1.2000
3) Placebo-9.600

[back to top]

LIDO Machine Score - Rate of Torque Increase, Extension

A modified servo-controlled torque motor system (Lido WorkSet II) was designed for this study to analyze the resistance to passive movement of the knee. It determines the amount of torque required to move the knee joint (without voluntary resistance) at high velocities (up to 200 degrees per second) and at slow velocities (as low as 10 degrees per second). The slow displacement torque is a measure of the passive resistance to movement (from the connective tissue and the non-contracting muscle) and the rapid displacement torques are the sum of the passive and active (involuntary) resistance. The active (involuntary) resistance is the result of the stretch reflex and correlates well with the clinical assessment of spasticity. The change was calculated by taking the value at Week 7 and subtracting the value at Week 0. A negative result indicates a decrease in the torque measured and correlates to a decrease in spasticity and a better outcome. (NCT00682929)
Timeframe: Week 0, Week 7

Interventiondegrees/second (Mean)
1) Inhaled Cannabis-0.0122
2) Oral THC-0.0019
3) Placebo0.0186

[back to top]

Change From Week 0 to Week 3 in 25 Foot Walk Time

The Timed 25 Foot Walk is a quantitative measure of lower extremity function. The patient is instructed to walk on a marked 25-foot course, as quickly and as safely as possible. The patient is allowed to use his/her typical walking aid, if applicable. The task is completed twice and the average time of the two trials was used for this outcome measure. The change was calculated by taking the Week 3 time and subtracting the Week 0 time. A negative result indicates an improvement in walking ability and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionseconds (Mean)
1) Inhaled Cannabis-0.0100
2) Oral THC-3.3714
3) Placebo0.1400

[back to top]

Change From Week 0 to Week 3 in 9 Hole Peg Test (Dominant Hand) Time

"The 9 hold peg test is a quantitative measure of upper extremity (arm and hand function). Patients are instructed to fill an 9 hole peg board with 1 peg at a time and then immediately remove the pegs, 1 at a time. The dominant hand is tested twice and the average time was used for this outcome measure. The change was calculated by taking the Week 3 time and subtracting the Week 0 time.~A negative result indicates an improvement in arm and hand function and correlates with a better outcome." (NCT00682929)
Timeframe: Week 0, Week 3

Interventionseconds (Mean)
1) Inhaled Cannabis-0.8929
2) Oral THC-1.5244
3) Placebo1.4450

[back to top]

Change From Week 0 to Week 3 in 9 Hole Peg Test (Non- Dominant Hand) Time

"The 9 hold peg test is a quantitative measure of upper extremity (arm and hand function). Patients are instructed to fill an 9 hole peg board with 1 peg at a time and then immediately remove the pegs, 1 at a time. The non-dominant hand is tested twice and the average time was used for this outcome measure. The change was calculated by taking the Week 3 time and subtracting the Week 0 time.~A negative result indicates an improvement in arm and hand function and correlates with a better outcome." (NCT00682929)
Timeframe: Week 0, Week 3

Interventionseconds (Mean)
1) Inhaled Cannabis-1.0250
2) Oral THC2.1318
3) Placebo-1.3933

[back to top]

Change From Week 0 to Week 3 in Ambulation Index (AI) Score

The AI is a 9-point rating scale used to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. Scores range from 0 (asymptomatic, fully active) to 9 (restricted to wheelchair, unable to transfer self independently). Lower scores represent a better outcome for MS patients. For this study, the AI score was based on the results of the 25 Foot Walk test, also performed at the study visit. The change was calculated by taking the Week 3 score and subtracting the Week 0 score. A negative result for this outcome indicates an improvement in ambulation and correlates to a better outcome. (NCT00682929)
Timeframe: Week 0, Week 3

Interventionunits on a scale (Mean)
1) Inhaled Cannabis0
2) Oral THC0
3) Placebo0.1818

[back to top]

Pain Tolerance

Change in pain tolerance from baseline (in seconds) as a function of drug condition. The cold pressor test was administered during each session to examine changes in pain threshold (how many seconds it takes for a participant to begin feeling pain after cold water immersion). (NCT00743119)
Timeframe: Within each session lasting approximately 5 minutes, for a total of five sessions

Interventionseconds (Mean)
High Dose Dronabinol + Inactive Marijuana6.1
Low Dose Dronabinol + Inactive Marijuana2.8
Placebo + Low THC Marijuana4.9
Placebo + High THC Marijuana1.5
Placebo + Inactive Marijuana 0% THC1.5

[back to top]

Post-Operative Care Unit Length of Stay (Min)

Length of time in PACU (minutes) measured from end of surgery to time of transfer to ambulatory care prior to home discharge or time to hospital admission if applicable. (NCT00757822)
Timeframe: Day of surgery (time from end of surgery to transfer to ambulatory pre-discharge unit or other unit)

Interventionminutes (Median)
Arm 1:Dronabinol99.5
Arm 2:Ondansetron97.0

[back to top]

Post-operative Nausea and Vomiting (PONV) Incidence 24-48 Hours Post Surgery

Participants were queried for presence of postoperative nausea (PON) or postoperative vomiting (POV) during the 24-48 hr window post surgery. (NCT00757822)
Timeframe: 24-48 hrs post surgery

,
Interventionpercentage of participants (Number)
24-48hr PON incidence24-48 hr POV incidence
Arm 1: Dronabinol23.46.3
Arm 2:Ondansetron22.83.5

[back to top]

Incidence of Postoperative Nausea and Vomiting

The incidence of postoperative nausea (PON) and postoperative vomiting (POV) was assessed during Post-operative Care Unit (PACU) stay. (NCT00757822)
Timeframe: Post-operative Care Unit (PACU) length of stay on day of surgery (time from end of surgery to transfer to discharge unit or other hospital unit)

,
Interventionpercentage of participants (Number)
Incidence PACU PONIncidence PACU POV
Arm 1:Dronabinol34.412.5
Arm 2:Ondansetron29.87

[back to top]

Patient Satisfaction 2: Willingness to Pay Extra Money for Post-Operative Nausea and Vomiting (PONV) Preventive Medication

Percent of participants willing to pay extra money for preemptive medication for PONV for subsequent surgical procedures when queried at post-operative 24-48 hr. and at 2-6 wk. follow-up interviews. (NCT00757822)
Timeframe: Post-operative follow-up interviews 24 hr to 6 weeks post surgery

,
Interventionpercent of participants (Number)
24-48 hr. post-op2-6 wk post-op
Arm 1:Dronabinol8073
Arm 2:Ondansetron7068

[back to top]

Post-operative Antiemetic Use

Percentage of participants requiring post-operative anti-emetic medications.. Anti-emetic medication need was assessed during a) post-operative care unit (PACU) stay and b)during the first 48 hrs. following discharge from PACU to home or if applicable to in-patient unit. (NCT00757822)
Timeframe: End of surgery to 48 hr post surgery

,
Interventionpercentage of participants (Number)
Medication need during PACU stayMedication need for first 48 hrs after discharge t
Arm 1:Dronabinol253
Arm 2: Ondansetron174

[back to top]

Post-Surgery Hospital Admissions (All Cause) After Out-patient Abdominal Procedure

Number of all-cause hospital admissions on day of elective out-patient surgery . (NCT00757822)
Timeframe: Post-operative Day of Surgery (DOS)

,
Interventionparticipants (Number)
DOS admission-observationDOS admission- urinary retensionDOS admission-pain managementDOS admission- low SpO2DOS admission -intractable nausea/vomitting
Arm 1:Dronabinol34110
Arm 2: Ondnasetron33100

[back to top]

Patient Satisfaction: Willingness to Take Pre-operative Medication for Post-operative Nausea and/or Vomiting

Percent of participants who responded that they would be willing to take preemptive medication for nausea and vomiting for subsequent surgeries when queried during post-operative follow-up interviews at 24-48 hrs or 2-6 weeks. (NCT00757822)
Timeframe: Post operative follow up interviews 24 hrs to 6 wks

,
Interventionpercent of participants (Number)
24-48 hr post-operative interview2-6 week post-operative interview
Arm 1:Dronabinol9287
Arm 2:Ondansetron8975

[back to top]

Maximum Reported Post-Operative Nausea Scores on Visual Analog Scale (VAS) Scale

"VAS Scale: 0=no nausea, 1-3=mild nausea, 4-6= moderate nausea, 7-9= severe nausea, 10=extreme nausea usually accompanied with vomiting.~VAS nausea score were obtained every 30 min from entry into post-operative care unit (PACU) for first 2 hrs. and then hourly until time of transfer out of PACU." (NCT00757822)
Timeframe: Post-operative Care Unit (PACU) stay from end of surgery to transfer to ambulatory unit

,
Interventionpercentage of participants (Number)
No nausea (VAS score=0)Mild Nausea (VAS score=1-3)Moderate Nausea (VAS score =4-6)Severe nausea (VAS score=7-9)Extreme nausea (VAS score=10)
Arm 1: Dronabinol59.415.67.87.89.4
Arm 2:Ondansetron70.212.31.87.08.8

[back to top]

CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing

"CANTAB RVIP is one component of this computerized battery and is a measure of sustained attention with a working memory component.~This study used two subscales of the RVIP.~RVP A' ( Target sensitivity, a measure of the ability to detect sequences.) The range is from 0-1; bad to good.~RVP B'' ( Response bias, which is a measure of the tendency to respond regardless of whether a target is present.~The range is from -1 to +1 ; bad to good~The numbers represent probabilities as units on a scale." (NCT00842985)
Timeframe: Once for each test session (4 total).

Interventionunits on a scale (Mean)
THC+Modafinil0.91
THC+Placebo0.9
Pla+Modafinil0.92
Placebo+Placebo0.9

[back to top]

Peak Effect of Marijuana Withdrawal

Total withdrawal based on a composite score of the Marijuana Withdrawal Checklist (range 0-32; higher scores indicate greater withdrawal). (NCT00893074)
Timeframe: Day 5 of the Dronabinol abstinence period

Interventionunits on a scale (Mean)
Placebo4.6
30mg Dronabinol4.1
60mg Dronabinol2.9
120mg Dronabinol1.7

[back to top]

Heart Rate

Heart rate measured after acute cannabis exposure (NCT00893074)
Timeframe: Assessed on Day 5 of dronabinol maintenance

Interventionbeats per minutes (Mean)
Placebo88
30mg Dronabinol85
60mg Dronabinol80
120mg Dronabinol76

[back to top]

"Subjective Drug Effect After Smoked Marijuana"

Subjective drug effects on a 100mm point Visual Analog Scale reported following acute cannabis dose administration during dronabinol maintenance, scale ranging 0-100, with 0 being no effect and 100 being maximum effect (NCT00893074)
Timeframe: Day 5 of the Dronabinol abstinence period

Interventionmm of subjective drug effect (Mean)
Placebo23
30mg Dronabinol28
60mg Dronabinol24
120mg Dronabinol29

[back to top]

fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC).

Average Z scores for the region-of-interest functional connectivity at the second scan (when subjects received either a cannabis cigarette or 15mg of dronabinol) between the bilateral nucleus accumbens (NAc) and ventral anterior cingulate cortex (vACC) for patients with schizophrenia and co-occurring cannabis use disorder. (NCT00946348)
Timeframe: Measures were acquired at peak THC level for each of the two drugs up to 4 hours.

InterventionZ score (Mean)
Dronabinol.40
Cannabis.33

[back to top]

21 Days of Consecutive Abstinence as Measured by the Time-line Followback.

(NCT01020019)
Timeframe: reported daily for 12 weeks/ or study participation

Interventionparticipants (Number)
Placebo18
Lofexidine and Dronabinol17

[back to top]

Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) .

The Subjective Opiate Withdrawal Scale is a self-administered 16 scale containing 16 symptoms ranging in severity from 0 (not at all) to 4 (extremely). The SOWS total score is the sum of 16 items, ranging from 0 (no opiate withdrawal ) to 64 ( severe opiate withdrawal). Values from multiple assessments during the 8-week outpatient phase were averaged. (NCT01024335)
Timeframe: 3x/week during 8 weeks of the trial or study participation

Interventionunits on a scale (Mean)
Naltrexone and Placebo11.16
Naltrexone and Dronabinol13.36

[back to top]

Retention

Of those participants randomized to the naltrexone and dronabinol arm, the number that completed all 8 weeks of treatment. (NCT01024335)
Timeframe: retention over 8 weeks.

Interventionparticipants (Number)
Naltrexone and Placebo7
Naltrexone and Dronabinol14

[back to top]

Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score

The MGH-HPS is a 7-item, self-report scale that rates urges to pull hair, actual amount of pulling, perceived control over behavior, and distress associated with hair pulling over the past seven days. Total possible score is a 28 indicating the highest level of severity out of a scale from 0-28. (NCT01093976)
Timeframe: Subjects were followed for their duration of participation in the study (12-weeks)

Interventionunits on a scale (Mean)
Dronabinol8.71

[back to top]

Ascending Colon Emptying T 1/2

Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data. (NCT01253408)
Timeframe: 48 hours after radiolabeled meal was ingested

Interventionhours (Mean)
Dronabinol 2.5 mg Bid9.50
Dronabinol 5 mg Bid9.90
Placebo14.53

[back to top]

Colonic Filling at 6 Hours

Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time. (NCT01253408)
Timeframe: 6 hours after radiolabeled meal was ingested

Interventionpercentage of meal (Mean)
Dronabinol 2.5 mg Bid48.60
Dronabinol 5 mg Bid51.62
Placebo57.46

[back to top]

Colonic Transit Geometric Center at 24 Hours

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (NCT01253408)
Timeframe: 24 hours

Interventionunits on a scale (Mean)
Dronabinol 2.5 mg Bid3.12
Dronabinol 5 mg Bid3.05
Placebo2.77

[back to top]

Gastric Emptying Half-Time (t1/2)

The time for half of the ingested solids or liquids to leave the stomach. (NCT01253408)
Timeframe: Approximately 2 hours after radiolabel meal is ingested

Interventionminutes (Mean)
Dronabinol 2.5 mg Bid137.3
Dronabinol 5 mg Bid130.7
Placebo138.2

[back to top]

Colonic Transit Geometric Center

The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (NCT01253408)
Timeframe: 28, 32, and 48 hours

,,
Interventionunits on a scale (Mean)
28 hours32 hours48 hours
Dronabinol 2.5 mg Bid3.393.784.21
Dronabinol 5 mg Bid3.604.054.60
Placebo3.243.544.02

[back to top]

Gastric Emptying at 2 and 4 Hours

Proportion of stomach contents emptied at a 2 and 4 hours. (NCT01253408)
Timeframe: 2, 4 hours

,,
Interventionproportion of stomach contents (Mean)
2 hours4 hours
Dronabinol 2.5 mg Bid0.380.90
Dronabinol 5 mg Bid0.490.90
Placebo0.450.88

[back to top]

Marijuana Self-administration - Progressive Ratio

Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) under a progressive ratio schedule. The number of progressive ratios completed (and thus, cannabis cigarettes consumed) is the primary study endpoint (NCT01394185)
Timeframe: 12-day Dronabinol maintenance period

InterventionProgressive Ratios Completed (Mean)
Placebo5.2
120mg Dronabinol4.5
240mg Dronabinol4.4

[back to top]

Marijuana Self-administration - Drug Vs Money Choice

Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) in 5 discrete choices each day between one cannabis cigarette and $1. The number of cannabis cigarettes chosen (and subsequently self-administered) is the primary study endpoint (NCT01394185)
Timeframe: 12-day Dronabinol maintenance period

InterventionCannabis Cigarettes Chosen (Mean)
Placebo3.5
120mg Dronabinol2.3
240mg Dronabinol2.5

[back to top]

Psychomotor Impairment (Driving)

The driving simulator will objectively measure driving behaviour during a number of pre-programmed driving scenarios. Zone/ Hazard performance measure: Mean Speed. (NCT01592409)
Timeframe: Approximate: at baseline (30 minutes before smoking), 30 minutes after smoking

Interventionchange in kph (Mean)
Active Cannabis3.38
Placebo-1.54

[back to top]

Frequency of Chest Pain Episodes

Number of people still experiencing the same amount of chest pain during treatment than previously without (NCT01598207)
Timeframe: Baseline and 1 month

Interventionparticipants (Number)
Marinol1
Placebo3

[back to top]

Frequency of Chest Pain in Treatment Group vs Baseline

Total (intensity (0(none) - 3(severe) + duration (0(none) - 3(longer than 30 mins)) at end of 1 month treatment; higher represents worse outcome; the total score ranges from 0 to 6 and is the sum of the intensity and duration (NCT01598207)
Timeframe: 1 month

Interventionunits on a scale (Mean)
Marinol1.87
Placebo1.8

[back to top]

Sensory Thresholds for First Sensation

This is determined by the Esophageal Balloon Distension Test; range 0-65 mmHg (NCT01598207)
Timeframe: Baseline and 1 month

InterventionmmHg (Mean)
Marinol2
Placebo2.7

[back to top]

Duration of Chest Pain Episodes

0 - is none and 3 is longer than 30 mins; higher values is worst outcome; chest pain totals are averaged (NCT01598207)
Timeframe: Baseline vs 1 month

,
Interventionunits on a scale (Mean)
Baseline1 Month
Marinol1.831.2
Placebo11

[back to top]

Intensity of Chest Pain Episodes

Intensity (0(none) - 3(severe)) at baseline vs 1 month for chest pain episodes; higher represents worse outcome; multiple chest pain totals are averaged (NCT01598207)
Timeframe: Baseline and 1 month

,
Interventionunits on a scale (Mean)
Baseline1 Month
Marinol1.330.67
Placebo0.60.8

[back to top]

Sensory Thresholds for Discomfort

When participants felt pain at earliest pressure; range 0-65 mmHg (NCT01598207)
Timeframe: Baseline and 1 month

,
InterventionmmHg (Mean)
Baseline1 Month
Marinol68
Placebo52

[back to top]

Sensory Thresholds for Pain

When highest amount of pain was felt; range is 0-65 mmHg (NCT01598207)
Timeframe: Baseline and 1 month

,
InterventionmmHg (Mean)
Baseline1 Month
Marinol4247
Placebo5351

[back to top]

Change in Craving Symptoms From Baseline at 14 Weeks

"Scores on the Marijuana Craving Questionnaire (Heishman et al. 2009) - The 4 Factor Total Score~Maximum Score = 84 Minimum Score = 12 The higher the score, the more severe marijuana craving symptoms endorsed by the subject." (NCT01598896)
Timeframe: At 14 weeks

Interventionscore on MCQ Total 4 Factor scale (Mean)
Dronabinol + Clonidine54.33
Placebo56

[back to top]

Change in Craving Symptoms From Baseline at 10 Weeks

"Scores on the Marijuana Craving Questionnaire (MCQ) (Heishman et al. 2009) - The 4 Factor Total Score.~Maximum Score = 84 Minimum Score = 12 The higher the score, the more severe marijuana craving symptoms endorsed by the subject." (NCT01598896)
Timeframe: At 10 weeks

Interventionscore on a MCQ 4 Factor Total scale (Mean)
Dronabinol + Clonidine51
Placebo52.33

[back to top]

Change From Baseline in Cannabis Use at 14 Weeks

Self-report cannabis use at 14 weeks after initiating the study. (NCT01598896)
Timeframe: At 14 weeks

Interventionhits/day (Mean)
Dronabinol + Clonidine18.95
Placebo16.29

[back to top]

Change From Baseline in Cannabis Use at 10 Weeks

Subject self-report hits of marijuana per day at week 10 (NCT01598896)
Timeframe: At 10 weeks

Interventionhits/day (Mean)
Dronabinol + Clonidine16.91
Placebo22.35

[back to top]

Tolerability

Assessment of tolerability will be determined by the number of subjects that withdrawal from the study due to SAEs. (NCT01747850)
Timeframe: six months

InterventionParticipants (Count of Participants)
Sativex # of Participants That Withdrew Due SAE0
Placebo # of Participants That Withdrew Due SAE0
Pilot Study # of Participants That Withdrew Due SAE0

[back to top]

Withdrawal

"Effect of Sativex on withdrawal symptom scores will be assessed using the Marijuana Withdrawal Checklist (MWC). Average Total score for the trial (6 months) is reported.~Range 0 - 46. Higher scores indicate more severe symptoms associated with marijuana withdrawal." (NCT01747850)
Timeframe: six months

InterventionTotal Withdrawal score (Mean)
Sativex Withdrawal5.0
Placebo Withdrawal5.1
Pilot Withdrawal2.7

[back to top]

Cannabis Use (in Days)

The percentage of days that participants self-reported use of cannabis over the study duration until 6 month follow-up will be assessed (i.e. smoking diary self-report) (NCT01747850)
Timeframe: six months

Interventionpercentage of days (Mean)
Sativex % Days Use of Cannabis42.9
Placebo % Days Use of Cannabis47.1
Pilot % Days Use of Cannabis48.3

[back to top]

Cannabis Craving

"Effect of Sativex on cannabis craving will be assessed using the Marijuana Craving Questionnaire (MCQ). Average Total score for the trial (6 months) is reported.~Participants rate the 12 items using a 7-item Likert scale ranging from strongly disagree to strongly agree, and the total score ranges from 4 to 28 (subscales compulsivity (mean items 2, 7 and 10), emotionality (mean items 4, 6 and 9), expectancy (mean items 5, 11 and 12) and purposefulness (mean items 1, 3 and 8); total score is the sum for the 4 subscales). Higher scores indicate more severe craving for marijuana." (NCT01747850)
Timeframe: six months

InterventionTotal Craving Scores (Mean)
Sativex Craving8.2
Placebo Craving9.6
Pilot Craving9.5

[back to top]

Cannabis Use (Grams)

Amount of cannabis used in grams over the study duration until 6 month follow-up will be assessed (NCT01747850)
Timeframe: six months

Interventiongrams of cannabis (Mean)
Sativex Cannabis Use (g)2.3
Placebo Cannabis Use (g)3.5
Pilot Cannabis Use (g)1.6

[back to top]

Feasibility

Feasibility will be assessed by analysing how many participants can be recruited/complete the whole (randomly assigned) experimental sequence with a period of one year. (NCT01748799)
Timeframe: 12 months

Interventionparticipants (Number)
Sequence 11
Sequence 21
Sequence 31
Sequence 42
Sequence 51
Sequence 61
Sequence 71
Sequence 81

[back to top]

Tolerability of Sativex in Persons That Are Cannabis Dependent

To assess what number of participants might withdrew due non-tolerability of Sativex (NCT01748799)
Timeframe: 8 weeks

Interventionparticipants (Number)
Sequence 10
Sequence 20
Sequence 30
Sequence 40
Sequence 50
Sequence 60
Sequence 70
Sequence 80

[back to top]

Cannabis Withdrawal

Withdrawal symptoms were assessed using the Cannabis Withdrawal Scale (CWS) (Minimum-Maximum Scores 0-190, high scores represent more withdrawal) and Cannabis Withdrawal Checklist (CWC) (Minimum-Maximum Scores 0-48, high scores represent more withdrawal) by establishing comparisons between Sativex/Placebo and Smoke as usual conditions (4 interventions: Fixed Sativex, Fixed Placebo, Self-titrated Sativex, Self-titrated Placebo and 4 corresponding Smoke as usual conditions). (NCT01748799)
Timeframe: 8 weeks

,,,,,,,
Interventionunits on a scale (Mean)
Cannabis Withdrawal Scale (CWS)Cannabis Withdrawal Checklist (CWC) Total
Fixed Dose Placebo17.97.4
Fixed Dose Sativex10.33.6
Self-titrated Placebo13.75.9
Self-titrated Sativex9.84.0
Smoke as Usual FP8.63.7
Smoke as Usual FS7.92.6
Smoke as Usual StP7.53.0
Smoke as Usual StS6.62.3

[back to top]

Adverse Events (AEs)

AEs will be evaluated and tracked throughout subject participation (up to 8 weeks) (NCT01755091)
Timeframe: Up to 8 weeks

InterventionNumber of adverse events per participant (Mean)
Sugar Pill3.4
2.5 mg/Day2.8
10 mg/Day5.8

[back to top]

Change in Apnea/Hypopnea Index (AHI)

Change in AHI derived as: AHI (end of treatment) minus AHI (pre-treatment) (NCT01755091)
Timeframe: Baseline and Week 6

Interventionevents/hour (Mean)
Sugar Pill7.99
2.5 mg/Day-1.71
10 mg/Day-5.21

[back to top]

Change in Sleep Latency: Maintenance of Wakefulness Test (MWT)

Change in MWT derived as: MWT (end of treatment) minus MWT (pre-treatment). The Maintenance of Wakefulness Test measures a person's ability to stay awake in a quiet, dark and nonstimulating room for a period of time. (NCT01755091)
Timeframe: Baseline and Week 6

Interventionminutes (Mean)
Sugar Pill-2.50
2.5 mg/Day-3.70
10 mg/Day1.40

[back to top]

Change in Epworth Sleepiness Scale (ESS)

Change in ESS derived as: ESS (end of treatment) minus ESS (pre-treatment). The ESS scale has a range of 0 to 24, with 0 representing the least degree of sleepiness and 24 the greatest degree of sleepiness. There are no subscales. (NCT01755091)
Timeframe: Baseline and Week 6

Interventionunits on a scale (Mean)
Sugar Pill-1.47
2.5 mg/Day-.26
10 mg/Day-4.00

[back to top]

Change in Desaturation Time (DT)

Change in DT (total minutes with arterial oxygen saturation below 85% during 8-hour polysomnography) derived as: DT (end of treatment) minus DT (pre-treatment) (NCT01755091)
Timeframe: 6 weeks

Interventionminutes (Mean)
Sugar Pill1.21
2.5 mg/Day-0.19
10 mg/Day-0.17

[back to top]

Postprandial Colonic Motility Index

Colonic phasic pressure activity is summarized as a motility index (MI)=log_e[number of contractions * sum of amplitudes) + 1]. A normal fasting average motility index (MI) would be about 12. An increase in MI means an increase in the phasic contractions (in contrast to tone) which is measured as a change in volume of the barostat balloon. (Therefore, an increase in MI means that the meal is moving more quickly through the colon.) (NCT01786109)
Timeframe: 1 hour after ingestion of standard meal

,,
Interventionlog mm Hg (Mean)
Proximal descending colonDistal descending colon
Dronabinol 2.5 mg11.249.97
Dronabinol 5 mg11.2210.23
Placebo10.7010.50

[back to top]

Post-Treatment Overall Sensory Rating in Response to 16, 24, 32, and 40 mm Hg Distensions

The sensory rating was measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain. (NCT01786109)
Timeframe: 1 hour after drug was ingested

,,
Interventionmm (Mean)
16 mm Hg Distension24 mm Hg Distension32 mm Hg Distension40 mm Hg Distension
Dronabinol 2.5 mg38.1849.6458.3657.18
Dronabinol 5 mg38.7142.7545.3548.17
Placebo37.039.7646.7645.52

[back to top]

Postprandial Change in Colonic Tone

Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon.) (NCT01786109)
Timeframe: 1 hour after ingestion of standard meal

InterventionmL (Mean)
Dronabinol 2.5 mg30.34
Dronabinol 5 mg27.41
Placebo26.31

[back to top]

Post-treatment Sensory Threshold for First Sensation

The sensory threshold for first sensation was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation. (NCT01786109)
Timeframe: 1 hour after drug was ingested

Interventionmm Hg (Mean)
Dronabinol 2.5 mg15.83
Dronabinol 5 mg15.5
Placebo18.37

[back to top]

Post-treatment Sensory Threshold for First Perception of Pain

The sensory threshold for first perception of pain was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation. (NCT01786109)
Timeframe: 1 hour after drug was ingested

Interventionmm Hg (Mean)
Dronabinol 2.5 mg42.83
Dronabinol 5 mg40.33
Placebo44.44

[back to top]

Fasting Colonic Tone

Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon.) (NCT01786109)
Timeframe: After 12 hour fast, before drug administered

InterventionmL (Mean)
Dronabinol 2.5 mg117.8
Dronabinol 5 mg118.5
Placebo114.3

[back to top]

Post-Treatment Sensory Threshold for First Perception of Gas

The sensory threshold for first perception of gas was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation. (NCT01786109)
Timeframe: 1 hour after drug was ingested

Interventionmm Hg (Mean)
Dronabinol 2.5 mg28.83
Dronabinol 5 mg27.33
Placebo29.04

[back to top]

Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)

"Colonic compliance is a measure of the stiffness of the colon, that is, what pressure was needed to reach half the maximum volume of the colon.~After the barostat catheter was inserted in the colon, the catheter was connected to a barostat machine. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg up to 64 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance." (NCT01786109)
Timeframe: 1 hour after drug was ingested

InterventionmL/mm Hg (Mean)
Dronabinol 2.5 mg17.57
Dronabinol 5 mg16.2
Placebo18.76

[back to top]

P50 Auditory Evoked Potential

electrophysiological measure of ability to filter extraneous stimuli measured as the amplitude of the evoked response to the second auditory stimulus divided by the amplitude of the evoked response to the first auditory stimulus in mV. (NCT01832766)
Timeframe: 2 hours after drug administration

Interventiontest to conditioning ratio (Mean)
Dronabinol.62
Placebo.52

[back to top]

California Verbal Learning Test Change at 2 Hours From Baseline

ability to remember a list of words given 5 trials. Number of words remembered is normalized to a schizophrenia population and average scores are calculated with age correction. The normal T-score is 50 and scores greater than 50 correspond with greater ability to remember words as compared to a schizophrenia population norm. (NCT01832766)
Timeframe: 2 hours after drug administration

InterventionT scores (Mean)
Dronabinol-.5
Placebo-.77

[back to top]

Brief Psychiatric Rating Scale Change From Baseline at 1 Hour

Measures psychiatric symptoms. Each item is scored from 1-7. Positive symptoms are calculated from sum of scores on hallucinatory behavior, unusual thought content and conceptual disorganization. Thus, the range of Total Positive Symptoms can be from a score of 3-21 .The higher the score, the more severe the symptom. Negative symptoms have been calculated from sum of blunted affect, emotional withdrawal and motor retardation. The range of Total Negative Symptoms can be from a score of 3-21. The higher the score, the more severe the symptoms. As this is a difference from baseline, there can be either negative or positive results as the subjects can either be better than baseline (positive score) or worse than baseline (negative score). (NCT01832766)
Timeframe: at 1 hour after drug administration

Interventionunits on a scale (Mean)
Dronabinol3.73
Placebo3.18

[back to top]

Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters

"Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following:~Physical exam~Safety bloods and urinalysis~12-lead ECG~Vital signs" (NCT02054754)
Timeframe: Participants will be followed until follow up visit, 6-11 days after dosing

Interventionparticipants (Number)
Dexanabinol9
Placebo1

[back to top]

Area Under the Curve of the Compound Dexanabinol (ETS2101) From Pre-dose up to 48 Hours Post Dose

Pharmacokinetic parameters will be assessed in a blinded fashion at the end of each cohort, prior to dose escalation. (NCT02054754)
Timeframe: Pre-dose, 0.5,1,1.5,2,3,4,5,6,8,10,12,16,24,36,48 hours post dose

Interventionng.h/mL (Mean)
Dexanabinol Dose Level 137.5
Dose Level 261.3
Dose Level 3109
Dose Level 4226
Dose Level 5192

[back to top]

Brain Measures

Mean functional magnetic resonance imaging (fMRI) BOLD activation extracted from each region of interests [amygdala; ventromedial prefrontal cortex; hippocampus] for each stimulus type (CS+E, CS+U, CS-). The units of BOLD values are expressed as arbitrary units. (NCT02069366)
Timeframe: Brain measures are collected on Visit 3, 14 days from baseline (Visit 1) and Visit 4, 15 days from baseline (Visit 1), for approximately 1.5 hours each day

,,,,,
Interventionarbitrary units (Mean)
Extinction Learning CS+E Amygdala- Visit 3Extinction Learning CS+E Hippocampus- Visit 3Extinction Learning CS+E vmPFC- Visit 3Extinction Learning CS- Amygdala- Visit 3Extinction Learning CS- Hippocampus- Visit 3Extinction Learning CS- vmPFC- Visit 3Recall CS+E Amygdala- Visit 4Recall CS+E Hippocampus-Visit 4Recall CS+E vmPFC-Visit 4Recall CS- Amygdala-Visit 4Recall CS- Hippocampus-Visit 4Recall CS- vmPFC-Visit 4Recall CS+U Amygdala-Visit 4Recall CS+U Hippocampus-Visit 4Recall CS+U vmPFC-Visit 4Renewal CS+E Amygdala-Visit 4Renewal CS+E Hippocampus- Visit 4Renewal CS+E vmPFC- Visit 4Renewal CS- Amygdala- Visit 4Renewal CS- Hippocampus-Visit 4Renewal CS- vmPFC-Visit 4Renewal CS+U Amygdala-Visit 4Renewal CS+U Hippocampus-Visit 4Renewal CS+U vmPFC-Visit 4
HC-dronabinol-0.05-0.05-0.180.02-0.07-0.170.010.0-0.110.160.04-0.120.090-0.140.100.03-0.080.040.06-0.100.03-0.01-0.15
HC-placebo-0.09-0.14-0.21-0.07-0.14-0.17-0.010.0-0.190.200.09-0.100.060-0.160.070.04-0.080.190.05-0.12-0.04-0.05-0.18
PTSD-dronabinol-0.08-0.06-0.11-0.01-0.04-0.100.200.05-0.190.140.02-0.150.12-0.04-0.180.160.110.00.040.02-0.100.050.01-0.20
PTSD-placebo0.27-0.03-0.220.19-0.05-0.230.10-0.02-0.060.180.0-0.050.14-0.05-0.080.190.06-0.090.250.06-0.050.220.06-0.07
TEC-dronabinol0.02-0.07-0.120.07-0.04-0.160.110.04-0.080.01-0.04-0.200.14-0.02-0.240.130.04-0.14-0.10-0.03-0.140.090.09-0.04
TEC-placebo0.03-0.06-0.140.04-0.01-0.100.030.01-0.14-0.02-0.02-0.16-0.06-0.05-0.200.060.04-0.12-0.020.01-0.150.090.06-0.12

[back to top]

Expectancy Ratings

"To assess the expected likelihood that an aversive cue (e.g. noise burst) will occur or not based on the CS shown on the screen. Participants rate their expectancy of the aversive cue using a button box on a scale from 1 to 3 [1 = certain that the aversive cue will be presented (Yes); 2 = certain that the aversive cue will not be presented (No); 3 = uncertain whether the aversive cue will be presented (I don't know)]. Counts of yes, no, and I don't know are collected on the first (early) trial of the CS and the last (late) trial of the CS." (NCT02069366)
Timeframe: Collected on Visit 2, 13 days from baseline (Visit 1), Visit 3, 14 days from baseline (Visit 1), and Visit 4, 15 days from baseline, during the task. Each day the task lasted approximately 20 minutes.

InterventionParticipants (Count of Participants)
Acquisition CS+E Early- Visit 271968077Acquisition CS+E Early- Visit 271968074Acquisition CS+E Early- Visit 271968075Acquisition CS+E Early- Visit 271968076Acquisition CS+E Early- Visit 271968078Acquisition CS+E Early- Visit 271968080Acquisition CS+U Early- Visit 271968080Acquisition CS+U Early- Visit 271968074Acquisition CS+U Early- Visit 271968075Acquisition CS+U Early- Visit 271968076Acquisition CS+U Early- Visit 271968077Acquisition CS+U Early- Visit 271968078Acquisition CS-Early- Visit 271968075Acquisition CS-Early- Visit 271968076Acquisition CS-Early- Visit 271968074Acquisition CS-Early- Visit 271968077Acquisition CS-Early- Visit 271968078Acquisition CS-Early- Visit 271968080Acquisition CS+E Late- Visit 271968076Acquisition CS+E Late- Visit 271968074Acquisition CS+E Late- Visit 271968075Acquisition CS+E Late- Visit 271968077Acquisition CS+E Late- Visit 271968078Acquisition CS+E Late- Visit 271968080Acquisition CS+U Late- Visit 271968076Acquisition CS+U Late- Visit 271968074Acquisition CS+U Late- Visit 271968075Acquisition CS+U Late- Visit 271968077Acquisition CS+U Late- Visit 271968078Acquisition CS+U Late- Visit 271968080Acquisition CS- Late- Visit 271968074Acquisition CS- Late- Visit 271968075Acquisition CS- Late- Visit 271968076Acquisition CS- Late- Visit 271968077Acquisition CS- Late- Visit 271968078Acquisition CS- Late- Visit 271968080Extinction CS+E Early- Visit 371968074Extinction CS+E Early- Visit 371968075Extinction CS+E Early- Visit 371968076Extinction CS+E Early- Visit 371968077Extinction CS+E Early- Visit 371968078Extinction CS+E Early- Visit 371968080Extinction CS- Early- Visit 371968074Extinction CS- Early- Visit 371968075Extinction CS- Early- Visit 371968076Extinction CS- Early- Visit 371968077Extinction CS- Early- Visit 371968078Extinction CS- Early- Visit 371968080Extinction CS+E Late-Visit 371968074Extinction CS+E Late-Visit 371968075Extinction CS+E Late-Visit 371968076Extinction CS+E Late-Visit 371968077Extinction CS+E Late-Visit 371968078Extinction CS+E Late-Visit 371968080Extinction CS- Late- Visit 371968074Extinction CS- Late- Visit 371968075Extinction CS- Late- Visit 371968076Extinction CS- Late- Visit 371968077Extinction CS- Late- Visit 371968078Extinction CS- Late- Visit 371968080Recall CS+E Early-Visit 471968080Recall CS+E Early-Visit 471968075Recall CS+E Early-Visit 471968074Recall CS+E Early-Visit 471968076Recall CS+E Early-Visit 471968077Recall CS+E Early-Visit 471968078Recall CS+U Early-Visit 471968074Recall CS+U Early-Visit 471968075Recall CS+U Early-Visit 471968076Recall CS+U Early-Visit 471968077Recall CS+U Early-Visit 471968078Recall CS+U Early-Visit 471968080Recall CS- Early-Visit 471968075Recall CS- Early-Visit 471968074Recall CS- Early-Visit 471968076Recall CS- Early-Visit 471968077Recall CS- Early-Visit 471968078Recall CS- Early-Visit 471968080Recall CS+E Late-Visit 471968074Recall CS+E Late-Visit 471968075Recall CS+E Late-Visit 471968076Recall CS+E Late-Visit 471968077Recall CS+E Late-Visit 471968078Recall CS+E Late-Visit 471968080Recall CS+U Late-Visit 471968074Recall CS+U Late-Visit 471968075Recall CS+U Late-Visit 471968076Recall CS+U Late-Visit 471968077Recall CS+U Late-Visit 471968078Recall CS+U Late-Visit 471968080Recall CS- Late-Visit 471968074Recall CS- Late-Visit 471968075Recall CS- Late-Visit 471968080Recall CS- Late-Visit 471968076Recall CS- Late-Visit 471968077Recall CS- Late-Visit 471968078Renewal CS+E Early-Visit 471968077Renewal CS+E Early-Visit 471968074Renewal CS+E Early-Visit 471968075Renewal CS+E Early-Visit 471968076Renewal CS+E Early-Visit 471968078Renewal CS+E Early-Visit 471968080Renewal CS+U Early-Visit 471968077Renewal CS+U Early-Visit 471968078Renewal CS+U Early-Visit 471968075Renewal CS+U Early-Visit 471968074Renewal CS+U Early-Visit 471968076Renewal CS+U Early-Visit 471968080Renewal CS- Early-Visit 471968075Renewal CS- Early-Visit 471968077Renewal CS- Early-Visit 471968074Renewal CS- Early-Visit 471968076Renewal CS- Early-Visit 471968078Renewal CS- Early-Visit 471968080Renewal CS+E Late-Visit 471968074Renewal CS+E Late-Visit 471968075Renewal CS+E Late-Visit 471968076Renewal CS+E Late-Visit 471968077Renewal CS+E Late-Visit 471968078Renewal CS+E Late-Visit 471968080Renewal CS+U Late-Visit 471968075Renewal CS+U Late-Visit 471968074Renewal CS+U Late-Visit 471968076Renewal CS+U Late-Visit 471968077Renewal CS+U Late-Visit 471968078Renewal CS+U Late-Visit 471968080Renewal CS- Late-Visit 471968075Renewal CS- Late-Visit 471968077Renewal CS- Late-Visit 471968078Renewal CS- Late-Visit 471968074Renewal CS- Late-Visit 471968076Renewal CS- Late-Visit 471968080
NoI don't knowYes
PTSD-dronabinol1
PTSD-dronabinol0
PTSD-dronabinol6
TEC-placebo12
PTSD-dronabinol5
TEC-dronabinol6
PTSD-dronabinol2
HC-placebo9
TEC-placebo11
HC-placebo10
PTSD-dronabinol7
HC-placebo1
PTSD-placebo4
PTSD-placebo5
PTSD-placebo7
HC-dronabinol10
PTSD-placebo9
TEC-placebo13
TEC-placebo0
TEC-dronabinol5
PTSD-placebo6
PTSD-placebo3
TEC-dronabinol4
PTSD-placebo1
TEC-dronabinol9
TEC-placebo7
HC-dronabinol7
TEC-dronabinol11
TEC-placebo1
PTSD-placebo8
HC-dronabinol9
PTSD-placebo0
PTSD-dronabinol3
TEC-dronabinol7
TEC-dronabinol8
PTSD-placebo2
TEC-dronabinol3
HC-dronabinol5
HC-placebo2
PTSD-dronabinol4
TEC-placebo5
HC-dronabinol3
HC-placebo5
PTSD-dronabinol8
TEC-placebo8
HC-placebo7
HC-dronabinol0
HC-dronabinol8
TEC-placebo2
HC-dronabinol1
TEC-dronabinol2
TEC-dronabinol10
TEC-placebo6
HC-dronabinol6
TEC-dronabinol0
TEC-placebo3
HC-dronabinol2
HC-placebo0
TEC-dronabinol1
TEC-placebo4
HC-dronabinol4
HC-placebo6
TEC-placebo9
HC-dronabinol11
HC-placebo8
HC-placebo4

[back to top]

Subjective Units of Distress (SUDS)

"Subjective Units of Distress (SUDS): used to measure fear ratings/subjective anxiety on a scale from 0-10; taken at three time points throughout the tasks: before the task begins, in the middle of the task, and at the end of the task. A rating of 0 means no anxiety and a ratings of 10 means worst anxiety ever experienced." (NCT02069366)
Timeframe: SUDS ratings are collected at Visit 3, 14 days from baseline (Visit 1), and Visit 4, 15 days from baseline (Visit 1), at 3 timepoints within each visit: before the task begins (Pre), in the middle of the task (Mid), and at the end of the task (Post).

,,,,,
Interventionscore on a scale (Mean)
Extinction Learning Pre- Visit 3Extinction Learning Mid-Visit 3Extinction Learning Post-Visit 3Recall Pre-Visit 4Recall Mid-Visit 4Recall Post-Visit 4Renewal Pre-Visit 4Renewal Mid-Visit 4Renewal Post-Visit 4
HC-dronabinol3.153.003.231.461.461.381.461.541.38
HC-placebo1.922.232.311.001.081.771.541.461.62
PTSD-dronabinol3.444.223.561.222.001.561.561.671.89
PTSD-placebo2.52.902.202.002.201.702.101.802.00
TEC-dronabinol2.833.502.750.921.421.251.251.251.17
TEC-placebo1.791.501.640.500.641.210.931.291.50

[back to top]

Beck Depression Inventory II

The Beck Depression Inventory is composed of items relating to symptoms of depression such as hopelessness and irritability, cognitions such as guilt or feelings of being punished, as well as physical symptoms such as fatigue, weight loss, and lack of interest in sex. Range of scores is from 0 to 63. A higher score is a worse score. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol7.815.615.265.524.365.25
Placebos8.057.685.765.325.505.32
Vaporized Cannabis 3.7% THC/5.6% CBD7.845.325.596.256.096.06

[back to top]

Driving Simulation (Car Following)

"Car Following: This simulation examines the participant's ability to closely match the speed of an automobile in front of them. Participants are to follow a lead vehicle at a safe and constant distance. The primary outcome is coherence between the participant and lead cars (a general correlation [0-1] of the participant's ability to accurately track the speed variations of the lead car. A higher score indicates worse performance.~The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy." (NCT02460692)
Timeframe: 270 minutes

,,
Interventionscore on a scale (Mean)
Pre DoseAfter First Dose 30 minutesAfter First Dose 100 minutesAfter First Dose 230 minutesAfter Second Dose 30 minutes
Dronabinol0.620.710.680.600.68
Placebos0.700.750.590.720.74
Vaporized Cannabis 3.7% THC/5.6% CBD0.490.610.560.620.60

[back to top]

Wechsler Adult Intelligence Scale-III Digit Symbol Test

The Digit Symbol test measures concentration, psychomotor speed, and graphomotor abilities. This pen and paper test involves having subjects substitute a series of symbols with numbers as quickly and accurately as possible during a 120 second period. The results are expressed as the number of correct substitutions with a score range of 0-133. A higher number indicates better performance. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionnumber of correct symbols (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol69.673.575.679.279.879.3
Placebos80.384.888.990.088.484.8
Vaporized Cannabis 3.7% THC/5.6% CBD72.278.377.683.181.087.3

[back to top] [back to top]

Profile of Mood States

"This questionnaire contains 65 words/statements that describe feelings people have. The questionnaire requires the patient to indicate for each word or statement how he or she has been feeling in the past week. There are 6 subscales: tension-anxiety (9 items, score range: 0-36), depression (15 items, range 0-60), anger-hostility (12 items, range 0-48), vigor-activity (8 items, range 0-32), fatigue (7 items, range 0-28), confusion-bewilderment (7 items, range 0-28).~The total mood disturbance (TMD) is calculated by adding the scores for tension-anxiety, depression, anger-hostility, fatigue and confusion-bewilderment and then subtracting the score for vigor-activity. The TMD is reported and has a score range of -32 to 200. A higher score indicates worse symptoms." (NCT02460692)
Timeframe: 8 weeks

,,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol53.846.242.940.037.741.0
Placebos57.351.548.646.345.542.5
Vaporized Cannabis 3.7% THC/5.6% CBD53.241.538.838.844.239.7

[back to top]

Numerical Pain Intensity

The primary outcome is self-reported daily average numerical pain intensity during the past 24 hours. The numerical pain intensity is an 11-point pain intensity numerical rating scale (PI-NRS), where 0 equals no pain and 10 equals worst possible pain. The time frame includes baseline and weeks 1, 3, 5, 7, 8. Baseline is the pain tensity reported at the first day in the daily diary, before the first dose. The follow-up pain intensities (weeks 1, 3, 5, 7, 8) are the daily diary average pain intensities since the previously reported timepoint. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol6.115.805.674.894.354.19
Placebos6.035.975.655.475.265.22
Vaporized Cannabis 3.7% THC/5.6% CBD6.245.645.434.824.724.45

[back to top]

Locally Developed Psychoactive Effect Scale - Good Drug Effect

"Visual Analogue Scale (VAS) ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel ___after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry.~This is a substudy. A good drug effect is presented. Range of scores is from 0 to 100. A higher score is a worse score." (NCT02460692)
Timeframe: 6 hours

,,
Interventionscore on a scale (Mean)
After dose 1 hourAfter dose 2 hoursAfter dose 3 hoursAfter dose 4 hoursAfter dose 5 hoursAfter dose 6 hours
Dronabinol19.133.533.236.329.732.4
Placebos14.214.05.887.4311.610.7
Vaporized Cannabis 3.7% THC/5.6% CBD58.845.727.537.044.440.4

[back to top]

Locally Developed Psychoactive Effect Scale - High

"A total of 15 separate VAS ratings will be presented as a 100-mm horizontal line, anchored on the left with 'not at all' and on the right with 'extremely'. Participants will pencil in a vertical line along the horizontal line that represents their current feeling (questions usually phrased, 'During the past week, did you feel ___after consuming the vaporized cannabis?'). Ratings will be: any drug effect, a good drug effect, a bad drug effect, high, drunk, impaired, stoned, as if you liked the drug effect, sedated, confused, nauseous, like you desired more of the drug, anxious, down, and very hungry.~This is a substudy. Drug high will be presented. Range of scores is from 0 to 100. A higher score is a worse score." (NCT02460692)
Timeframe: 6 hours

,,
Interventionscore on a scale (Mean)
After dose 1 hourAfter dose 2 hoursAfter dose 3 hoursAfter dose 4 hoursAfter dose 5 hoursAfter dose 6 hours
Dronabinol14.925.831.828.621.524.8
Placebos5.385.755.564.001.751.71
Vaporized Cannabis 3.7% THC/5.6% CBD49.836.720.529.543.931.7

[back to top]

Marijuana Subscale (M-scale) of the Addiction Research Center Inventory

The Marijuana subscale (M-scale) of the Addiction Research Center Inventory consists of 12 true or false questions corresponding to symptoms of cannabis intoxication; the minimum and maximum scores are 0 and 12 respectively. A higher score indicates a worse score. The questions were rephrased to evaluate the experience from the past week rather than an acute response to cannabis. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionscore on a scale (Mean)
Week 1Week 3Week 5Week 7Week 8
Dronabinol1.812.472.932.462.29
Placebos1.591.631.311.611.11
Vaporized Cannabis 3.7% THC/5.6% CBD2.312.332.672.802.31

[back to top]

Hopkins Verbal Learning Test

"The Hopkins Verbal Learning Test provides information on the ability to learn and immediately recall verbal information across trials, as well at the ability to retain, reproduce, and recognize this information after a delay. A list of 12 words is presented to the subject over three trials. After each trial, the subject is to recall as many items as possible from the list in any desired order. A 20-minute delay follows the administration of the three trials, after which the subject is asked to recall the list.~The ability to learn is represented by the number of correct words, with a score range of 0-36. A higher score indicates better performance." (NCT02460692)
Timeframe: 8 weeks

,,
InterventionNumber of correct words (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol23.723.323.624.024.724.5
Placebos24.124.022.925.624.324.0
Vaporized Cannabis 3.7% THC/5.6% CBD24.424.022.824.623.824.8

[back to top]

Cold Pressor Test - Pain Tolerance

Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionseconds (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol40.644.840.043.644.237.5
Placebos47.250.546.241.461.737.9
Vaporized Cannabis 3.7% THC/5.6% CBD58.360.964.360.754.762.3

[back to top]

Neuropathic Pain Scale

The Neuropathic Pain Scale (NPS) is an 11-point numerical scale consisting of 13 questions that ask ratings of various pain descriptors (including pain intensity, sharpness, burning, aching, cold, sensitivity, itching,unpleasantness, deep, and surface pain). The NPS is scored as the sum of these pain descriptors. Range of scores is from 0 to100. A higher score is a worse score. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol45.138.934.630.829.628.2
Placebos45.940.437.035.136.034.6
Vaporized Cannabis 3.7% THC/5.6% CBD48.342.339.237.533.433.2

[back to top]

Grooved Pegboard Test - Dominant Hand

"The Grooved Pegboard Test is a test of fine motor coordination and speed. Subjects are required to place 25 small metal pegs into holes on a 3 x 3 metal board. All pegs are alike and have a ridge on one side, which corresponds to a notch in each hole on the board. First the dominant hand is tested, and subjects are asked to place the pegs in the holes as fast as they can. This is then repeated with the non-dominant hand, and the total time for each hand is recorded. A higher score indicates worse performance." (NCT02460692)
Timeframe: 8 weeks

,,
Interventionseconds (Mean)
BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol73.469.563.169.068.769.2
Placebos63.760.761.159.959.760.8
Vaporized Cannabis 3.7% THC/5.6% CBD69.164.564.161.762.561.7

[back to top]

Driving Simulation (Lane Tracking)

"Lane Tracking: This task requires subjects to drive down a straight 2-lane road, maintain a constant speed of 55 mph, maintain appropriate lane position, and respond to divided attention tasks in the upper corners of the screen. The primary outcome is standard deviation of lateral deviation (swerving) with a score range of 0.51 - 3.24. A higher score indicates worse performance.~The driving simulation assessments are conducted in a substudy, which only includes completers with a valid driver's license and who agreed to participate in the substudy." (NCT02460692)
Timeframe: 270 minutes

,,
Interventionscore on a scale (Mean)
Pre DoseAfter First Dose 30 minutesAfter First Dose 100 minutesAfter First Dose 230 minutesAfter Second Dose 30 minutes
Dronabinol1.281.411.781.511.65
Placebos0.751.181.121.311.13
Vaporized Cannabis 3.7% THC/5.6% CBD1.141.121.211.111.24

[back to top]

Cold Pressor Test - Pain Sensitivity

Each Cold Pressure Test will begin with an immersion of the left hand into a warm water bath for 3 min. During this time, blood pressure and heart rate will be measured. After removal of the hand from the warm water, skin temperature of the thumbpad will be recorded and participants will listen to a standardized script describing the procedures. Participants will then immerse the left hand into the cold water bath, and will be instructed to report the first painful sensation after immersion. They will then be asked to tolerate the stimulus as long as possible, but will be permitted to withdraw their hand from the cold water at any point. Maximum immersion time will be 2 min. Latency to first feel pain (pain sensitivity) and latency to withdraw the hand from the water (pain tolerance) will be recorded. Blood pressure and heart rate will be measured before and after each immersion using the arm that was not immersed in the water bath. (NCT02460692)
Timeframe: 8 weeks

,,
Interventionseconds (Mean)
Pain sensitivity BaselineWeek 1Week 3Week 5Week 7Week 8
Dronabinol18.323.018.820.421.515.8
Placebos20.029.421.920.920.421.1
Vaporized Cannabis 3.7% THC/5.6% CBD26.320.521.024.720.923.9

[back to top]

Cannabis Withdrawal Scale - Withdrawal Intensity

The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). Range of scores for withdrawal intensity is from 0 to 190. A higher score is a worse score. (NCT02460692)
Timeframe: Week 8 and Week 10

,,
Interventionscore on a scale (Mean)
Week 8Week 10
Dronabinol6.126.32
Placebos13.512.7
Vaporized Cannabis 3.7% THC/5.6% CBD12.49.97

[back to top]

Cannabis Withdrawal Scale - Negative Impact of Withdrawal

The Cannabis Withdrawal Scale is an assessment tool used to quantify the presence and intensity of various withdrawal symptoms (e.g., strange dreams, mood swings, depression, lack of appetite, and an inability to get to sleep). The outcome is measured during the tapering period (weeks 8 and 10), at which patients slowly withdrew from medication over two weeks. Range of scores for the negative impact of withdrawal is from 0 to 190. A higher score is a worse score. (NCT02460692)
Timeframe: Week 8, Week 10

,,
Interventionscore on a scale (Mean)
Week 8Week 10
Dronabinol3.422.32
Placebos8.428.18
Vaporized Cannabis 3.7% THC/5.6% CBD10.34.31

[back to top]

BOLD Signal Measured by Functional Magnetic Resonance Imaging (fMRI)

Mean BOLD hippocampal signal during extinction learning and retention task in brain responsebetween the placebo (PBO) and the dronabinol (THC) group. Target areas are analyzed from fMRI scans. The scans were completed on days 1, 2, 3, and 9. Participants were randomized to the PBO and THC condition and received either placebo or dronabinol on day 2, 2 hours prior to extinction learning. Data from days 1, 2, 3, & 9 was combined and a single value was averaged for each group. (NCT02472847)
Timeframe: Day 1, 2, 3, & 9

Interventionparameter estimates (arbitrary units) (Mean)
Placebo0.1631
Dronabinol0.5079

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.25-0.290.33-0.751.290.83
ALC Placebo Arm-0.17-0.670.08-0.920.920.33
AMP Arm-0.17-0.580.13-0.460.580.08
AMP Placebo Arm-0.25-0.580.13-1.171.960.5
THC Arm-0.04-0.710.38-0.792.920.42
THC Placebo Arm0.540.33-0.170.250.420.42

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.33-1.130.79-2.045.461.08
ALC Placebo Arm-0.71-1.290.04-0.831.63-0.04
AMP Arm2.173.330.381.67-1.081.83
AMP Placebo Arm-0.17-0.125-0.13-11.710.25
THC Arm-0.08-0.961-1.542.881.42
THC Placebo Arm-0.04-0.08-0.08-0.381.080.17

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm76.8345.0843.9650.3824.75
ALC Placebo Arm17.8314.3816.6811.510.0
AMP Arm43.4253.8815.7130.542.17
AMP Placebo Arm21.5816.6317.7112.5410.96
THC Arm38.2528.7525.6331.7517.46
THC Placebo Arm18.6325.2915.7912.9618.96

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm61.2129.9250.4641.8325.88
ALC Placebo Arm12.7511.3815.337.257.71
AMP Arm34.9255.6716.5427.9250.21
AMP Placebo Arm16.4610.4217.546.836.54
THC Arm31.5420.0823.2529.2116.54
THC Placebo Arm13.1713.2515.967.5812.88

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.54-1.540.79-2.045.460.75
ALC Placebo Arm-0.54-1.25-0.13-0.671.58-0.21
AMP Arm2.292.960.51.75-11.54
AMP Placebo Arm-0.130.130.09-0.430.650.22
THC Arm-0.17-0.960.58-1.292.580.83
THC Placebo Arm-0.08-0.08-0.17-0.420.790.08

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.887.3322.719.214.54
ALC Placebo Arm0.960.251.290.833.83
AMP Arm11.0818.388.546.2532.5
AMP Placebo Arm2.171.967.460.332.25
THC Arm5.794.886.834.968.79
THC Placebo Arm1.084.384.540.426.17

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm22.219.0429.514.137.0
ALC Placebo Arm2.081.754.291.254.04
AMP Arm16.1331.0811.5411.6738.38
AMP Placebo Arm3.52.544.251.632.46
THC Arm15.677.3316.1311.7910.04
THC Placebo Arm2.544.04.631.045.04

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm30.8321.3340.7520.4612.58
ALC Placebo Arm4.632.424.292.135.04
AMP Arm19.7939.511.2516.3344.08
AMP Placebo Arm5.836.748.092.872.87
THC Arm18.6311.7117.7914.759.38
THC Placebo Arm4.634.966.421.966.21

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm43.9223.7944.9229.3817.5
ALC Placebo Arm7.964.8311.085.086.54
AMP Arm27.0843.7511.9218.8845.38
AMP Placebo Arm11.927.0413.385.043.13
THC Arm24.081819.6321.969.92
THC Placebo Arm7.888.678.884.839.88

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm1.921.382.63-0.883.713.42
ALC Placebo Arm-0.33-1.170.29-0.961.540.29
AMP Arm2.883.711.131.63-13.21
AMP Placebo Arm000.33-0.832.250.42
THC Arm0.17-0.541.54-1.382.962.04
THC Placebo Arm0.710.880.130.041.130.96

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.75-1.290.54-1.53.630.08
ALC Placebo Arm-0.33-1.08-0.04-0.380.71-0.13
AMP Arm1.581.920.461.13-0.461.21
AMP Placebo Arm-0.040.330.04-0.330.210.13
THC Arm-0.21-0.670.54-1.292.130.71
THC Placebo Arm-0.17-0.170.04-0.290.42-0.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.71-1.170.33-1.253.170.08
ALC Placebo Arm-0.54-0.791.67-0.380.21-0.17
AMP Arm1.01.380.630.83-0.290.96
AMP Placebo Arm-0.170.130.25-0.17-0.290
THC Arm-0.46-0.880.54-0.831.040.21
THC Placebo Arm0.080.040.04-0.130.13-0.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.29-0.381.79-2.546.212.25
ALC Placebo Arm-0.58-1.290.29-1.131.920.13
AMP Arm2.963.671.082.17-1.212.63
AMP Placebo Arm-0.33-0.29-0.04-1.292.670.42
THC Arm0-0.831.42-1.713.542.04
THC Placebo Arm-0.08-0.130.08-0.671.580.29

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.8318.6711.718.8313.5
ALC Placebo Arm9.3810.0411.05.53.71
AMP Arm4.7916.084.213.2914.21
AMP Placebo Arm12.179.010.716.965.63
THC Arm11.0811.7512.3810.586.54
THC Placebo Arm4.59.670.833.6711.0

[back to top]

Actigraph Change in Sleep Efficiency

"Daily sleep measures were collected using the Actigraph Watch at baseline and throughout the study period. Data were processed using the Actigraph Software according to the User Manual to measure sleep efficiency, which is defined as the proportion of the estimated sleep periods spent asleep. Change in sleep efficiency was calculated and compared across the four treatment groups to assess whether there was any improvement or worsening in sleep efficiency before and after the 4-week treatment period. Other measures included number of days data were collected and average duration in minutes of time that were excluded and not recorded. Daily data were aggregated to analyze participants' average weekly sleep patterns." (NCT02759185)
Timeframe: Change in sleep efficiency from baseline to end of 4-week treatment period (visit 6)

Interventionpercentage of total sleep time (Mean)
High CBD Cannabis0.17
High THC Cannabis6.83
THC/CBD Cannabis1.80
Placebo Cannabis-0.28

[back to top]

Change in PTSD Checklist (PCL-5) From Baseline to Stage 1 Primary Endpoint

The PTSD Checklist (PCL-5) is a 20-item self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms. Participants indicate how much distress they have experienced due to various PTSD symptoms on a five-point Likert-type scale (0=not at all, 4=extremely). The total PCL-5 score (a sum of all 20 items) ranges from 0 to 80, with higher scores indicating greater symptom severity. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Stage 1 Primary Endpoint (Visit 6, 3 weeks post self-administration and prior to cessation)

Interventionscore on a scale (Mean)
High THC Cannabis-23.5
High CBD Cannabis-12.1
THC/CBD Cannabis-16.4
Placebo Cannabis-14.6

[back to top]

Stage 1 Primary Endpoint CAPS-5 Total Severity Scores (Visit 5)

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance), and D (hypervigilance); and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT02759185)
Timeframe: Visit 5 (between end of week 3 and start of week 4) of Stage 1

Interventionscore on a scale (Mean)
High THC Cannabis20.5
High CBD Cannabis28.1
THC/CBD Cannabis29.6
Placebo Cannabis24.2

[back to top]

Change in Inventory of Psychosocial Functioning (IPF) From Baseline to Stage 1 Primary Endpoint

The Inventory of Psychosocial Functioning (IPF) is an 80-item measure that was developed for use among individuals with PTSD. It assesses current psychosocial functioning across seven domains: romantic relationships, family, work, friendships, parenting, education, and self-care. Items are scored on a 0 (never) to 6 (always) scale. Summation of scores across domains yields a total score for psychosocial functioning, with higher scores indicating greater functional impairment. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Stage 1 Primary Endpoint (Visit 6, 3 weeks post self-administration and prior to cessation)

Interventionscore on a scale (Mean)
High THC Cannabis1.2
High CBD Cannabis-1.2
THC/CBD Cannabis4.1
Placebo Cannabis-0.2

[back to top]

Change in Inventory of Depression and Anxiety (IDAS) Social Anxiety Total Scores From Baseline to Stage 1 Primary Endpoint

The Inventory of Depression and Anxiety (IDAS) is a 64-item self-report measure of non-overlapping scales that assess specific depression and anxiety symptoms. Respondents indicate on a scale of 1 (not at all) to 5 (extremely) how much they have felt or experienced several symptoms in the past two weeks. The IDAS consists of 10 symptom scales: Suicidality, Lassitude, Insomnia, Appetite Loss, Appetite Gain, Ill Temper, Well-Being, Panic, Social Anxiety, and Traumatic Intrusions. Items that assess social anxiety are summed and range from 5 to 25 with higher scores indicating greater anxiety symptoms. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Stage 1 Primary Endpoint (Visit 6, 3 weeks post self-administration and prior to cessation)

Interventionscore on a scale (Mean)
High THC Cannabis-3.7
High CBD Cannabis-2.7
THC/CBD Cannabis-2.2
Placebo Cannabis-2.4

[back to top]

Change in Inventory of Depression and Anxiety (IDAS) General Depression Total Scores From Baseline to Stage 1 Primary Endpoint

The Inventory of Depression and Anxiety (IDAS) is a 64-item self-report measure of non-overlapping scales that assess specific depression and anxiety symptoms. Respondents indicate on a scale of 1 (not at all) to 5 (extremely) how much they have felt or experienced several symptoms in the past two weeks. The IDAS consists of 10 symptom scales: Suicidality, Lassitude, Insomnia, Appetite Loss, Appetite Gain, Ill Temper, Well-Being, Panic, Social Anxiety, and Traumatic Intrusions. Items that assess general depression are summed and range from 20 to 100 with higher scores indicating greater depressive symptoms. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Stage 1 Primary Endpoint (Visit 6, 3 weeks post self-administration and prior to cessation)

Interventionscore on a scale (Mean)
High THC Cannabis-16.1
High CBD Cannabis-11.4
THC/CBD Cannabis-13.4
Placebo Cannabis-8.3

[back to top]

Change in Insomnia Severity Index (ISI) Scores From Baseline to Stage 1 Primary Endpoint

The Insomnia Severity Index (ISI) is a brief self-reported measure of insomnia. It consists of seven questions, with responses made on a five-point Likert scale. Three items address difficulty at sleep onset, maintaining sleep, and early waking, and four questions address perceived quality of sleep and effects of sleep difficulties on daily function. Questions are summed into a total score that ranges from 0 to 28 and can be interpreted as ranging from no signs of insomnia to severe insomnia. Higher scores indicate more severe insomnia. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Stage 1 Primary Endpoint (Visit 6, 3 weeks post self-administration and prior to cessation)

Interventionscore on a scale (Mean)
High THC Cannabis-8.8
High CBD Cannabis-5.9
THC/CBD Cannabis-6.6
Placebo Cannabis-6.1

[back to top]

Change in CAPS-5 Total Severity Scores From Baseline to Stage 1 Primary Endpoint (Visit 5)

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance), and D (hypervigilance); and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization) to Primary Endpoint (Visit 5, between end of week 3 and start of week 4)

Interventionscore on a scale (Mean)
High THC Cannabis-15.2
High CBD Cannabis-8.4
THC/CBD Cannabis-8.5
Placebo Cannabis-13.1

[back to top]

Baseline CAPS-5 Total Severity Score

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a CAPS-5 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance), and D (hypervigilance), and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT02759185)
Timeframe: Baseline (3 weeks after randomization)

Interventionscore on a scale (Mean)
High THC Cannabis36.6
High CBD Cannabis36.8
THC/CBD Cannabis38.0
Placebo Cannabis37.3

[back to top]

Brain Measures

Mean functional magnetic resonance imaging (fMRI) BOLD activation extracted from each region of interests [amygdala; ventromedial prefrontal cortex; hippocampus] for each stimulus type (CS+E, CS+U, CS-). The units of BOLD values are expressed as arbitrary units. (NCT03008005)
Timeframe: Brain measures are collected on Visit 3, 14 days from baseline (Visit 1), Visit 4, 15 days from baseline (Visit 1), and Visit 5, 21 days from baseline (Visit 1), for approximately 1.5 hours each day

,,
Interventionarbitrary units (Mean)
Extinction Learning CS+E Amygdala-Visit 3Extinction Learning CS+E Hippocampus-Visit 3Extinction Learning CS+E vmPFC-Visit 3Extinction Learning CS- Amygdala-Visit 3Extinction Learning CS- Hippocampus-Visit 3Extinction Learning CS- vmPFC-Visit 3Recall CS+E Amygdala-Visit 4Recall CS+E Hippocampus-Visit 4Recall CS+E vmPFC-Visit 4Recall CS- Amygdala-Visit 4Recall CS- Hippocampus-Visit 4Recall CS- vmPFC-Visit 4Recall CS+U Amygdala-Visit 4Recall CS+U Hippocampus-Visit 4Recall CS+U vmPFC-Visit 4Renewal CS+E Amygdala-Visit 4Renewal CS+E Hippocampus-Visit 4Renewal CS+E vmPFC-Visit 4Renewal CS- Amygdala-Visit 4Renewal CS- Hippocampus-Visit 4Renewal CS- vmPFC-Visit 4Renewal CS+U Amygdala-Visit 4Renewal CS+U Hippocampus-Visit 4Renewal CS+U vmPFC-Visit 4Recall CS+E Amygdala-Visit 5Recall CS+E Hippocampus-Visit 5Recall CS+E vmPFC-Visit 5Recall CS- Amygdala-Visit 5Recall CS- Hippocampus-Visit 5Recall CS- vmPFC-Visit 5Recall CS+U Amygdala-Visit 5Recall CS+U Hippocampus-Visit 5Recall CS+U vmPFC-Visit 5Renewal CS+E Amygdala-Visit 5Renewal CS+E Hippocampus-Visit 5Renewal CS+E vmPFC-Visit 5Renewal CS- Amygdala-Visit 5Renewal Hippocampus-Visit 5Renewal CS- vmPFC-Visit 5Renewal CS+U Amygdala-Visit 5Renewal CS+U Hippocampus-Visit 5Renewal CS+U vmPFC-Visit 5
Dronabinol Cap 10 Milligrams (MG)0.1494463570.0734664-0.0141016430.160143-0.022569714-0.0582643930.021313529-0.008622411-0.0422977140.0847859710.021303429-0.0235826430.1065742140.039578357-0.068200429-0.0389713760.022821236-0.0447827140.0898715710.0265971570.0159766710.043506750.037054743-0.0286422930.1758579290.1279933570.0072105710.1548382140.0426459-0.0563484210.0898212860.073768357-0.0261016430.0913021430.0313422430.0485981290.151682050.041636779-0.0483541430.0958719140.0099841070.016284214
Dronabinol Cap 5 Milligrams (MG)0.0921736360.000147182-0.140956909-0.006294273-0.133546182-0.1444995450.05063-0.009476018-0.046500136-0.045574364-0.012782118-0.111483273-0.002491309-0.048798436-0.110820.0854932910.053855418-0.0519276360.0410822730.028653909-0.035996455-0.0190352730.040038355-0.063822713-0.112056636-0.017467364-0.017208209-0.0602914090.006147773-0.0276624550.052176091-0.009212182-0.0246728050.0769368180.0312234360.0402830.1240697270.0560264360.03441490.1826938450.0573692730.085382818
Placebo Oral Capsule0.039567327-0.021618-0.1003984550.058886909-0.059069435-0.1084751180.064068818-0.018730882-0.0925623270.0231798910.016318864-0.0250441730.0733185180.0027553-0.063881291-0.007166727-0.042572273-0.0254624550.0386679090.010737545-0.01159750.0339221820.001226509-0.0243116550.1020819090.0662363640.03270430.0951676360.0074816360.0178999090.0679712180.023053471-0.0417236730.0618997270.0631495550.0666091820.1839167270.0131740.0183599990.3122604550.1116707270.056020818

[back to top]

Expectancy Ratings

"To assess the expected likelihood that an aversive cue (e.g. noise burst) will occur or not based on the CS shown on the screen. Participants rate their expectancy of the aversive cue using a button box on a scale from 1 to 3 [1 = certain that the aversive cue will be presented (Yes); 2 = certain that the aversive cue will not be presented (No); 3 = uncertain whether the aversive cue will be presented (I don't know)]. Counts of yes, no, and I don't know are collected on the first (early) trial of the CS and the last (late) trial of the CS." (NCT03008005)
Timeframe: Collected on Visit 2, 7 days from baseline (Visit 1), Visit 3, 14 days from baseline (Visit 1), Visit 4, 15 days from baseline (Visit 1), and Visit 5, 21 days from baseline (Visit 1) during the task. Each day the task lasts approximately 20 minutes.

InterventionParticipants (Count of Participants)
Acquisition CS+E Early-Visit 272577701Acquisition CS+E Early-Visit 272577702Acquisition CS+E Early-Visit 272577703Acquisition CS+U Early-Visit 272577701Acquisition CS+U Early-Visit 272577703Acquisition CS+U Early-Visit 272577702Acquisition CS- Early-Visit 272577701Acquisition CS- Early-Visit 272577702Acquisition CS- Early-Visit 272577703Acquisition CS+E Late-Visit 272577701Acquisition CS+E Late-Visit 272577702Acquisition CS+E Late-Visit 272577703Acquisition CS+U Late-Visit 272577701Acquisition CS+U Late-Visit 272577702Acquisition CS+U Late-Visit 272577703Acquisition CS- Late-Visit 272577701Acquisition CS- Late-Visit 272577702Acquisition CS- Late-Visit 272577703Extinction CS+E Early-Visit 372577701Extinction CS+E Early-Visit 372577702Extinction CS+E Early-Visit 372577703Extinction CS- Early-Visit 372577701Extinction CS- Early-Visit 372577702Extinction CS- Early-Visit 372577703Extinction CS+E Late-Visit 372577701Extinction CS+E Late-Visit 372577702Extinction CS+E Late-Visit 372577703Extinction CS- Late-Visit 372577701Extinction CS- Late-Visit 372577702Extinction CS- Late-Visit 372577703Recall CS+E Early-Visit 472577701Recall CS+E Early-Visit 472577702Recall CS+E Early-Visit 472577703Recall CS+U Early-Visit 472577701Recall CS+U Early-Visit 472577702Recall CS+U Early-Visit 472577703Recall CS- Early-Visit 472577701Recall CS- Early-Visit 472577702Recall CS- Early-Visit 472577703Recall CS+E Late-Visit 472577701Recall CS+E Late-Visit 472577703Recall CS+E Late-Visit 472577702Recall CS+U Late-Visit 472577703Recall CS+U Late-Visit 472577701Recall CS+U Late-Visit 472577702Recall CS- Late-Visit 472577701Recall CS- Late-Visit 472577702Recall CS- Late-Visit 472577703Renewal CS+E Early-Visit 472577701Renewal CS+E Early-Visit 472577702Renewal CS+E Early-Visit 472577703Renewal CS+U Early-Visit 472577701Renewal CS+U Early-Visit 472577702Renewal CS+U Early-Visit 472577703Renewal CS- Early-Visit 472577703Renewal CS- Early-Visit 472577702Renewal CS- Early-Visit 472577701Renewal CS+E Late-Visit 472577703Renewal CS+E Late-Visit 472577701Renewal CS+E Late-Visit 472577702Renewal CS+U Late-Visit 472577702Renewal CS+U Late-Visit 472577701Renewal CS+U Late-Visit 472577703Renewal CS- Late-Visit 472577701Renewal CS- Late-Visit 472577702Renewal CS- Late-Visit 472577703Recall CS+E Early-Visit 572577703Recall CS+E Early-Visit 572577701Recall CS+E Early-Visit 572577702Recall CS+U Early-Visit 572577703Recall CS+U Early-Visit 572577701Recall CS+U Early-Visit 572577702Recall CS- Early-Visit 572577701Recall CS- Early-Visit 572577702Recall CS- Early-Visit 572577703Recall CS+E Late-Visit 572577702Recall CS+E Late-Visit 572577703Recall CS+E Late-Visit 572577701Recall CS+U Late-Visit 572577701Recall CS+U Late-Visit 572577702Recall CS+U Late-Visit 572577703Recall CS- Late-Visit 572577701Recall CS- Late-Visit 572577702Recall CS- Late-Visit 572577703Renewal CS+E Early-Visit 572577701Renewal CS+E Early-Visit 572577702Renewal CS+E Early-Visit 572577703Renewal CS+U Early-Visit 572577701Renewal CS+U Early-Visit 572577702Renewal CS+U Early-Visit 572577703Renewal CS- Early-Visit 572577703Renewal CS- Early-Visit 572577701Renewal CS- Early-Visit 572577702Renewal CS+E Late-Visit 572577701Renewal CS+E Late-Visit 572577702Renewal CS+E Late-Visit 572577703Renewal CS+U Late-Visit 572577701Renewal CS+U Late-Visit 572577703Renewal CS+U Late-Visit 572577702Renewal CS- Late-Visit 572577701Renewal CS- Late-Visit 572577702Renewal CS- Late-Visit 572577703
NoI Don't KnowYes
Dronabinol Cap 5 Milligrams (MG)5
Placebo Oral Capsule8
Dronabinol Cap 10 Milligrams (MG)2
Placebo Oral Capsule10
Dronabinol Cap 5 Milligrams (MG)8
Placebo Oral Capsule6
Dronabinol Cap 5 Milligrams (MG)9
Placebo Oral Capsule1
Dronabinol Cap 5 Milligrams (MG)0
Placebo Oral Capsule3
Dronabinol Cap 5 Milligrams (MG)1
Placebo Oral Capsule2
Dronabinol Cap 5 Milligrams (MG)2
Dronabinol Cap 5 Milligrams (MG)4
Dronabinol Cap 10 Milligrams (MG)1
Dronabinol Cap 10 Milligrams (MG)4
Placebo Oral Capsule7
Dronabinol Cap 5 Milligrams (MG)6
Dronabinol Cap 10 Milligrams (MG)8
Placebo Oral Capsule11
Dronabinol Cap 5 Milligrams (MG)7
Placebo Oral Capsule0
Dronabinol Cap 5 Milligrams (MG)3
Placebo Oral Capsule4
Dronabinol Cap 10 Milligrams (MG)6
Dronabinol Cap 10 Milligrams (MG)3
Placebo Oral Capsule9
Dronabinol Cap 10 Milligrams (MG)9
Dronabinol Cap 10 Milligrams (MG)7
Dronabinol Cap 10 Milligrams (MG)5
Dronabinol Cap 10 Milligrams (MG)11
Dronabinol Cap 10 Milligrams (MG)10
Dronabinol Cap 10 Milligrams (MG)0
Placebo Oral Capsule5
Dronabinol Cap 5 Milligrams (MG)10

[back to top]

Changes in Tic Severity

Yale Global Tic Severity Scale (YGTSS) (Total Tic Score) The YGTSS tool gives ratings in 5 domains: Total Motor Tic Score, Total Verbal Tic Score, Total Tic Score (Motor + Verbal), Overall Impairment Rating, and Global Severity Score. When calculating the Global Severity score, it is found by adding together the total motor, verbal and impairment scores. The Total Tic Severity Score has a range of 0-50, and the Global Severity Score has a range of 0- 100. A higher score on all scales suggests a more severe Tic, or a greater impact the Tic has on the person's life. (NCT03066193)
Timeframe: 12 weeks

Interventionscore on a scale (Mean)
Dronabinol and Palmitoylethanolamide7.6

[back to top]

Number of BILAG-2004 Disease Flares

"The number of BILAG-2004 disease flares as defined as one new BILAG A or two new BILAG B scores will be assessed.~The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems.~* BILAG-2004: British Isles Lupus Assessment Group 2004." (NCT03093402)
Timeframe: Visit 3 (Day 29)

,,,
InterventionNumber of Participants (Number)
One new BILAG A FlareTwo new BILAG B Flares
High: JBT-101 20mg/20mg00
Low: JBT-101 5mg/5mg00
Medium: JBT-101 20mg/Placebo01
Placebo00

[back to top]

Number of BILAG-2004 Disease Flares

"The number of BILAG-2004 disease flares as defined as one new BILAG A or two new BILAG B scores will be assessed.~The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems.~* BILAG-2004: British Isles Lupus Assessment Group 2004." (NCT03093402)
Timeframe: Visit 4 (Day 57)

,,,
InterventionNumber of Participants (Number)
One new BILAG A FlareTwo new BILAG B Flares
High: JBT-101 20mg/20mg00
Low: JBT-101 5mg/5mg01
Medium: JBT-101 20mg/Placebo00
Placebo10

[back to top]

Number of BILAG-2004 Disease Flares

"The number of BILAG-2004 disease flares as defined as one new BILAG A or two new BILAG B scores will be assessed.~The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems.~* BILAG-2004: British Isles Lupus Assessment Group 2004." (NCT03093402)
Timeframe: Visit 5 (Day 85)

,,,
InterventionNumber of Participants (Number)
One new BILAG A FlareTwo new BILAG B Flares
High: JBT-101 20mg/20mg20
Low: JBT-101 5mg/5mg00
Medium: JBT-101 20mg/Placebo00
Placebo10

[back to top]

Number of BILAG-2004 Disease Flares

"The number of BILAG-2004 disease flares as defined as one new BILAG A or two new BILAG B scores will be assessed.~The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems.~* BILAG-2004: British Isles Lupus Assessment Group 2004." (NCT03093402)
Timeframe: Visit 6 (Day 113)

,,,
InterventionNumber of Participants (Number)
One new BILAG A FlareTwo new BILAG B Flares
High: JBT-101 20mg/20mg01
Low: JBT-101 5mg/5mg10
Medium: JBT-101 20mg/Placebo00
Placebo00

[back to top]

Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)

"The number of mild/moderate and severe disease flares will be assessed using the SFI instrument to define disease flare(s) and severity.~The SELENA SLEDAI Flare Index categorizes disease flares as mild/moderate or severe, based on the highest categories of clinical features recorded or by treatment recommendations by the physician." (NCT03093402)
Timeframe: Visit 3 (Day 29)

,,,
InterventionNumber of Participants (Number)
SevereMild/ModerateNo Flare
High: JBT-101 20mg/20mg1416
Low: JBT-101 5mg/5mg1023
Medium: JBT-101 20mg/Placebo1222
Placebo0322

[back to top]

Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)

"The number of mild/moderate and severe disease flares will be assessed using the SFI instrument to define disease flare(s) and severity.~The SELENA SLEDAI Flare Index categorizes disease flares as mild/moderate or severe, based on the highest categories of clinical features recorded or by treatment recommendations by the physician." (NCT03093402)
Timeframe: Visit 4 (Day 57)

,,,
Interventionparticipants (Number)
SevereMild/ModerateNo Flare
High: JBT-101 20mg/20mg1217
Low: JBT-101 5mg/5mg0321
Medium: JBT-101 20mg/Placebo0320
Placebo0717

[back to top]

Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)

"The number of mild/moderate and severe disease flares will be assessed using the SFI instrument to define disease flare(s) and severity.~The SELENA SLEDAI Flare Index categorizes disease flares as mild/moderate or severe, based on the highest categories of clinical features recorded or by treatment recommendations by the physician." (NCT03093402)
Timeframe: Visit 5 (Day 85)

,,,
Interventionparticipants (Number)
SevereMild/ModerateNo Flare
High: JBT-101 20mg/20mg0317
Low: JBT-101 5mg/5mg2219
Medium: JBT-101 20mg/Placebo1418
Placebo1419

[back to top]

Number of SLE Disease Flares by Severity Using the SELENA-SLEDAI Flare Index (SFI)

The number of mild/moderate and severe disease flares will be assessed using the SFI instrument to define disease flare(s) and severity. The SELENA SLEDAI Flare Index categorizes disease flares as mild/moderate or severe, based on the highest categories of clinical features recorded or by treatment recommendations by the physician. (NCT03093402)
Timeframe: Visit 6 (Day 113)

,,,
Interventionparticipants (Number)
SevereMild/ModerateNo Flare
High: JBT-101 20mg/20mg0713
Low: JBT-101 5mg/5mg0914
Medium: JBT-101 20mg/Placebo0518
Placebo2913

[back to top]

Percentage of Participants as Responders Using the SLE Responder Index (SRI)

The SRI is a validated SLE disease activity instrument used to detect clinically meaningful improvement of disease in SLE clinical trials. The SRI is a composite instrument comprised of the SELENA-SLE Disease Activity Index [SELENA-SLEDAI], Physician Global Assessment (PGA) and British Isles Lupus Assessment Group (BILAG) 2004. A responder is defined as having at least a 4 point reduction in the SELENA-SLEDAI score, no new BILAG A or no more than 1 new BILAG B domain score, and no increase in the PGA of 0.3 points or more. The percentage of participants who met the criteria for a responder in the SRI at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Subjects (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg19.040.050.021.1
Low: JBT-101 5mg/5mg25.041.754.533.3
Medium: JBT-101 20mg/Placebo28.034.839.134.8
Placebo20.033.339.129.2

[back to top]

Percentage of Participants Who Had 100% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits

"The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.~The percent change from baseline in the 7-day average of the maximum NRS-Pain scores prior to study Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Participants (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg0000
Low: JBT-101 5mg/5mg004.50
Medium: JBT-101 20mg/Placebo04.34.80
Placebo0000

[back to top]

Percentage of Participants Who Had at Least 30% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits

"The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.~The percent change from baseline in the 7-day average of the maximum NRS-Pain scores prior to study Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Participants (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg19.038.942.136.4
Low: JBT-101 5mg/5mg30.440.940.946.7
Medium: JBT-101 20mg/Placebo33.347.842.931.3
Placebo20.026.127.327.3

[back to top]

Percentage of Participants Who Had at Least 50% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits

"The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.~The percent change from baseline in the 7-day average of the maximum NRS-Pain scores prior to study Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Participants (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg14.316.726.39.1
Low: JBT-101 5mg/5mg17.418.222.720.0
Medium: JBT-101 20mg/Placebo16.713.023.812.5
Placebo8.013.04.50

[back to top]

Percentage of Participants Who Had at Least 75% Improvement From Baseline in the 7-day Average of the Maximum NRS-Pain Score Prior to Study Visits Score

"The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.~The percent change from baseline in the 7-day average of the maximum NRS-Pain scores prior to study Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Participants (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg011.15.30
Low: JBT-101 5mg/5mg8.74.59.10
Medium: JBT-101 20mg/Placebo4.28.74.812.5
Placebo4.04.300

[back to top]

Percentage of Participants With Increased Scores From Baseline on ARCI-M

"The percentage of participants who experienced ≥1 score increase on the ARCI-M from the Visit 1 (Day 1) pre-dose assessment at Visit 1 (Day 1) post-dose, Visit 3 (Day 29) and Visit 5 (Day 85) will be assessed.~The ARCI-M questionnaire was completed by subjects at Visit1 (Day 1) pre- and post-dosing, Visit 3 (Day 29) and Visit 5 (Day 85). This is a 12-item true/false questionnaire developed by the National Institutes of Drug Abuse, designed to detect the full range of subjective responses experienced by marijuana users. An answer of true has an assigned value of 1 and an answer of false has an assigned value of 0. The ARCI-M score was computed as the sum of the assigned values for all 12 questions and can range from 0 to 12. If a question is missed, the score is not calculated." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1-prior to treatment initiation), Visit 1 (Baseline, Day 1-post-treatment initiation) Visit 3 (Day 29) and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionPercentage of Participants (Number)
Day 1 Post-DoseDay 29Day 85
High: JBT-101 20mg/20mg25.045.011.1
Low: JBT-101 5mg/5mg20.829.227.3
Medium: JBT-101 20mg/Placebo11.137.539.1
Placebo4.036.056.5

[back to top]

Percentage of Participants With Presence of Arthritis in SELENA-SLEDAI

"The Safety of Estrogen in Lupus National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a validated tool for assessing SLE disease activity.~The percentage of participants with arthritis indicated as Present on the SELENA SLEDAI at Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. [A single question on the SELENA SLEDAI with a response of Present or Absent was assessed.]" (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionPercentage of Participants (Number)
Day 29Day 57Day 85Day 113
High: JBT-101 20mg/20mg14.330.045.015.0
Low: JBT-101 5mg/5mg20.845.847.834.8
Medium: JBT-101 20mg/Placebo28.039.139.139.1
Placebo16.025.033.325.0

[back to top]

Change From Baseline in Physician Assessed Swollen Joint Count

The change from baseline in the number of swollen joints identified by the physician in the Physician Joint Exam at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. The number of swollen joints can range from 0 to 66 joints. (NCT03093402)
Timeframe: Baseline, (Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionNumber of Swollen Joints (Mean)
Baseline/ Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg5.45.63.43.3
Low: JBT-101 5mg/5mg6.84.52.32.1
Medium: JBT-101 20mg/Placebo7.64.03.03.1
Placebo9.05.35.14.0

[back to top] [back to top]

Number of Treatment Emergent Events With Elevated Liver Tests

The number of participants with elevated liver tests, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 x upper limit of normal and total bilirubin > 1.5 x the upper limit of normal, present on repeat testing, at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. (NCT03093402)
Timeframe: Day 1 through Visit 6 (Day 113)

InterventionNumber of Events (Number)
High: JBT-101 20mg/20mg0
Medium: JBT-101 20mg/Placebo0
Low: JBT-101 5mg/5mg0
Placebo0

[back to top]

Change in Baseline in PROMIS-29 Short Form Score - Physical Function T-score

"The Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Short Form (Version 2.0) will be used to assess trends over time in this state of health measure. The PROMIS-29 consists of 7 domains related to physical, mental and social health. Raw scores are calculated for each domain and translated into a T-score per the PROMIS-29 scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents better functioning for the Physical Function domain.~The change from baseline in the PROMIS-29 Physical Function T-score at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85)." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionT-Score (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg37.738.539.939.8
Low: JBT-101 5mg/5mg39.242.142.241.5
Medium: JBT-101 20mg/Placebo39.239.840.041.1
Placebo38.540.540.440.3

[back to top]

Number of Treatment Emergent Intolerability Events

The number of intolerability events of the study drug, defined as incidence of discontinuation of study product due to TEAEs at least possibly related to study product from Visits 1 (Day 1) through 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Day 1 after initiation of study intervention through Visit 5 (Day 85 - Last Day of Treatment)

InterventionNumber of Events (Number)
High: JBT-101 20mg/20mg6
Medium: JBT-101 20mg/Placebo4
Low: JBT-101 5mg/5mg0
Placebo0

[back to top]

Number of Treatment Emergent QTc Prolongation Events

The number of treatment emergent QTc prolongation events will be identified when QTc prolongation > 500 msec total duration and when the change from Visit 1 (Day 1) QTc interval prior to study drug administration > 60 msec Twelve-lead ECGs were recorded in triplicate at Screening and Visits 1 (Day 1) and 5 (Day 85). The ECGs were evaluated for medically significant abnormalities and QT/QTc intervals. The QT/QTc intervals were measured at Visit 1 (Day 1) before administration and between 2.5 and 3.5 hours after administration of study product in the clinic, at the time of maximum JBT-101 concentration in the blood. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1) and Visit 5 (Day 85 - Last Day of Treatment)

InterventionNumber of Events (Number)
High: JBT-101 20mg/20mg0
Medium: JBT-101 20mg/Placebo0
Low: JBT-101 5mg/5mg0
Placebo0

[back to top]

Percentage of Participants Indicating Clinical Benefit in Treatment Satisfaction

"At the end of treatment, the participant and their physician will complete separately a survey asking what treatment assignment they believe they received (e.g., JBT-101, placebo, or cannot tell), whether the participant received benefit from their assigned treatment and whether the participant or their physician would choose the treatment received.~The percentage of participants who responded that they received clinical benefit from the experimental drug treatment at the end of treatment will be assessed." (NCT03093402)
Timeframe: Visit 5 (Day 85 - Last Day of Treatment)

InterventionPercentage of Participants (Number)
High: JBT-101 20mg/20mg59.1
Medium: JBT-101 20mg/Placebo76.0
Low: JBT-101 5mg/5mg69.6
Placebo52.2

[back to top]

Percentage of Participants With Improvement From Baseline in Arthritis in BILAG-2004

The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems. The severity of arthritis at baseline will be determine by the highest arthritis severity level where arthritis is indicated as improving, same, new or worse* BILAG-2004: British Isles Lupus Assessment Group 2004. The percentage of participants who met the criteria for improvement of arthritis in the BILAG-2004 Musculoskeletal assessments (using the mild, moderate and severe arthritis questions on the assessment) at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

InterventionPercentage of Subjects (Number)
High: JBT-101 20mg/20mg50.0
Medium: JBT-101 20mg/Placebo56.5
Low: JBT-101 5mg/5mg78.2
Placebo58.3

[back to top]

Percentage of Physicians Indicating Participant Clinical Benefit in Treatment Satisfaction

"At the end of treatment, the participant and their physician will complete separately a survey asking what treatment assignment they believe they received (e.g., JBT-101, placebo, or cannot tell), whether the participant received benefit from their assigned treatment and whether the participant or their physician would choose the treatment received.~The percentage of physicians who responded that the participant received clinical benefit from the experimental drug treatment at the end of treatment will be assessed." (NCT03093402)
Timeframe: Visit 5 (Day 85 - Last Day of Treatment)

InterventionPercentage of Physicians (Number)
High: JBT-101 20mg/20mg43.5
Medium: JBT-101 20mg/Placebo60.0
Low: JBT-101 5mg/5mg65.2
Placebo66.7

[back to top]

Change From Baseline in Lupus Disease Activity - SELENA-SLEDAI Score

"The change from baseline in the SELENA-SLEDAI score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed.~The Safety of Estrogen in Lupus National Assessment (SELENA) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) is a validated tool for assessing SLE disease activity. The SLEDAI is a one page assessment that contains 24 items scored as present or absent. Each item is assigned a weighted score which is summed to calculate the overall SLEDAI score. SLEDAI score ranges from 0-105 points. Higher scores represent more disease activity, with a score of 6 being considered clinically important and may impact the decision to treat." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScores on a Scale (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg6.96.15.44.7
Low: JBT-101 5mg/5mg7.56.05.04.5
Medium: JBT-101 20mg/Placebo7.05.54.54.5
Placebo8.26.66.15.5

[back to top]

Change From Baseline in Lupus Disease Activity - Total BILAG-2004 Score

"For each of the nine domains, a numerical score will be assigned based on the BILAG score as follows: A=12, B=8, C=1 and D/E=0. A single numerical BILAG total score will be calculated for each participant visit as the summation of the numerical scores for each of the nine domains. The BILAG total score can range from 0 to 108, with higher scores indicating more disease activity. The change from baseline in the total BILAG-2004 score at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. The BILAG-2004* is a validated index for assessing SLE disease activity. The BILAG-2004 includes 97 clinical and laboratory items to evaluate SLE disease activity in 9 organ systems.~* BILAG-2004: British Isles Lupus Assessment Group 2004." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg12.28.87.98.6
Low: JBT-101 5mg/5mg11.56.25.44.9
Medium: JBT-101 20mg/Placebo9.75.86.55.1
Placebo13.15.58.17.7

[back to top]

Change From Baseline in Lupus Disease Activity -Physician's Global Assessment (PGA) Score

The change from baseline in the total PGA score at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. The PGA utilizes a 0 to 3 visual analogue scale for assessing disease activity in SLE that is anchored by the verbal descriptors as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe. An increase of >=0.3 points is considered worsening of the PGA. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg1.21.21.00.9
Low: JBT-101 5mg/5mg1.41.00.90.7
Medium: JBT-101 20mg/Placebo1.20.90.80.8
Placebo1.31.11.00.9

[back to top]

Change From Baseline in Lupus Disease Activity- Patient Global Assessment Score

"The change from baseline in the total Patient Global Assessment score at Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85) and Visit 6 (Day 113) will be assessed. The total Patient Global Assessment is performed with a visual analogue scale (0 to 100) in which the participant is asked to indicate how active she/he thinks their disease is. The visual analogue scale is anchored by two descriptors: not active (score of 0) and extremely active (score of 100)." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), Visit 5 (Day 85 - Last Day of Treatment) and Visit 6 (Day 113)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg60.248.148.337.0
Low: JBT-101 5mg/5mg65.647.550.248.7
Medium: JBT-101 20mg/Placebo67.049.250.548.0
Placebo65.554.459.458.7

[back to top]

Change From Baseline in Physician Assessed Tender Joint Count

The change from baseline in the number of tender joints identified by the physician in the Physician Joint Exam at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. The number of tender joints can range from 0 to 68 joints. (NCT03093402)
Timeframe: Baseline, (Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment

,,,
InterventionNumber of Tender Joints (Mean)
Baseline/ Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg14.112.19.510.3
Low: JBT-101 5mg/5mg13.18.85.04.7
Medium: JBT-101 20mg/Placebo15.012.312.311.9
Placebo18.410.010.711.3

[back to top]

Change in Baseline in PROMIS - Anxiety T-Score

"The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Anxiety T-Score will be used to assess trends over time in this health measure.~The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents worse symptomology for the Anxiety domain. The change from baseline in PROMIS Anxiety Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionT-Score (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg57.054.755.752.9
Low: JBT-101 5mg/5mg56.954.156.054.7
Medium: JBT-101 20mg/Placebo52.453.252.650.0
Placebo55.151.653.453.5

[back to top]

Change in Baseline in PROMIS - Depression T-Score

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Depression T-Score will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents worse symptomology for the Depression domain. The change from baseline in PROMIS Depression Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg57.753.852.953.0
Low: JBT-101 5mg/5mg52.749.851.850.0
Medium: JBT-101 20mg/Placebo49.649.149.750.0
Placebo52.152.051.150.6

[back to top]

Change in Baseline in PROMIS - Fatigue T-Score

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Fatigue T-Score will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents worse symptomology for the Fatigue domain. The change from baseline in PROMIS Fatigue Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionT-Score (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg64.061.861.759.7
Low: JBT-101 5mg/5mg63.158.055.857.9
Medium: JBT-101 20mg/Placebo62.459.657.856.7
Placebo63.760.159.459.0

[back to top]

Change in Baseline in PROMIS - Pain Intensity

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Pain Intensity will be used to assess trends over time in this health measure. The Pain Intensity on the PROMIS is a single item numerical rating scale where the respondent selects a whole number representing the average pain of the past 7 days ranging from 0 (no pain) to 10 (worst pain imaginable). The change from baseline in PROMIS Pain Intensity Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/ Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg6.65.55.24.7
Low: JBT-101 5mg/5mg7.05.24.94.6
Medium: JBT-101 20mg/Placebo6.95.35.15.2
Placebo6.95.85.85.8

[back to top]

Change in Baseline in PROMIS - Pain Interference T-Score

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Pain Interference T-Score will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents worse symptomology for the Pain Interference domain. The change from baseline in PROMIS Pain Interference Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg64.961.661.158.5
Low: JBT-101 5mg/5mg65.060.457.760.0
Medium: JBT-101 20mg/Placebo64.761.658.560.4
Placebo66.161.262.061.1

[back to top]

Change in Baseline in PROMIS - Sleep Disturbance T-Score

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Sleep Disturbance T-Score will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents worse symptomology for the Sleep Disturbance domain. The change from baseline in PROMIS Sleep Disturbance Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg58.656.656.055.4
Low: JBT-101 5mg/5mg57.957.756.456.3
Medium: JBT-101 20mg/Placebo56.454.553.756.4
Placebo62.657.257.757.2

[back to top]

Change in Baseline in PROMIS - Social Role Satisfaction T-Score

The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Social Role Satisfaction T-Score will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score better functioning for the Social Role Satisfaction domain. The change from baseline in PROMIS Social Role Satisfaction Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed. (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionScore (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg42.244.944.246.1
Low: JBT-101 5mg/5mg44.345.147.047.8
Medium: JBT-101 20mg/Placebo42.544.947.148.2
Placebo42.447.345.946.8

[back to top]

Change in Baseline in PROMIS Cognitive Function T-Score

"The Patient-Reported Outcomes Measurement Information System (PROMIS) Item Bank version 2.0 - Cognitive Function scale will be used to assess trends over time in this health measure. The raw score is calculated for and translated into a T-score per the PROMIS scoring guide. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A higher score represents better cognitive function.~The change from baseline in PROMIS Cognitive Function Score at Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85) will be assessed." (NCT03093402)
Timeframe: Visit 1 (Baseline, Day 1), Visit 3 (Day 29), Visit 4 (Day 57), and Visit 5 (Day 85 - Last Day of Treatment)

,,,
InterventionT-Score (Mean)
Baseline/Day 1Day 29Day 57Day 85
High: JBT-101 20mg/20mg45.543.644.745.0
Low: JBT-101 5mg/5mg42.345.445.645.8
Medium: JBT-101 20mg/Placebo45.148.347.148.1
Placebo42.445.443.444.2

[back to top]

Improvement in the Maximum Daily NRS-Pain Score at Day 84

"The numeric rating scale for pain (NRS-Pain) consists of an 11-point NRS ranging from 0 (no pain) to 10 (pain as bad as you can imagine). A rating of 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.~Participants will be asked to report their maximum daily pain using the NRS-Pain. Participants will call into an interactive voice response e diary system (IVRS) and record the number that best reflects their maximum amount of pain experienced in the last 24 hours. Participants will be asked to call at the same time each day, preferably before bedtime.~Longitudinal trends over the course of the treatment period will be modeled and used to estimate difference between means at baseline and Day 84 for each treatment group." (NCT03093402)
Timeframe: Day 1 through Day 84

,,,
InterventionNRS Pain Score (Least Squares Mean)
Day 1Day 84
High: JBT-101 20mg/20mg6.35.1
Low: JBT-101 5mg/5mg6.05.1
Medium: JBT-101 20mg/Placebo6.44.9
Placebo6.25.9

[back to top]

Time to First New Pulmonary Exacerbation (PEx)

Time to first new PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo. An primary PEx is defined on the physician's decision to treat with oral, intraveneous or inhaled antibiotics in the presence 4/12 Fuch's criteria (Change in sputum, new/increased hemoptysis, increased cough, increased dyspnea, malaise, fatigue/lethargy, Temperature greater than 38C, weight loss, sinus pain, change in sinus discharge, change in exam of chest, decrease in FEV1 of more than 10%, radiographic change). This excludes prophylactic antibiotics. A new PEx is a one that occurs at 28 days after the previous PEx. The rate is calculate over a 28 week period from visit 1 to week 28 visit (NCT03451045)
Timeframe: 28 weeks (Baseline Day 0 to Week 28)

Interventiondays (Median)
Lenabasum 20 mg BID162
Lenabasum 5 mg BID148
Placebo143

[back to top]

Pulmonary Exacerbation (PEx) Rate Over 28 Weeks

Rate of PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo, during the treatment period. An primary PEx is defined on the physician's decision to treat with oral, intraveneous or inhaled antibiotics in the presence 4/12 Fuch's criteria (Change in sputum, new/increased hemoptysis, increased cough, increased dyspnea, malaise, fatigue/lethargy, Temperature greater than 38C, weight loss, sinus pain, change in sinus discharge, change in exam of chest, decrease in FEV1 of more than 10%, radiographic change). This excludes prophylactic antibiotics. A new PEx is a one that occurs at 28 days after the previous PEx. (NCT03451045)
Timeframe: 28 weeks (Baseline Day 0 to Week 28)

Interventionevents per participant/28 weeks (Number)
Lenabasum 20 mg BID0.911
Lenabasum 5 mg BID0.749
Placebo BID0.842

[back to top]

Pulmonary Exacerbation (PEx) Rate

Event rate of PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo. The secondary definition of a PEx is based on the physician's diagnosis of pulmonary exacerbation and commencement of new oral, intravenous, or inhaled antibiotics. A new PEx is defined one that starts 28 or more days after the previous confirmed PEx. The PEx rate is calculated as the number of PEx/28 weeks (NCT03451045)
Timeframe: 28 weeks (Baseline Day 0 to Week 28)

Interventionevents per participant/28 weeks (Number)
Lenabasum 20 mg BID1.08
Lenabasum 5 mg BID0.91
Placebo1.03

[back to top]

Pulmonary Exacerbation (PEx)

Time to first PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo. The secondary definition of a PEx is based on the physician's diagnosis of pulmonary exacerbation and commencement of new oral, intravenous, or inhaled antibiotics. A new PEx is defined one that starts 28 or more days after the previous confirmed PEx. (NCT03451045)
Timeframe: 28 weeks (Baseline Day 0 to Week 28)

Interventiondays (Median)
Lenabasum 20 mg BID116
Lenabasum 5 mg BID113
Placebo120

[back to top]

FEV1 % Predicted

Change from baseline to week 28 in Forced Expiratory Volume in 1 second (FEV1) expressed as a percentage of a normal range. A lower percentage FEV1 is indicative of decrease in lung functionality. The changes observed from baseline to week 28 for lenabasum will be compared with those observed for placebo treated participants. (NCT03451045)
Timeframe: 28 weeks (Change from Baseline Day 0 to Week 28)

Interventionpercentage of Predicted FEV1 (Least Squares Mean)
Lenabasum 20 mg BID0.014
Lenabasum 5 mg BID-0.005
Placebo-0.012

[back to top]

CFQ-R Respiratory Symptom Domain

Cystic Fibrosis Questionnaire - Revised measures change from baseline in CFQ-R respiratory symptom domain with lenabasum compared to placebo. Subjects >/= 14 years of age. 5 distinct 4-point Likert scales (e.g., always/often/ sometime/never) Scores for each HRQoL domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health. (NCT03451045)
Timeframe: 28 weeks (Change from Baseline Day 0 to Week 28)

Interventionscores on a scale (Least Squares Mean)
Lenabasum 20 mg BID1.16
Lenabasum 5 mg BID-2.92
Placebo-0.96

[back to top]

Skin Picking Symptom Assessment Scale (SP-SAS)

The entire study lasts 10 weeks. Every two weeks subjects will take the SP-SAS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of skin-picking symptoms. The SP-SAS score ranges from 0 to 48, with 0 being no symptoms and 48 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline reported

Interventionscore on a scale (Mean)
Dronabinol24.44
Placebo28.5

[back to top]

NIMH Trichotillomania Symptom Severity Scale (NIMH-TSS)

The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH-TSS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of trichotillomania symptoms. The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline data reported

Interventionscore on a scale (Mean)
Dronabinol12.38
Placebo10.63

[back to top]

Maximum Self-reported Pain Score on a Numeric Rating Scale

Women will text responds to surveys within 24 hours after misoprostol administration indicating their maximum self-reported pain using an 11-point numeric rating scale (NRS 0-10) where 0=no pain and 10=worst possible pain. (NCT03604341)
Timeframe: 24 hours after misoprostol administration

Interventionscore on a scale (Median)
Gestational Age up to 10w0d - Dronabinol7
Gestational Age up to 10w0d - Placebo7

[back to top]

Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans During Resting State.

"Subjects completed resting-state fNIRS scans before and after receiving a combination of active dronabinol or placebo dronabinol and active ethanol or placebo ethanol. During the task, the fNIRS device was used to capture concentration of oxygenated hemoglobin to assess prefrontal brain activity.~Outcomes reflect average change from baseline in HbO concentration over pre-dose scan and average change from baseline in HbO concentration over post-dose scan (expected peak intoxication)." (NCT03655717)
Timeframe: The first resting-state scan session was run before dosing (t ≈ -45min). Drug was administered (t = 0min). The second resting-state scan session was run at the time of expected peak high (t ≈ 90min). Each scan session was six minutes in duration.

,,,,,
InterventionΔ mol/L (Mean)
PredosePeak
Phase 2A: Dronabinol Only-0.00000000056-0.00000000043
Phase 2A: Placebo Dronabinol Only0.000000000090.00000000115
Phase 2B: Dronabinol and Ethanol0.000000001980.00000000025
Phase 2B: Dronabinol and Placebo Ethanol0.000000000210.00000000190
Phase 2B: Placebo Dronabinol and Ethanol0.000000001440.00000000195
Phase 2B: Placebo Dronabinol and Placebo Ethanol-0.00000000051-0.00000000014

[back to top]

Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans of Patients Completing the N-back Task.

"Subjects completed the N-back task before and after receiving a combination of active dronabinol or placebo dronabinol and active ethanol or placebo ethanol. During the task, the fNIRS device was used to capture change in concentration of oxygenated hemoglobin to assess prefrontal brain activity.~Outcomes reflect average change from baseline in HbO concentration over pre-dose scan and average change from baseline in HbO concentration over post-dose scan (expected peak intoxication)." (NCT03655717)
Timeframe: The first Nback scan session was run before dosing (t ≈ -35min). Drug was administered (t = 0min). The second Nback scan session was run at the time of expected peak pharmacokinetic effect (t ≈ 100min). Each scan session was six minutes in duration.

,,,,,
InterventionΔ mol/L (Mean)
PredosePeak
Phase 2A: Dronabinol Only0.000000000420.00000000013
Phase 2A: Placebo Dronabinol Only-0.000000001260.00000000029
Phase 2B: Dronabinol and Ethanol-0.00000000271-0.00000000041
Phase 2B: Dronabinol and Placebo Ethanol-0.00000000114-0.00000000020
Phase 2B: Placebo Dronabinol and Ethanol-0.00000000151-0.00000000018
Phase 2B: Placebo Dronabinol and Placebo Ethanol-0.000000002190.00000000070

[back to top]

Accelerometry-based Assessment of Tremor Severity

The spectral power density measure of accelerometry data to measure will serve as a measure of tremor severity, comparing tremor amplitude from this digital biomarker at the time of the primary outcome to the same measure at baseline. (NCT03805750)
Timeframe: Baseline and Day 22

InterventionProportion of baseline spectral power (Mean)
CBD/THC0.012
Placebo0.007

[back to top]

Change in Score on a Scale From Baseline of the Tremor Research Group Essential Tremor Rating Scale (TETRAS)

The performance sub scale of the TETRAS will be used to measure tremor severity. The scale ranges from 0 to 60 points (0 being no tremor). (NCT03805750)
Timeframe: Baseline and Day 22

Interventionscore on a scale (Mean)
CBD/THC-8.07
Placebo-10.3

[back to top]

Digital Spirography

The tremor mean amplitude calculated using computerized spirography to measure kinetic tremors. (NCT03805750)
Timeframe: Day 22 (100 minutes post-dose)

Interventionmillimeters of tremor amplitude (Mean)
CBD/THC1.04
Placebo1.00

[back to top]

Number of Participants at Risk for Suicide Based on Columbia-Suicide Severity Rating Scale (C-SSRS)

This is a scale looking at risk assessment of suicidality. The presence of any positive responses will lead to further evaluation. (NCT03805750)
Timeframe: Day 22

InterventionParticipants (Count of Participants)
CBD/THC0
Placebo0

[back to top] [back to top]

Number of Participants Reporting Adverse Events Based on Common Terminology Criteria

Side effects survey (NCT03805750)
Timeframe: Days 1, 3, 6, 22

,
InterventionParticipants (Count of Participants)
Ringing in earsNumbness/tinglingDyspnea on exertionWatery eyesRunny noseDecreased concentrationSleepinessInsomniaIncreased sleepinessDizzinessMemory problemsImbalanceMild headacheGroggyTiredThumb painAnxietyHeadacheLightheadedFelt highDecreased libidoDiarrheaDry mouthEuphoriaFatigueFeels relaxedIncreased thirstFelt buzzedQuivering voiceVisual slowing
CBD/THC744337402433000022211111111111
Placebo644320121000111100000000000000

[back to top]

Global Impression of Change

The Global impression of change will be calculated based on both physician and patient report. The scale ranges from a score of 1 (very much improved) to 7 (very much worse) with a score of 4 indicating 'no change'. (NCT03805750)
Timeframe: Day 22

,
Interventionscore on a scale (Mean)
Clinical Global Impression of ChangePatient Global Impression of Change
CBD/THC33
Placebo44

[back to top]

Peak Change From Baseline Number of Correct Trials on Paced Auditory Serial Addition Task (PASAT)

Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Reported data reflect the peak change from baseline in the total correct trials out of 90 recorded (lower scores indicate worse performance) obtained 1, 2, 3, 4, 6, or 8 hours post-dose. (NCT04201197)
Timeframe: 8 hours

InterventionCorrect trials (Mean)
Inje Cocktail-1.1
Inje Cocktail + THC Extract-6.6
Inje Cocktail + THC/CBD Extract-22.7

[back to top]

Peak Change From Baseline Cognitive Performance as Assessed by the Divided Attention Task

Cognitive performance will be evaluated with the Divided Attention Task. Reported data reflect the peak change from baseline performance measured as the mean distance (in computer pixels) of the mouse cursor from the central stimulus recorded 1, 2, 3, 4, 6, or 8 hours post-dose. Higher scores indicate worse performance. (NCT04201197)
Timeframe: 8 hours

InterventionComputer pixels (Mean)
Inje Cocktail-2.1
Inje Cocktail + THC Extract15.9
Inje Cocktail + THC/CBD Extract32.7

[back to top]

Peak Change From Baseline Beats Per Minute for Heart Rate (HR)

HR will be obtained using an automated monitor to evaluate changes in beats per minute as a function of conditions. Data reflect the peak change from baseline measured 1, 2, 3, 4, 6, or 8 hours post-dose. (NCT04201197)
Timeframe: 8 hours

InterventionBeats per minute (Mean)
Inje Cocktail-4.4
Inje Cocktail + THC Extract10.1
Inje Cocktail + THC/CBD Extract25.4

[back to top]

Omeprazole AUC in Plasma

Area under the curve concentration (h*ng/mL) of omeprazole in plasma using data points obtained 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose (NCT04201197)
Timeframe: 24 hours

Interventionh*ng/mL (Geometric Mean)
Inje Cocktail + Placebo385
Inje Cocktail + THC379
Inje Cocktail + THC/CBD1183

[back to top]

Number of Correct Trials on the Digit Symbol Substitution Task (DSST)

Computerized version of Digit Symbol Substitution Task will be administered to assess psychomotor performance. Results reported reflect the peak change from baseline on the total correct trials in 90 seconds (lower scores indicate worse performance) assessed 1, 2, 3, 4, 6, or 8 hours post-dose. (NCT04201197)
Timeframe: 8 hours

InterventionCorrect trials (Mean)
Inje Cocktail2.5
Inje Cocktail + THC Extract-2.7
Inje Cocktail + THC/CBD Extract-9.9

[back to top]

Midazolam AUC in Plasma

Area under the curve concentration (h*ng/mL) of midazolam in plasma using data points obtained 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose (NCT04201197)
Timeframe: 24 hours

Interventionh*ng/mL (Geometric Mean)
Inje Cocktail + Placebo23
Inje Cocktail + THC24
Inje Cocktail + THC/CBD36

[back to top]

Losartan Area Under the Curve (AUC) in Plasma

Area under the curve concentration (h*ng/mL) of losartan in plasma using data points obtained 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose (NCT04201197)
Timeframe: 24 hours

Interventionh*ng/mL (Geometric Mean)
Inje Cocktail + Placebo164
Inje Cocktail + THC185
Inje Cocktail + THC/CBD289

[back to top]

Drug Effect Questionnaire (DEQ) - Peak Score for Feel Drug Effect

"The DEQ will be used to obtain subjective ratings of feel drug effects. Score range from 0 (none) to 100 (extreme) using a 100mm line anchored with none/extreme designation. Peak rating within 24 hours post-dose is reported." (NCT04201197)
Timeframe: 24 hours

InterventionScore on a scale (Mean)
Inje Cocktail9.4
Inje Cocktail + THC Extract59.2
Inje Cocktail + THC/CBD Extract72.8

[back to top]

Dextromethorphan AUC in Plasma

Area under the curve concentration (h*ng/mL) of dextromethorphan in plasma using data points obtained 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose (NCT04201197)
Timeframe: 24 hours

Interventionh*ng/mL (Geometric Mean)
Inje Cocktail + Placebo10.4
Inje Cocktail + THC13.2
Inje Cocktail + THC/CBD13.6

[back to top]

Caffeine AUC in Plasma

Area under the curve concentration (h*ng/mL) of caffeine in plasma using data points obtained 0, 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose (NCT04201197)
Timeframe: 24 hours

Interventionh*ng/mL (Geometric Mean)
Inje Cocktail + Placebo18948
Inje Cocktail + THC18554
Inje Cocktail + THC/CBD26264

[back to top]

Change From Baseline in Profile of Mood States (POMS)

The POMS measures individuals' mood states. This is a validated scale to measure positive and negative mood states. The POMS consists of 72 mood adjectives rated on a Likert scale from 0 (not at all) to 4 (extremely), divided into 8 subscales: Friendliness, Anxiety, Elation, Anger, Fatigue, Depression, Confusion and Vigor, and two composite scales: Positive Mood (Elation minus Depression) and Arousal (Vigor plus Anxiety minus Confusion plus Fatigue). Scoring of this instrument provides a global score of 0 to 120 or individual domain scores of 0 to 20. Lower scores indicate better mood state. The POMS brief form is a simple self-rating instrument. (NCT04294966)
Timeframe: Through Study Completion, an average of 3 weeks (Baseline - time 0 to Time point 9 (Study Completion))

,,
Interventionunits on a scale (Mean)
POMS Anxiety Week 1POMS Depression Week 1POMS Vigor Week 1POMS Fatigue Week 1POMS Friendliness Week 1POMS Anxiety Week 3POMS Depression Week 3POMS Vigor Week 3POMS Fatigue Week 3POMS Friendliness Week 3
15 mg THC18.556.258.258.258.2519.258.256.226.2511.25
7.5 mg THC12.465.058.0514.2516.2514.255.286.878.658.22
Placebo5.754.0813.006.676.425.503.9216.836.09.42

[back to top]

Apnea-Hypopnea Index (AHI)4% Events Per Hour

Compares high dose atomoxetine (80/10) versus baseline (NCT05101122)
Timeframe: 28 days

Interventionevents/hour (Median)
Baseline28.6
AD313 80/1026.6

[back to top]